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The increasing prevalence in type-2 diabetes (T2D), driven by changes in lifestyle and 
environment, has also increased the surge to find optimal strategies for T2D prevention. Clinical 
trials have shown that lifestyle interventions are the most effective tool in the prevention of T2D 
and they should be directed at individuals with the highest risk (1). Obesity is one of the strongest 
risk factors for developing T2D (2) and merely being overweight imposes a three-fold increased 
risk of T2D (3). One of the hallmarks of both obesity and T2D is increased insulin resistance (4), 
but exact mechanisms by which obesity links with insulin resistance remain unknown. 
Enlargement of lipid depots have been associated with insulin resistance (5) and especially when 
visceral adipose tissue depots expand, odds of insulin resistance increase (6).   
Reducing insulin resistance and T2D risk can be achieved by losing body weight. Modest weight 
reduction of 5 to 10 percent was shown to already lead to clinically relevant health benefits, 
including the amelioration of insulin resistance (7). Weight loss occurs when energy expenditure 
exceeds energy intake and while this is relatively simple to achieve for a short period, long-term 
weight loss has proven to be very difficult to maintain (8). To this end, lifestyle interventions have 
been directed at establishing long-term body weight loss (9, 10). Within these interventions, 
different dietary lifestyle regimes have been evaluated throughout the years and recently a high 
protein/low GI diet vs low protein/high GI diet has been suggested to yield supreme results for 
long-term weight loss (11). Based on the association between increased body weight and T2D 
development, a high-protein /low GI diet may thus be effective for the prevention of T2D 
development (12). It remains unclear whether high protein diets have additional effects on insulin 
resistance beyond effects on body weight management (CHAPTER 4). Protein may affect 
underlying mechanisms that could influence metabolic parameters irrespective of body weight. 
Based on short-term studies there may be protein-specific effects on intrahepatic lipid content 
and brain activation, which aid in the prevention of T2D (CHAPTER 7 and 8). Moreover, 
combining high-protein intake with lower glycaemic index (GI)/glycaemic load (GL) has been 
suggested to be the optimal diet for prevention of T2D. International guidelines already include 
recommendations for lower GI foods (13), but long-term effects of lower GI foods on the 
prevention of T2D have not been tested in large trials.    
Other important lifestyle components are physical activity and exercise. Increasing physical 
activity may be a potent strategy to reduce T2D risk. Increased physical activity was shown to 
increase insulin sensitivity (14) and an exercise intervention led to a decrease in the incidence of 
T2D over a 6-year period compared to a control group (15). 
In this perspective, The PREVIEW-study (Prevention of Diabetes through Lifestyle Intervention and 
Population Studies in Europe and around the World), has been initiated. The PREVIEW-study is a 
multi-centre trial to determine effects of a lifestyle intervention on T2D development in 
individuals with pre-diabetes (CHAPTER 2) and started in 2013. The multi-centre trial was 
performed in eight centers including Maastricht University in Maastricht, the Netherlands. 
Pre-diabetes was defined as having impaired fasting glucose and/or impaired glucose tolerance in 
combination with overweight/obesity, in accordance with the American Diabetes Association 
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(ADA) criteria (16). Individuals with pre-diabetes present a highly vulnerable group with up to 70 
percent of the individuals eventually developing diabetes (17).  
The PREVIEW-study started with an eight-week low energy diet to establish body weight loss 
(CHAPTER 6), followed by a lifestyle intervention with four intervention arms, differing in physical 
activity and dietary programs. Physical activity programs of the PREVIEW intervention consisted of 
two groups differing in physical activity intensities. While it is know that physical activity is able to 
increase insulin sensitivity (14), it is unknown whether altering physical activity intensity or 
duration may have differential effects on insulin resistance and T2D development (CHAPTER 3).  
Dietary programs of the PREVIEW intervention consisted of two groups differing in protein intake 
and GI/GL. Increasing protein intake has been recommended to achieve weight loss and 
especially to maintain body-weight after weight loss (18). Body-weight management may be 
improved by increased protein intake via increased satiety and energy expenditure and decreased 
body-fat percentage (CHAPTER 4). A reduction in body-fat percentage during energy restriction 
corresponds with a reduction in fat mass and sparing of fat-free mass and thereby limits the 
reduction of energy expenditure. Especially a reduction in ectopic fat mass relative to total body-
fat mass has been related to improved metabolic health, including insulin resistance (19). 
Intrahepatic lipid accumulation has been suggested as both a cause and consequence of insulin 
resistance (20). Short-term studies showed that protein supplementation was able to reduce 
intrahepatic lipid content (21, 22). Intrahepatic lipid content can be quantified using magnetic 
resonance spectroscopy (MRS) (23). Using MRS, metabolites can be non-invasively identified 
within tissues based on their resonance frequency. Proton (
1
H)-MRS can be specifically used to 
quantify lipid accumulation in the liver. During the PREVIEW-study, 
1
H-MRS was used to 
determine long-term effects of weight loss and weight maintenance with increased protein intake 
on intrahepatic lipid content and its implications for insulin resistance (CHAPTER 7).  
The difficulties of achieving long-term body weight maintenance are partly explained by 
decreased compliance to dietary guidelines, which is therefore also an important issue within the 
three year intervention of the PREVIEW-study. A reduction in compliance may be caused by a 
reduced rewarding value of food in response to lower levels of energy intake (24-26). Alterations 
in brain reward activity may overrule the homeostatic control of energy balance, leading to 
increased food intake and weight (re)gain (27). Neuroimaging studies have identified brain 
regions involved in food-reward processing. Especially the mesolimbic pathway has been 
associated with reward and motivation and consists of dopaminergic neurons originating in the 
ventral tegmental area projecting to the nucleus accumbens, striatum and prefrontal cortex (28, 
29). The mesolimbic pathway interacts with pathways associated with emotion and cognitive 
control to modulate activity of homeostatic brain regions and regulate eating behavior (30). 
Protein supplementation was shown to alter the brain reward response and hence may improve 
long-term weight management (31). Furthermore, converging evidence suggests that brain 
reward activity is affected by insulin resistance (CHAPTER 5) (32). This may also explain 
differences found in food-reward related brain activation between individuals with T2D or obesity 
and healthy individuals (24, 33). Functional magnetic resonance imaging (fMRI) was used to 
measure brain reactivity to food cues during the PREVIEW-study (CHAPTER 8). The technique 
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that was used to determine brain activity was blood oxygen level dependent imaging, which 
utilizes the differential magnetic properties of de-oxygenated and oxygenated hemoglobin. In 
response to neuronal activation, the ratio between de-oxygenated and oxygenated hemoglobin 
changes leading to changes in signal intensity.  
Changes in body weight and insulin resistance during The PREVIEW-study may also lead to 
differences in brain structure (CHAPTER 9). Grey matter volume and cortical thickness have 
reportedly been reduced in individuals with obesity and T2D (34, 35). Grey matter comprises 
neuronal cell bodies, dendrites and glial cells and its volume has been shown to decrease with 
aging and in neurodegenerative diseases (36, 37). Grey matter volume is a function of both 
cortical surface area and cortical thickness and in past years especially the latter has been posed 
as a relevant marker of brain functionality (38). However, while the relationships between cortical 
thickness, grey matter volume and brain function are far from clear, even less is known about the 
dynamic properties of these variables.  
In this thesis, the effects of a lifestyle intervention with increased protein intake to prevent 
diabetes were studied. This included effects on body weight, body composition and insulin 
resistance, with special focus for the role of intrahepatic lipid content and brain reward system. 
The studies in this thesis present data of the complete PREVIEW-cohort including the Maastricht 
cohort and of sub-studies performed solely in the Maastricht cohort. Studies are presented in 
temporal order of data collection, beginning with a general description of the methods, followed 
by reports on baseline, and lastly intervention related results.  
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ABSTRACT 
Type-2 diabetes (T2D) is one of the fastest growing chronic diseases worldwide. The PREVIEW 
project has been initiated to find the most effective lifestyle (diet and physical activity) for the 
prevention of T2D, in overweight and obese participants with increased risk for T2D. The study is a 
3-y multi-centre, 2x2 factorial, randomised controlled. The impact of a high-protein, low-
glycaemic index (GI) vs. moderate protein, moderate-GI diet in combination with moderate or 
high-intensity physical activity on the incidence of T2D and related clinical end-points is 
investigated. The intervention started with a 2-month 8-week weight reduction using a low-
calorie diet, followed by a randomised 34-month weight maintenance phase comprising 4 
treatment arms. Eight intervention centres are participating (Denmark, Finland, United Kingdom, 
the Netherlands, Spain, Bulgaria, Australia, New Zealand). Data from blood specimens, urine, 
faeces, questionnaires, diaries, body composition assessments and accelerometers are collected at 
months 0, 2, 6, 12, 18, 24 and 36. In total, 2,326 adults were recruited. Mean age was 51.6 (SD 
11.6) years, 67% were women. PREVIEW is to date the largest, multinational trial to address 
prevention of T2D in pre-diabetic adults through diet and exercise intervention. The final 
participant will complete the intervention in March, 2018. 
PREVIEW: Prevention of diabetes through lifestyle intervention and populations studies 
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INTRODUCTION 
Type-2 diabetes (T2D) is a disease associated with serious comorbidities, including microvascular 
(retinopathy, nephropathy, neuropathy) and macrovascular (cardiovascular) events (1). The 
estimated global prevalence is approximately 8% and a prediction suggests that this will increase 
by 55% up to the year 2035 (2, 3). An important risk factor for T2D is obesity (BMI>30 kg/m2) 
predicting a more than 10-fold increase in incidence compared to normal weight (4). Weight gain 
during adulthood is also a independent risk factor for T2D (5), as are genetic inheritance, 
unhealthy dietary habits and insufficient physical activity (6–8). 
Long-term studies have shown benefits of a lifestyle intervention (diet and exercise), on T2D 
incidence in China (9), USA (10) and Finland (11). Lifestyle change (diet, physical activity, weight 
loss) may reduce the incidence of T2D by 28%–59% (12). The American Diabetes Prevention 
Program (DPP) (13), the Finnish Diabetes Prevention Study (DPS) (14) and the Chinese Da Qing 
Diabetes Prevention Study (15) were all designed to produce weight loss by prescribing a high-
carbohydrate (CHO) (>50 percent of energy (E%) from CHO), low-fat (<30 E%) diet approach 
which reflected the understanding of a prudent diet 20 years ago. No attention was paid to 
glycaemic index (GI) per se, and to date no studies have investigated the role of GI for prevention 
of type-2 diabetes. Other dietary prescriptions that produce significant and sustainable weight 
loss may also be effective in T2D prevention. Current international recommendations include 
lower ranges for CHO intake (16) and a recommendation to choose lower GI foods (17). A 
combination of lower CHO (45 E%), higher protein together with lower GI might be the optimal 
diet for prevention of T2D (18), perhaps related to sustained weight loss as shown in medium 
term trials (19). To date these hypotheses have not been tested in large trials of long duration 
(20).  
The program for physical activity in the trials described above followed the international public 
health recommendations, that is, a total of approximately 150 minutes per week of moderate-
intensity aerobic activities or 75 minutes of vigorous intensity activity (10, 14). A question, not 
examined in earlier studies, is whether the metabolic responses are different between higher- and 
lower-intensity exercise programs. Moderate-intensity exercise relies relatively more on fat 
oxidation, whereas vigorous-intensity exercise relies more on CHO oxidation and use of 
intramuscular substrates (21). Houmard et al. found that total exercise time, not intensity or 
exercise energy expenditure, was associated with the greatest improvement of insulin sensitivity 
in obese participants (22). However, the hypothesis that physical activity with different intensity 
levels may differentially affect T2D prevention has yet to be tested in any large-scale intervention. 
Since obesity is a strong risk factor for T2D, any successful prevention program should be able to 
prevent weight regain in individuals after a significant weight loss. The high heterogeneity of 
dietary intervention design prevents firm conclusions being drawn regarding preferred 
macronutrient composition (23). Notably a recent multi-centre trial ‘DiOGenes’ (Diet, Obesity and 
Genes) identified a higher-protein, moderate-CHO and low-GI diet as superior to other diets of 
varying macronutrient composition in preventing weight regain over six months (19) and in a 
smaller subset over 12 months (24), after 2 months of rapid weight loss. 
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Despite the evidence that a lifestyle program combining prudent diet, increased physical activity 
and weight loss reduces the risk for T2D in susceptible individuals (12), important details remain 
unanswered. These include the long-term effects and sustainability of diets higher in protein with 
a lower glycaemic load, combined with the effects of higher intensity exercise. The present paper 
describes PREVention of diabetes through lifestyle Intervention and population studies in Europe 
and around the World (PREVIEW), a large multi-centre international randomised controlled trial in 
adults designed to answer these questions.  
METHODS 
Aims of the study 
The aim is to determine the effects and interactions of two diets and two physical activity 
programmes on the prevention of T2D in overweight, pre-diabetic adults, who have undergone a 
short period of significant weight loss. Our primary hypothesis is that a higher protein, lower 
CHO/low GI diet (based on the DiOGenes study(19)) will be superior in preventing T2D when 
compared with a moderate protein, higher CHO/moderate GI diet (based on the DPS and DPP 
studies (10, 14)). We also hypothesise that high-intensity physical activity will be superior 
compared to moderate-intensity physical activity (25).Each participant receives one of the two 
dietary programs, and one of the two physical activity programs, thus we have four groups (high 
protein diet and high-intensity physical activity; moderate protein diet and high-intensity physical 
activity; high protein diet and moderate-intensity physical activity; moderate-protein diet and 
moderate-intensity physical activity). The majority of outcomes will be analysed by using these 
four arms. The primary endpoint and statistical power calculations are based on a two-arm design 
(diets compared against each other).  
Primary and secondary endpoints 
The primary endpoint is incidence of T2D in high vs. moderate protein diet measured over a 36-
month intervention period, based on the WHO criteria (26) of either (i) OGTT with fasting plasma 
glucose FPG >7.0 mmol/l and/or 2-h post prandial  (75g glucose load) plasma glucose ≥11.1 
mmol/l, or (ii) T2D diagnosed by a medical doctor between the Clinical Investigation Days (CID) of 
PREVIEW, by using random plasma glucose ≥11.1 mmol/L in the presence of symptoms of 
diabetes, OGTT or glycated hemoglobin (HbA1c). Asymptomatic individuals with a single 
abnormal value will have to repeat the test within 2—4 weeks to confirm the T2D diagnosis. The 
secondary endpoints include changes in HbA1c, body weight, BMI, waist, and thigh 
circumference, body composition, insulin sensitivity, including Matsuda Index (27), glucose 
tolerance assessed by area under the curve during OGTT, blood pressure, serum lipids, C-reactive 
protein, liver enzymes, perceived quality of life and work ability, habitual well-being, sleep, chronic 
stress, and subjective appetite sensations. Other endpoints assessed by sub-group studies include 
liver fat content using magnetic resonance imaging (MRI) and proton magnetic resonance 
spectroscopy (H-MRS); colorectal cancer risk assessed from faecal markers; gut microbiome 
community assessment from faecal collections; maximal oxygen uptake capacity (VO2 max); urine 
metabolite profiles using metabolomic techniques and food reward outcomes. 
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Study setting and design 
The PREVIEW intervention study for adult participants has eight study sites:  University of 
Copenhagen (Denmark), University of Helsinki (Finland), University of Maastricht (The 
Netherlands), University of Nottingham (UK), University of Navarra (Spain), Medical University of 
Sofia (Bulgaria), University of Sydney (Australia) and University of Auckland (New Zealand). The 
36-month intervention consists of two phases (FIGURE 1): a 2-month period of rapid weight 
reduction achieved using a commercial low-calorie diet (about 800 kcal/day), followed by a 34-
month randomised lifestyle (diet and physical activity) intervention phase for weight loss 
maintenance. 
 
 
 
 
 
 
 
 
 
 
FIGURE 1. PREVIEW intervention: the general study design 
 
Clinical investigation days (CID) are conducted throughout the intervention, from CID1 (baseline) 
to CID7 (end of trial). At CID visits, anthropometry, blood tests and questionnaires are performed 
and collection of completed diet records, accelerometers, and 24-h urine samples is done. 
Adverse (AE) and serious adverse events (SAE) and concomitant medications are recorded. In 
addition, a total of 17 group visits, leaded by instructors, are held throughout the trial to support 
lifestyle modification. The CID assessments and group visits are conducted within University 
settings or associated Clinics. Participants follow the diet and physical activity counselling advice 
in a “real-life” setting without daily supervision from researchers. 
  
Participants, recruitment and randomisation               
The inclusion criteria were: age 25 – 70 years (from mid 2013 to mid 2014 individuals aged 25—45 
and 55—70 years were enrolled, and from mid 2014 onwards additionally age-group 45—54 
years); BMI >25 kg/m2; pre-diabetes confirmed by an OGTT using ADA criteria (13): (i) IFG, with 
venous plasma glucose concentration of 5.6 – 6.9 mmol/l when fasted, and/or (ii) IGT, with venous 
plasma glucose concentration of 7.8 – 11.0 mmol/l at 2 h after oral administration of standard 75 
g glucose dose, and fasting plasma glucose <7.0 mmol/l.  The main exclusion criteria were T2D, 
and any illness and/or medication with known or potential effect on compliance (e.g. unable to 
follow the physical activity program) or the main outcomes. A complete list of inclusion and 
exclusion criteria is presented as Supplementary Table 1. 
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TABLE 1. Description of the PREVIEW dietary interventions 
 
Higher protein (25 E%
a
) 
Moderate carbohydrate (45 E%) 
Low GI
b
 (<50) diet 
Moderate protein (15 E%) 
Higher carbohydrate (55 E%) 
Medium GI (>56) diet 
Comparison between 
the groups 
 Protein intake higher 
 Carbohydrate intake lower  
 GI lower 
 Protein intake lower  
 Carbohydrate intake higher  
 GI medium 
Food items with 
increased use (relative 
to the other group) 
 Whole-grain cereals with low GI 
 Pasta 
 Low-fat dairy  products 
 Poultry 
 Fish 
 Legumes 
 Whole-grain cereals with 
moderate/high GI, e.g. bread 
 Potatoes, sweet potatoes, 
couscous, rice 
 Bananas 
Similar use  Most fruits and vegetables 
 Vegetable oils, margarine 
 Red meat (decreased in both) 
 Sugar-sweetened beverages (decreased in both) 
a 
E%, percentage of energy; 
b 
GI, glycaemic index 
Participants were recruited using multiple methods across the eight study sites, e.g., newspaper 
advertisements, newsletters, radio and television advertisements/interviews, and direct contact 
with primary and occupational health care providers. Interested individuals were contacted for the 
pre-screening. In the interview, inclusion and exclusion criteria were queried, including the Finnish 
Diabetes Risk Score (28) assessment. Potential participants were given written and oral 
information. Signed informed consent was required prior to commencement of laboratory 
screening. The laboratory screening comprised measurements of weight, height, resting blood 
pressure, electrocardiography (in those aged 55 y or more), and an OGTT. A fasting blood sample 
was collected from the ante-cubital vein for later assessment of full inclusion and exclusion 
criteria, whilst glucose concentration was immediately analysed at each study site (HemoCue™, 
Angelholm, Sweden; Reflotron™, Roche diagnostics, Switzerland; or EML105 Radiometer, 
Copenhagen). Participants were then given a standard glucose drink (75 g glucose, dissolved in 
300 ml water), which they had to take within 3—5 minutes, and a second venous blood sample 
was collected after 2 h.  No other food or drinks or smoking were allowed and participants were 
required to remain sedentary during the test. The 0 and 2 h glucose concentration were used to 
identify those with pre-diabetes.  Potentially eligible participants had fasting blood samples 
analysed to assess safety with haemoglobin, creatinine and alanine (ALT)/aspartate transaminase 
(AST). Upon confirmation of eligibility, participants were enrolled into the trial and randomised to 
one of the four treatment groups. Randomisation was stratified by gender and age group (25—
45, 46—54 and 55—70 y), and sequentially assigned from each stratum to different interventions, 
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hence, securing an even distribution of gender and age group over the four intervention arms in 
each centre.  
Low-calorie diet (LCD) 
The trial started with a 2-month (8-wk) weight reduction program using a commercial LCD, with a 
requirement to lose >8% initial body weight in order to continue to the weight maintenance 
phase. The LCD consisted of 3.4 MJ (800 kcal), 15-20 E% fat, 35-40 E% protein (84 g protein) and 
45-50 E% CHO. The daily diet comprised of 4 x 40 g Cambridge Weight Plan® meal replacement 
sachets (Cambridge Weight Plan Ltd, UK), three of which were dissolved in 250 ml low fat milk or 
similar lactose-free alternatives and one in 250 ml water. Energy-free drinks were permitted. 
Moreover, a maximum of 400 g of non-starchy, low CHO vegetables such as lettuce, asparagus, 
broccoli, celery, cucumber, mushrooms, radish, tomato and watercress could be consumed. 
During the LCD, participants attended group visits at weeks 2, 4, 6, 8. Body weight, AE, SAE and 
concomitant medications were recorded, LCD sachets dispensed, and dietary and behavioural 
instructions given. No specific instructions on physical activity were given during the LCD weight-
reduction phase. Upon completion of the two months (CID2), participants who failed to reach the 
target weight reduction (i.e. >8% of initial body weight) were excluded from the intervention.  
Weight maintenance phase: intervention diets 
The two intervention diets are described in TABLE 1. The moderate protein (MP) diet is based on 
the DPS-dietary advice (14) aiming to reach a moderate protein (15 E%) and higher CHO (55 E%) 
macronutrient distribution with at least moderate dietary GI (>56), following current 
recommendations for prevention of T2D (17). The (HP) diet has a higher protein (25 E%) and 
moderate CHO (45 E%) distribution with lower dietary GI (<50), based on the most successful 
weight-loss maintenance diet in the DiOGenes study (19). Protein intake is higher and CHO intake 
is lower than the recommended range for prevention of T2D (16,17). Both intervention diets are 
moderate in fat (30 E%) and the target macronutrient profile and food choices are supported by 
evidence for prevention of weight gain and/or T2D (8,23). Notably, increased intake of sugar-rich 
foods or refined grains is not encouraged as a means to reach the higher CHO level, nor is 
increased consumption of red meat encouraged within the higher protein diet. The diets are 
consumed ad libitum with respect to energy, with no provision of an individual target for daily 
energy intake. Self-monitoring of total energy consumption is not required. However, participants 
are instructed about controlling portion sizes of specific food types in order to achieve the 
macronutrient and GI prescriptions, and in self-monitoring and adjustment of portion sizes in 
general, in order to maintain their body weight loss. They are also encouraged to follow a regular 
meal pattern. Additional weight reduction is allowed, but without anything other than adherence 
to the maintenance diet and physical activity regimens. The participants are given examples of 
daily eating plans with foods in appropriate proportions to reflect the macronutrient and GI 
requirements of the two interventions. A food-exchange list assists in self-selected variety, whilst 
preserving the required macronutrient and GI levels. Cooking books (one for each diet) with 
recipes suitable for all countries were specifically prepared for PREVIEW.  
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Weight maintenance phase: physical activity programmes 
The trial has two physical activity interventions with a similar target for energy expenditure (>4.2 
MJ/wk, >1000 kcal/wk), comprising high-intensity (HI) exercise or moderate-intensity (MI) 
exercise, as shown in TABLE 2. Measured heart-rate using a heart-rate monitor or wrist palpation, 
and/or perceived exertion using the Borg scale (29) are the principal methods of controlling the 
intensity. The participants may choose from several exercise options with similar level of 
metabolic turnover (energy expenditure divided by resting metabolic rate, i.e. MET values). The 
specific advice is based on the U.S. Centers for Disease Control and Prevention (CDC) 
recommendations of 75 min high-intensity (HI) or 150 min moderate-intensity (MI) physical 
activity weekly (30). We developed a leaflet and other written instruction materials for the two PA 
groups. Physical activity is generally not supervised by the PREVIEW team, but participants are 
allowed to join supervised exercise groups of their own choice. A critical issue in PREVIEW is that 
many participants may be morbidly obese (BMI>40) and therefore their ability to cope with a 
high-intensity exercise program is likely to be limited and even risky. We addressed this point 
during the recruitments by specifically asking about perceived competence in coping with our 
program, and by ECG in all volunteers aged >55 years. Moreover, significant weight reduction 
(>8% of baseline body weight) during the first 2 months’ LCD period will simultaneously decrease 
also the cardiovascular risks. The flexibility of our exercise program (only target energy 
expenditure is specified, the modes of exercise are due to the participant) is also likely to improve 
safety and adherence. 
Group visits and the behavioural modification program 
Group visits (8-12 individuals), are conducted throughout the three year intervention to deliver 
the behaviour modification information in relation to diet and physical activity (31). There are 17 
group visits, each 1-2 hours, with decreasing frequency as the trial progresses. The behaviour 
modification programme is developed based on theories and evidence from health psychology 
and behaviour change (32–34). For example, participants’ beliefs about the consequences of 
behaviour (i.e. outcome expectancies), their intention to change their behaviour in the long run, 
and their belief in their ability to achieve the behaviour change goals (self-efficacy) are relevant 
predictors of successful behaviour change. Counsellors may apply respective behaviour change 
techniques (35) that are scheduled to common stages of behaviour change (36). At the beginning 
of the weight-maintenance phase (i.e. month 2), the participants are instructed on how to plan, to 
start and to follow the physical activity programme. In the group sessions, the participants are 
also instructed on basic principles of increasing physical activity and in motivational and self-
regulative behaviour techniques to overcome barriers to exercise and behaviour modification. 
Stretching and home-based muscle-conditioning exercises are also supervised in a group-based 
session accompanied with written educational material (31).  
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TABLE 2. Description of the physical activity interventions 
 High-intensity  
physical activity (HI) 
Moderate-intensity physical 
activity (MI) 
Heart rate 76-90% HRmax
a
 or 61-80% HRR
b
 60-75% HRmax or 45-60% HRR 
Examples of activities  
(these may vary depending 
on the fitness level of the 
participant) 
 Bicycling, vigorous effort 
 Strenuous ball games 
 Aerobics with very vigorous 
effort, e.g. with extra weights 
 Jogging>8 km/h 
 Swimming, vigorous effort 
 Cross-country skiing 
 Bicycling, moderate effort 
 Leisurely ball games 
 Most conditioning exercises 
(aerobic, power yoga, etc.) 
 Brisk walking (4-6 km/h) 
 Swimming, recreational 
 Downhill skiing 
Weekly duration (in total) at least 75 min at least 150 min 
Recommended weekly 
frequency 
2-3 times 3-5 times 
Daily duration (guideline) 25-40 min 30-50 min (may be broken down 
into shorter sessions) 
Additional exercises  Muscle conditioning exercises, by using own weight: twice weekly at 
home, 15-20 min per session.  
 Stretching: twice weekly, 15-20 min per session 
  
a 
HRmax = max heart rate, defined as 220 – age (220 in children under 16 y) 
  
b 
HRR = heart rate reserve, defined as the difference between measured resting HR and 
estimated HRmax  
Collection of data and description of analyses 
Data are collected from biological specimens (blood, urine, faecal), self-administered records and 
questionnaires, and an activity-monitoring device (Actigraph GT3X accelerometer) (see TABLE 3 
with a description of timing). The CID’s are scheduled for a specific week and the aim is to make 
the measurements as precisely as scheduled. To accommodate as complete a data collection as 
possible we allow the following visit windows: month 2: -3 to +5 days; month 6: +1 weeks; month 
12: +2 weeks; the remaining measurement points: +4 weeks. Blood samples are initially stored 
locally at -80
o
C, then transported and analysed centrally at the National Institution for Health and 
Welfare (THL) in Helsinki, Finland. Diet records are analysed at each site using local food 
composition data and software. If available, local GI data for individual food items are used, and 
when not available, generic global GI data are used. Accelerometer data are downloaded at local 
sites, and collated and analysed centrally at the Swansea University, Wales, UK. All questionnaires 
used in PREVIEW were prepared in English, then translated into the local language in Finland, 
Denmark, The Netherlands, Spain and Bulgaria using authorized translators. A second authorized 
translator then back-translated the local versions to English, with this iterative process repeated 
until a final version of sufficient quality was obtained.   
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Data management 
All data are stored in a central project database at the University of Copenhagen. The central 
database ensures standardized handling and storing of data and the possibility for easy extraction 
and delivery of data both within and after the official project period (2013-2018). Currently, the 
database receives input from four data sources on a regular basis: 1) All immediate data 
measured (e.g. anthropometrics, blood glucose) and interviewed (e.g. use of medication) during 
the CID’s and entered into OpenClinica server (electronic Case Report Form); 2) Data on social-
cognitive determinants of behaviour, on cultural and socio-demographic as well as socio-
economic components are collected by the Questionnaire Delivery Platform (QDP), designed for 
PREVIEW by NetUnion. The participants enter their own data into the QDP. A paper version of the 
questionnaires is also available. 3) Physical activity is reported using the Baecke inventory, and an 
electronic Physical Activity Log (PAL), designed by Swansea University, University of Stuttgart, and 
implemented by NetUnion. 4) The Central Lab at the National Institute for Health and Welfare 
(THL) enters all laboratory analyses into the data hub. Data from analyses of the ActiGraph data 
accelerometers, from food diaries and from the maximal oxygen uptake (VO2max) analyses are 
imported from all sites. 
Governance and quality management 
The intervention trial is led by Prof. Fogelholm at the University of Helsinki, in collaboration with 
the project coordinator, Prof. Raben at the University of Copenhagen. In this large, international 
multi-centre trial, we are collaborating intensively to ensure data collection of high quality and 
consistency of the intervention across all sites. Specific working groups were formed with relevant 
site representatives. The purpose of these working groups is to discuss and agree on questions 
related to dietary topics, physical activity, data management, and other methodological and 
medical issues. During the recruitment phase, principal investigators from each centre 
participated in a monthly teleconference, which continues at regular intervals throughout the 
intervention.The core personnel for each site meet annually at a 3-day General Assembly for the 
full PREVIEW consortium. PREVIEW has a website (http://previewstudy.com/) with both public 
access and restricted area for the PREVIEW researchers.An electronic trial master file with relevant 
documents has been designed and is maintained by the University of Copenhagen within the 
private part of the PREVIEW website. All written study material is uploaded and made available at 
the PREVIEW website private area, including the protocol and amendments, standard operation 
procedures (SOPs), and instruction materials for the intervention subjects, in order ensure that 
comparable methods are followed across individual sites. The SOPs are reviewed and revised as 
needed and also new SOPs are prepared, if necessary.Representatives from each intervention site 
participated in two training sessions, each of 2 – 3 days duration, in 2013. One session focussed 
on the main study protocol, the CID protocols and all outcome measurements (University of 
Copenhagen),. The other session focused on instructor training in group counselling (behaviour 
change) methods (University of Stuttgart). Attendees then trained their local staff.  
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TABLE 3. Overview of data collection methods at different Clinical Investigation Days (CID) in PREVIEW 
Outcome Data collection method Assessment time-points (month) 
  0 2 6 12 18 24 36 
  CID1 CID2 CID3 CID4 CID5 CID6 CID7 
Glucose tolerance/ 
diagnosis of T2D 
75 g Oral Glucose 
Tolerance Test ▪  ▪ ▪  ▪ ▪ 
Blood chemistry  
(lipid metabolism, 
glucose metabolism, 
inflammation markers, 
etc.) 
Fasting venous blood 
specimen 
▪ ▪ ▪ ▪ ▪ ▪ ▪ 
Urinary nitrogen 24-h urine collection ▪  ▪ ▪  ▪ ▪ 
Risk markers for colon 
cancer (e.g. Short 
Chain Fatty Acids) 
3-d faecal collection
a
 
▪ ▪ ▪ ▪ ▪ ▪ ▪ 
Gut microbiota Faecal spot sample
a
 ▪   ▪    
Weight, height, BMI 
and anthropometrics 
Weight; height (week 0 
and 156); waist and hip 
circumference 
▪ ▪ ▪ ▪ ▪ ▪ ▪ 
Body composition Body composition by 
DXA, BodPod or 
Bioelectrical impedance 
(BIA) 
▪ ▪ ▪ ▪  ▪ ▪ 
Blood pressure and 
resting heart rate 
Resting blood pressure 
and heart rate ▪ ▪ ▪ ▪ ▪ ▪ ▪ 
Nutrient intakes, 
dietary GI and food 
consumption 
4-d food record 
▪  ▪ ▪  ▪ ▪ 
Physical activity 7-d accelerometer, 7-d 
physical activity log, 
Baecke questionnaire 
▪  ▪ ▪  ▪ ▪ 
Maximal oxygen 
uptake 
VO2max test by 
ergometer or treadmill
b
 ▪  ▪   ▪  
Psycho-social 
mediators and 
moderators health 
behaviour 
Several questionnaires 
(listed with references 
in Supplementary Table 
2 (online only)) 
▪ ▪ ▪ ▪  ▪ ▪ 
Eating behaviour Three Factor Eating 
Questionnaire (TFEQ) ▪ ▪ ▪ ▪  ▪ ▪ 
Sleeping Epworth Sleepiness 
Scale (ESS), Pittsburgh 
Sleep Quality Index 
(PSQI) 
▪ ▪ ▪ ▪  ▪ ▪ 
Stress and mood Perceived Stress Scale 
(PSS), Profile of Mood 
Scale (POMS) 
▪ ▪ ▪ ▪  ▪ ▪ 
a
 In a subgroup (n=250) in Helsinki and Auckland 
b
 In a subgroup (n=120) in Copenhagen, Maastricht, 
Navarra and Nottingham 
C
H
A
P
T
E
R
 2
 
 
 CHAPTER 2 
24 
Statistical power and basic analyses 
The anticipated 3-y incidence of T2D in the PREVIEW trial is 21%, based on data from the Finnish 
DPS and US DPP (10, 11). The power calculation was derived for comparison of the two dietary 
interventions (HP vs. MP). It was hypothesized that a risk reduction of one quarter (1/4) in the MP 
group would reduce the incidence of T2D incidence from 21% to 16%, and that a risk reduction of 
one half (1/2) in the HP group would reduce the incidence of T2D from 21% to 10.5%. 
Consequently, the sample size required to detect this difference in T2D incidence (16% vs. 10.5%) 
was at least 649 per diet group or 1,298 participants in total (for a two-sided comparison with a 
power (1-ß) of 80% and p < .05), with a 10% drop-out during the first 10 months from month 2 
(CID2) onwards and another 20% drop-out between months 12 (CID4) and 36 (CID7). Thus, the 
number of participants needed for the intervention was 1,802. To allow an estimated drop-out of 
25% as a result of failure to lose >8% of initial body weight during the 2-month LCD period, the 
number of participants required to be enrolled into PREVIEW was initially estimated to be 2,403. 
The primary data are analysed statistically using the principle of ‘intention-to-treat’ (ITT cohort) 
and also as a completers’ cohort. A ‘completer’ is defined as a participant who has remained in 
the trial for the full three year intervention period, or who has been diagnosed with T2D before 
the end of the intervention. The primary outcome in the adults’ trial is incidence of T2D. For 
statistical analysis assessing the effect of the two diets on the T2D is ‘Semi-parametric Cox 
proportional hazards regression model’. Missing data are addressed using hot-deck imputation. 
Missing covariate information is addressed using multiple imputation. Sensitivity analyses (e.g. 
complete-case analyses without drop-outs) will be carried out to assess if censoring was 
informative or non-informative. For statistical analysis of the continuous secondary outcomes (e.g. 
blood chemistry, anthropometrics, etc.) a ‘linear mixed model’ is used. For the categorical 
outcomes (e.g. sex, educational attainment, proportion of subjects maintaining a defined weight 
loss, etc.), the type of statistical analysis is ‘logistic’ or ‘ordinal mixed-effects model’. The 
parameter of interest is the difference in odds ratio between the intervention groups. Although 
the main statistical analyses will be done by using the entire cohort, one of the most important 
stratified analyses will use an age-group (e.g. above and below 65 years) stratification. By 
comparing older against younger participants we might get new insight on whether dietary 
protein content in this respect has different effects on, e.g., body composition, weight and clinical 
variables. 
Ethical issues 
The study protocol and amendments were reviewed and approved by local Human Ethics 
Committees at all study sites. The work of PREVIEW is carried out in full compliance with the 
relevant requirements of the latest version of the Declaration of Helsinki (59th WMA General 
Assembly, Seoul, Korea, October 2008), and the ICH-GCP, The International Conference on 
Harmonisation (ICH) for Good Clinical Practice to the extent that this is possible and relevant. All 
participants provided written informed consent prior to commencing screening procedures in 
clinic. All information obtained during the trial is handled according to local regulations and the 
European Directive 95/46/CE (directive on protection of individuals with regard to the processing 
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of personal data and on the free movement of such data). The trial is registered with 
ClinicalTrials.gov, NCT01777893. 
RESULTS 
As PREVIEW is an on-going trial, only results obtained from participant screening and baseline 
phases are presented here. Screening was conducted from June 2013 to February 2015. On 
average, 35% of the pre-screened individuals were eligible for the laboratory screening. Further, 
43% of the screened participants were found to be eligible for the trial. In total, 2,326 overweight, 
pre-diabetic adults were enrolled and randomised into the trial. This was 97% of the original pre-
specified target (FIGURE 2). Approximately half of the participants were 55—70 years at baseline 
(TABLE 4). 
 
FIGURE 2. PREVIEW intervention: the subjects’ flow-chart 
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Baseline characteristics from blood biochemistry and anthropometric assessments are shown 
assigned to each intervention group in TABLE 5. The basic characteristics of the groups are 
similar. A notable feature of the participants is that the mean baseline fasting glucose 
concentration was approximately at the mid of the eligibility range, whereas the mean 2-h 
glucose concentration was at the lower cut-off point. According to the OGTT laboratory data, 
1389 (62%) of all participants had increased fasting glucose at baseline, 506 (23%) had impaired 
glucose tolerance and 286 (13%) had both of these pre-diabetic indicators. At baseline (CID1), 25 
participants (1%) – who all had been diagnosed with pre-diabetes at screening – were not 
diagnosed with pre-diabetes anymore. The prevalence of pre-diabetes described above were not 
significantly different between the four study groups.   
TABLE 4. Number and age distribution of participants recruited for the PREVIEW intervention trial  
 
 
Site 
Pre- 
screened 
(n) 
 
Screened 
(n) 
 
Randomised  
(n) 
 
Men  
(n) 
 
Women  
(n) 
Age  
25-45 yrs  
(n) 
Age  
46-54 yrs  
(n) 
Age  
55 -70 yrs 
(n) 
Mean age  
yrs (SD) 
UCPH 2061 908 379 159 220 86 62 233 54.2 (10.9) 
HEL 1269 633 289 88 201 39 33 221  58.2 (8.9) 
UM 675 553 203 94 109 42 17 145 56.6 (10.0) 
UNOTT 3914 979 264 102 162 95 42 133 51.6 (12.0) 
UNAV 1740 732 307 93 214 145 82 93 47.5 (10.6) 
MU 1190 488 368 87 281 190 7 158 47.8 (12.0) 
UNSYD 3108 595 195 56 139 59 36 102 53.0 (10.8) 
UOA 1654 584 321 77 244 156 47 103 47.0 (11.4) 
Total 15,611 5,472 2,326 756 1,570 812 326 1,188 51.6 (11.6) 
Abbreviations for study sites: UCPH = University of Copenhagen (Denmark); HEL = University of 
Helsinki (Finland); UM = Maastricht University (The Netherlands); UNOTT = University of Nottingham 
(UK); UNAV = University of Navarra (Spain);  MU = Medical University of Sofia (Bulgaria);  UNSYD = 
University of Sydney (Australia); UOA = University of Auckland (New Zealand). 
DISCUSSION 
To our knowledge, PREVIEW is the first trial of its kind comparing two potentially effective 
interventions, a novel higher protein/low GI diet vs. current best practice moderate protein, higher 
CHO/moderate GI diet, in order to determine whether there is a more efficient lifestyle strategy to 
prevent T2D. Moreover, previous studies have neither used an effective weight-loss phase by LCD 
as a start of the intervention, nor a multi-country design. 
Our inclusion criteria for “pre-diabetes” differed from the Finnish DPS. Here, IGT was an 
unconditional requirement without limits for IFG (14). In the US DPP, both IGT and IFG were 
required (37) and the lower limit for IFG was 5.3 mmol/l (vs. 5.6 mmol/l in PREVIEW). It is unclear if 
the differences in diagnostic criteria between these studies have any major effects on the 
outcome.  
In addition to the diagnostic cut-offs per se, also the distribution of results within the diagnostic 
criteria (i.e., above the lower and below the upper cut-off points) may have an effect on the 
outcome (38). In PREVIEW, a majority of the subjects were eligible due to higher fasting blood 
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glucose, rather than impaired glucose tolerance (higher 2-h value). A small proportion (1%) was 
not diagnosed anymore with pre-diabetes at baseline. This may be explained by change of 
method (HemoCue™ or Reflotron™ at screening, laboratory assessment at baseline), to normal 
day-to-day variance in the assessed variables, or to change in lifestyle after being accepted as a 
participant to PREVIEW. For future studies of T2D prevention, a single measurement of HbA1c, 
which is becoming standard clinical practice in many countries may save both time and costs (39). 
Still, there remains some controversy as to the utility of HbA1c when compared with standard 
OGTT as a diagnostic tool (40). 
TABLE 5. Number of participants, age, anthropometric results, blood chemistry and blood pressure for 
all intervention groups, assessed at baseline (CID1) before weight reduction. The results are shown as 
mean (±SD).  
 HP: Higher protein (25 E%) 
Moderate carbohydrate (45 E%) 
Low GI (<50) diet 
MP: Moderate protein (15 E%) 
Higher carbohydrate (55 E%) 
Medium GI (>56) diet 
 Moderate-intensity 
physical activity  
High-intensity 
physical activity  
Moderate-intensity 
physical activity  
High-intensity 
physical activity  
No. (men/women) 556 (184/372) 556 (177/379) 559 (180/379) 553 (179/374) 
Age, years 51.6 ± 11.5 51.8 ± 11.7 51.4 ± 11.2 51.4 ± 11.8 
Anthropometrics     
Height, cm 168 ± 9 168 ± 9 168 ± 9 168 ± 10 
Weight, kg 99.3 ± 20.8 100.6 ± 21.0 101.6 ± 22.6 98.7 ± 20.9 
Body Mass Index, kg/m
2
 35.1 ± 6.5 35.6 ± 6.7 35.7 ± 6.6 35.0 ± 6.4 
Waist circumference, cm 109.6 ± 15.2 111.0 ± 15.3 111.1 ± 15.4 109.6 ± 14.5 
Hip circumference, cm 117.6 ± 14.5 118.8 ± 14.8 119.2 ± 13.9 117.8 ± 13.8 
Body fat (% of weight) 43.0 ± 7.5 43.5 ± 7.5 43.5 ± 7.9 43.1 ± 7.8 
Blood chemistry and blood pressure    
f P-glucose, mmol/l 6.2 ± 0.8 6.2 ± 0.6 6.2 ± 0.7 6.2 ± 0.8 
2hP-glucose, mmol/l 7.8 ± 2.3 7.7 ± 2.25 7.5 ± 2.2 7.7 ± 2.1 
fP-insulin, mU/L 13.6 ± 7.9 14.0 ± 8.7 13.2 ± 7.7 13.1 ± 7.2 
HbA1c, mmol/mol 36.6 ± 3.9 36.8 ± 3.9 36.7 ± 4.2 36.7 ± 4.0 
Cholesterol, mmol/l 5.2 ± 1.0 5.1 ± 1.0 5.3 ± 1.0 5.1 ± 1.0 
LDL cholesterol, mmol/l 3.3 ± 0.9 3.2 ± 0.8 3.3 ± 0.9 3.2 ± 0.8 
HDL cholesterol, mmol/l 1.3 ± 0.3 1.3 ± 0.3 1.3 ± 0.3 1.3 ± 0.3 
Triglycerides, mmol/l 1.5 ± 0.8 1.5 ± 0.7 1.5 ± 0.9 1.5 ± 0.8 
CRP, mg/l 5.3 ± 6.3 6.0 ± 8.7 5.2 ± 5.1 5.1 ± 7.5 
Systolic BP, mmHg 128.5 ± 15.6 129.7 ± 16.2 128.7 ± 16.3 129.3 ± 15.5 
Diastolic BP, mmHg 78.2 ± 10.9 77.6 ± 11.2 78.4 ± 11.5 78.3 ± 10.7 
GI = glycaemic index; BP = blood pressure 
PREVIEW is a much larger trial than both the Finnish DPS (n = 522) (11) and Chinese Da Qing 
study (n = 577) (9), although smaller than the DPP (n = 3,234) (10). However, in the DPP a third of 
the participants received ‘Metformin’ in addition to dietary advice, hence the number of 
participants without medical treatment, but adhering to lifestyle intervention (diet and physical 
activity) was 2,161 which is similar to PREVIEW.  Of the above interventions, the geographical and 
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ethnic variation is greatest in PREVIEW. The age-range of participants in DPP and DPS was 33-67 
years, slightly narrower than in PREVIEW, but the mean age of participants is similar across the 
studies (50-55 years). The large proportion of older participants in PREVIEW, (> 55 years), was 
expected since the risk for T2D increases with age (2), and due to the growing health 
consciousness of this age group, many of whom are retired and have the time to participate in a 
demanding intervention. The smaller proportion of middle age-adults is also explained by later 
initiation of recruitment in this age group, compared with younger and older participants. In 
general, finding an adequate number of pre-diabetic subjects was a real challenge in most 
countries, given the “hidden” status of this condition. Thus, recruitment took about 3 times as 
long as planned from the beginning of the project.  
One major challenge in PREVIEW is related to adherence to the diet and physical activity 
programs. The HP-diet is novel and, with the higher protein content, also somewhat outside the 
current boundaries of nutritional guidelines (41, 42). Whether the HP diet results in better 
adherence than the MP diet with high CHO and whole-grain cereal intakes is one of the key 
interests in PREVIEW. Nutrient intakes and food consumption patterns will be assessed in 
PREVIEW by repeated 4-d diet-records. The poor accuracy of dietary assessment is well known 
(43), but it is expected that the difference in dietary protein and CHO intakes should be 
sufficiently large to be detected using this method. Moreover, protein intake is verified using 24h 
urinary nitrogen excretion (44). 
It may be more difficult to create a verifiable difference for GI than for protein-to-CHO ratio. 
Whilst GI values of foods have been shown to provide a good summary of postprandial glycaemia 
(45), difficulties in attributing GI values to foods for which there are no validated data available 
may add to variability (46), particularly in a multi-centre intervention such as PREVIEW. In 
DiOGenes, the reported observed difference in mean dietary GI was small (56 vs. 60 units) (19) 
which increases the requirements of precision. 
The physical activity intervention in PREVIEW is not a supervised training programme. Participants 
are expected to integrate activity into their daily lives and use local opportunities to achieve their 
goals. To improve adherence, there is flexibility with the type of activities chosen. A combination 
of measures of physical activity is used to analyse the compliance to the type of intervention and 
our methods allow a description of activities that were used to achieve this. It is probable that the 
HI-program will be more challenging in the long-term. Warming-up, cooling-down, muscular 
conditioning exercises and stretching are carefully explained to the participants in order to 
decrease the risk for injuries. It should be noted that the HI-program in PREVIEW is not high-
intensity interval-training (HIIT). While there are some data on potential benefits from HIIT on 
cardiovascular function and glucose metabolism (47), we considered the data on feasibility and 
long-term maintenance of this kind of training still too limited.  
In addition to good compliance of the programmes, keeping the drop-out rate as low as possible 
will be challenging. Frequent contact with the research staff is one way to reduce the drop-out 
rate.  However, PREVIEW has been planned to study how behavioural change is realized under 
‘real life’ conditions, and hence the fading visit design where group visits are infrequent during 
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years ‘2’ and ‘3’ of the intervention. Adherence is encouraged through a number of practices, 
including use of specific behaviour change techniques (31), such as implementation intentions, or 
Facebook groups, one for each randomised group, to promote attendance at group visits and 
CIDs. In addition, the sites can also conduct general information lectures and/or physical activity 
sessions and/or send a newsletter to the participants, once or twice a year. 
Compared to DPS and DPP studies, a particular feature of PREVIEW is related to the different 
settings in which the intervention is conducted, including not only genetic background, but also 
attitudes, norms, and socio-economic features. Although the participating countries are well-
developed, considerable variations exist, e.g., regarding food attitudes and habits, as well as 
traditions of practicing physical activity. 
The unique feature in the PREVIEW intervention is the direct comparison of two potentially 
efficacious diet and physical activity intervention programs. Hence, PREVIEW has a clear potential 
to identify a recommended optimal diet and physical activity programme to prevent T2D, a 
programme which is also suitable across different countries. It is also possible, however, that 
PREVIEW data will demonstrate that there are several, equally efficacious alternatives. Clearly, 
both answers are important from a public health viewpoint.  
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SUPPLEMENTARY MATERIALS  
The following are available online at www.mdpi.com/link, Table S1: Inclusion and exclusion criteria 
in the PREVIEW screening, Table S2: Questionnaires on moderators, mediators, behaviour and 
social environment. 
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ABSTRACT 
Objective  
The aim of the present cross-sectional study was to examine the association between physical 
activity (PA), sedentary time (ST) and cardio-metabolic risk in adults with pre-diabetes.  
Design and Methods  
Participants (n=2,326; 25-70 years, 67% female) from eight countries with a body mass index 
(BMI) >25 kg·m
-2
, impaired fasting glucose (IFG; 5.6–6.9 mmol·l-1) and/or impaired glucose 
tolerance (IGT; 7.8–11.0 mmol·l-1 at 2 hr) participated. Seven-day accelerometry objectively 
assessed PA levels and sedentary time.  
Results  
Multiple linear regression revealed that moderate-to-vigorous physical activity (MVPA) was 
negatively associated with homeostatic model assessment of insulin resistance (HOMA-IR) 
(standardized β = -0.078 [-0.128,-0.027]), waist circumference (WC); β=-0.177 [-0.122,-0.134]), 
fasting insulin (β=-0.115 [-0.158,-0.072]), 2-hour glucose (β=-0.069 [-0.112,-0.025]), triglycerides 
(β=-0.091 [-0.138, -0.044]) and C-reactive protein (CRP; β=-0.086 [-0.127,-0.045]). Sedentary time 
was positively associated with HOMA-IR (β=0.175 [0.114,0.236]), WC (β=0.215 [0.026,0.131]), 
fasting insulin (β=0.155 [0.092,0.219]), triglycerides (β=0.106 [0.052,0.16]), CRP (β=0.106 
[0.39,0.172]), systolic blood pressure (BP) β=0.078 [0.026,0.131]) and diastolic BP (β=0.106 [0.39,-
0.172]). Associations reported between total PA (counts·minute
-1
) and all risk factors were 
comparable or stronger than MVPA; HOMA-IR (β=-0.151 [-0.194,-0.107]), WC (β=-0.179 [-0.224,-
0.134]), fasting insulin (β=-0.139 [-0.183,-0.096]), 2-hour glucose (β=-0.088 [-0.131,-0.045]), 
triglycerides (β=-0.117 [-0.162,-0.071]) and CRP (β=-0.104 [-0.146,-0.062]).  
Conclusions  
In adults with pre-diabetes, objectively measured PA and ST were associated with cardio-
metabolic risk markers. Total PA was at least as strongly associated with cardio-metabolic risk 
markers as MVPA, which may imply that the accumulation of total PA over the day is as important 
as achieving the intensity of MVPA.  
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INTRODUCTION   
The global prevalence of diabetes among adults has almost quadrupled since 1980 to 422 million 
cases in 2014 and expected to continue to grow (1). This dramatic rise in prevalence is largely due 
to the increase in type 2 diabetes which accounts for the majority of all diagnosed cases in adults 
(1). Changes in lifestyle factors such as sedentary behaviour, insufficient PA, dietary choices and 
excess weight are important contributors in the development of type 2 diabetes (2). Physical 
activity plays an important role, independent of weight, in the prevention of type 2 diabetes 
through its effect on insulin resistance (3). Physical activity leads to the translocation of GLUT-4 
transporters to the plasma membrane increasing glucose uptake into skeletal muscle (4). 
Sedentary time has also been associated with insulin resistance and fasting triglyceride levels, 
independent of PA and obesity (5). Sedentary time is thought to affect carbohydrate metabolism 
by decreasing muscle GLUT-4 concentrations while also reducing lipoprotein lipase (LPL) activity 
and triglycerides clearance (6,7). Light activity is also associated with cardio-metabolic health and, 
together with sedentary time, occupies the majority of waking hours (8). Indeed, light-intensity 
activity substantially contributes to overall daily energy expenditure and may also mean spending 
less time in sedentary behaviours.  
Many studies reporting associations between PA, ST and cardio-metabolic risk factors are limited 
by the self-reported measures of PA and ST (9,10) which are susceptible to reporting and recall 
bias. In the limited number that have used objective measures of PA, investigations of 
international samples measured concurrently with the same protocol are lacking, little consistency 
exists with regards to the devices, wear time criteria, intensity cut points or epoch lengths used, 
thereby limiting the ability to make comparisons between these studies. Furthermore, despite 
those with pre-diabetes being at the highest risk of developing type-2 diabetes and representing 
the population at which many lifestyle interventions are targeted, few studies have described the 
relationship between PA and insulin resistance in this population.   
Typically, epidemiological research assessing the effect of PA and ST on cardio metabolic risk 
factors has been conducted in the general population (8,11,12). The few studies conducted in 
high risk populations have included participants based on a risk score questionnaire (5), family 
history of type 2 diabetes (9,13) or participants diagnosed with diabetes and pre-diabetes have 
been combined (14). Consequently, physical characteristic and metabolic parameters of study 
participants varied substantially. As a result, it is unclear to what extent reported associations 
could be inferred to individuals with pre-diabetes.  
Therefore, the purpose of this study was to quantify the relationship between objectively 
measured PA and ST with cardio metabolic health and risk of diabetes. 
METHODS  
Participants and setting  
A detailed account of the PREVention of diabetes through lifestyle Intervention and population 
studies in Europe and around the World (PREVIEW) project has been published elsewhere (15). 
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Participants were recruited into the PREVIEW project between June 2013 and February 2015. The 
PREVIEW study is a large multi-national diabetes prevention intervention being conducted at 
eight study sites: University of Copenhagen (Denmark), University of Helsinki (Finland), University 
of Maastricht (The Netherlands), University of Nottingham (UK), University of Navarra (Spain), 
Medical University of Sofia (Bulgaria), University of Sydney (Australia) and University of Auckland 
(New Zealand). 
Participants were selected through an internet-based pre-screening tool or telephone interview 
using the Finnish Diabetes Risk Score (16). A total of 15,611 individuals were contacted for pre-
screening. Potential participants were sent a written description of the trial, given verbal 
information at the study site and signed informed consent prior to a laboratory screening. The 
laboratory screening was attended by 5,472 participants and included assessment of body mass, 
stature, resting blood pressure (BP), and a 2-hour OGTT (17). Glucose concentrations were 
analysed at each study site (HemoCue™, Angelholm, Sweden; Reflotron™, Roche diagnostics, 
Switzerland; or EML105 Radiometer, Copenhagen) to identify people with pre-existing diabetes.  
At the end of this process, 2,326 participants met the following inclusion criteria and found 
eligible to take part in the study: age 25 – 70 years; BMI >25 kg/m2; pre-diabetes confirmed at 
OGTT. Pre-diabetes was defined, in line with WHO/IDF and ADA criteria (17), as either (i) IFG, with 
venous plasma glucose concentration of 5.6 – 6.9 mmol·l-1 and/or (ii) IGT, with venous plasma 
glucose concentration of 7.8 – 11.0 mmol·l-1 at 2 hours and fasting plasma glucose <7.0 mmol·l-1. 
Participants were free of pre-existing type 2 diabetes, and any illness and/or medication with 
potential effect on compliance or the outcomes of the study. 
Measurements and procedures 
Physical activity 
Participants wore an ActiSleep+ (ActiGraph LLC, Pensacola, FL) accelerometer attached to an 
elastic waist belt worn over the right mid-axillary line. The ActiSleep+ was worn 24 h·day
-1
 for 
seven consecutive days, removing only for water-based activities. The principal output from the 
ActiSleep+ is an activity count, which represents raw accelerations that have been rescaled and 
filtered. Activity counts were collected at 100Hz and aggregated to 60-second epochs (18). Sleep 
time was determined using a fully-automated algorithm developed for use in 24-hour waist-worn 
accelerometer protocols. The algorithm produces estimates of nocturnal sleep period that are 
compared to an expert visual inspection of accelerometer trace (19). After the removal of 
nocturnal sleep episodes, participants were included in the analyses if they wore the monitor for  
≥10 hours on ≥4 days (18) including 1 weekend day (20). Mean activity count during valid wear 
time (counts·minute
-1
; CPM) has been shown to correlate well with total activity energy 
expenditure measured by the doubly labelled water technique (21) and was used as an indicator 
of total PA volume (18, 28). Troiano cut points (18) were used to determine time (minutes·day
-1
) 
spent at different  intensity categories (Sedentary <100, moderate <2,020 and vigorous <5,999 
counts per minute). Moderate and vigorous activity were summed to obtain moderate to vigorous 
physical activity (MVPA).  
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Cardio-metabolic risk factors 
In all study centres, standardized procedures were followed and measurements were performed 
by trained personnel. Self-administered questionnaires, accelerometer data and fasting blood 
samples, were collected at baseline. Blood was drawn from the vein in the antecubital fossa after 
fasting (>10 hours). Blood samples were initially stored locally at -80
o
C, then transported and 
analysed centrally at the National Institution for Health and Welfare (THL) in Helsinki, Finland 
where they were analysed for insulin, HbA1c, glucose, high sensitivity C-reactive protein (hs-CRP), 
total cholesterol, triglycerides, HDL-cholesterol (HDL-C) and LDL-cholesterol (LDL-C) 
concentrations. Insulin resistance was calculated using the homeostasis model assessment for 
insulin resistance, HOMA-IR using the equation: HOMA-IR= Fasting insulin (mU·l
-1
) x Fasting 
glucose (mmol·l
-1
) / 22.5. HOMA-IR has been validated against the gold standard 
hyperinsulinemic-euglycemic clamp technique (23). Total adiposity was assessed by dual energy 
X-ray absorptiometry (DEXA) in four (Copenhagen, Nottingham, Sydney and Auckland), 
bioelectrical impedance in 3 (Helsinki, Sofia, and Navarra) and with Bodpod (Maastricht.) in one 
site. Self-administered questionnaires assessed general and socio-economic variables, including 
ethnicity, educational status and household income. 
Statistical analysis  
Descriptive statistics (mean ± SD) were calculated for continuous variables and frequencies (%) for 
categorical variables. Two-fifths of the participants had a missing value on at least one variable, 
HOMA-IR was missing in 7.8% of all cases, while 17% of values were missing for the 
accelerometer values (CPM, MVPA, and sedentary time). Multiple imputation with fully conditional 
specification model, (Markov chain Monte Carlo) was used to impute missing values. All variables 
were included in the imputation and all variables with skewed distribution were log10 or square 
root transformed prior to imputation (24). Ten multiple imputed data sets were generated and 
pooled estimates were reported. Due to their positively skewed distribution, HDL-C, triglycerides 
hs-CRP, and waist circumference were logarithmically transformed (log10) while HOMA-IR was 
square root transformed. Separate multiple linear regression models were performed to test the 
independent association between MVPA, CPM and ST with cardio-metabolic health markers 
(HOMA-IR, fasting insulin, FPG, 2h glucose, HbA1c, waist circumference, triglycerides, total C, HDL-
C and LDL-C-) and CRP while adjusting for potential confounders. Model 1 was adjusted for age, 
sex, ethnicity (Caucasian, Asian, Black, Arabic, Hispanic or other), smoking (daily, less than weekly, 
no smoker), accelerometer wear time, intervention centre, sleep duration, body fat%, education 
level (no formal education, primary/junior school, secondary school, secondary vocational 
education, higher vocational education or university education) and household income (less than 
£9360, £9360 - £12,479.99, £12,480 - £15,599.99, £15,600 - £18,719.99, £18,720 -£22,879.99, 
£22,880 - £27,559.99, £27,560 - £32,759.99, £32,760 – £41,079.99, £41,080 – £53,559.99, £53,560 
or more per year). Model 2 was additionally adjusted for ST while MVPA was the main exposure 
variables or for MVPA when ST was the main exposure variable. Sex, age (<45.9, 46-54.9, >55 
years), BMI and intervention centre differences in the associations between MVPA, sedentary time, 
or CPM and each cardio-metabolic risk factor were tested for by adding interaction terms to the 
model. A variance inflation factor < 4 confirmed that multicollinearity was not a concern (25). 
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Square root and log-transformations were directly compared across cardio-metabolic markers, 
and results of linear regression analysis presented as standardised beta coefficients. Data were 
analysed using the Statistical Package for the Social Sciences version 22.0 (SPSS Inc., Chicago, IL, 
USA) and alpha was set to p < .05. 
 
TABLE 1 Descriptive, metabolic and physical activity characteristics of 2,326 pre-diabetic adults from 
the PREVIEW study 
 Characteristics  Female (n=1570) Male (n= 755) 
Age (years) 51.6 ± 11.6 53.5 ± 11.6 
Height (m) 1.64 ± 0.07 1.77 ± 0.07 
Weight (kg) 95.88 ± 20.33 108.87 ± 20.98 
BMI (kg·m
2
) 35.70 ± 6.76 34.55 ± 6.01 
Fat (%) 46.45 ± 5.85 36.67 ± 6.92 
Waist (cm) 107.7 ± 14.6 116.8 ± 14.5 
Systolic BP (mmHg) 126.98 ± 5.88 133.10 ± 14.8 
Diastolic BP (mmHg) 77.07 ± 11.15 80.88 ± 9.96 
Fasting insulin (mU·l
-1
) 12.53 ± 6.54 14.03 ± 6.68 
Fasting plasma glucose (mmol·l
-1
) 6.08 ± 0.67 6.33 ± 0.66 
2 h plasma glucose (mmol·l
-1
) 7.64 ± 2.21 7.73 ± 2.24 
HbA1c (mmol·l
-1
) 36.61 ± 4.03 36.73 ± 4.06 
HbA1c (%) 5.50 ± 0.37 5.51 ± 0.37 
HOMA-IR 3.44 ± 1.90 4.00 ± 2.01 
Triglycerides (mmol·l
-1
) 1.45 ± 0.77 1.62 ± 0.82 
Total cholesterol (mmol·l
-1
) 5.25 ± 0.99 5.03 ± 0.97 
HDL-cholesterol (mmol·l
-1
) 1.33 ± 0.29 1.15 ± 0.23 
LDL-cholesterol (mmol·l
-1
) 3.28 ± 0.84 3.16 ± 0.85 
CRP (mg/l) (mg·l
-1
) 4.81 ± 4.02 3.46 ± 3.35 
Accelerometer Variables   
Waking wear Time (minutes.day
-1
) 933.10 ± 83.85 928.40 ± 83.37 
Sleep (minutes.day
-1
) 474.69 ± 80.26 471.83 ± 85.16 
Sedentary (minutes.day
-1
) 579.46 ± 91.76 617.54 ± 98.06 
Light (minutes.day
-1
) 320.84 ± 82.62 280.12 ± 78.20 
Moderate (minutes.day
-1
) 25.30 ± 6.88 30.33 ± 20.33 
MVPA (minutes.day
-1
) 26.18 ± 17.03 31.58 ± 20.62 
CPM (counts.minute
-1
) 294.30 ± 96.77 297.98 ± 17.28 
Ethnicity   
Caucasian (%) 86.02 89.9 
Asian (%) 2.66 2.71 
Black (%) 1.82 1.2 
Arabic (%) 0.2 0.3 
Hispanic (%) 2.33 1.38 
Other (%) 6.61 4.25 
Smoking   
Yes (Daily) % 10.72 9.57 
Sometimes (less than weekly) (%) 3.3 2.93 
No (%) 85.98 87.48 
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TABLE 1 continued 
Education Female (n=1570) Male (n= 755) 
No formal education (%) 0.5 -- 
Primary/junior school (%) 2.1 2.8 
Secondary school (%) 15.1 14.2 
Secondary vocational education (%) 17.7 19.2 
Higher vocational education (%) 16.4 18.6 
University education 40.5 35.6 
Other 7.6 9.7 
Household income per year (%)   
less than £9360, (%) 8.8 5.3 
£9360 - £12,479.99 (%) 5.8 2.9 
£12,480 - £15,599.99 (%) 5.1 2.5 
£15,600 - £18,719.99 (%) 6.5 3.5 
£18,720 -£22,879.99 (%) 5.7 4.6 
£22,880 - £27,559.99 (%) 8.1 5.9 
£27,560 - £32,759.99 (%) 10.6 8.1 
£32,760 – £41,079.99 (%) 11.2 10.9 
£41,080 – £53,559.99 (%) 13.4 14.2 
£53,560 or more (%) 24.9 42 
BMI, body mass index; BP, blood pressure; HbA1c, haemoglobin A1c; HOMA-IR, homeostatic model 
assessment of insulin resistance; HDL, high density lipoprotein; LDL, low density lipoprotein; CRP, C-
reactive protein; MVPA, moderate to vigorous physical activity; CPM, counts per minute. 
RESULTS  
TABLE 1 displays the descriptive physical and biochemical characteristics of the 2,326 participants 
(32% male, age 52.2 ± 11.5 years). Waking accelerometer wear time was 928.40 ± 83.37 and 
933.10 ± 83.85 minutes/day for men and women respectively. Mean ST was 617.54 ± 98.06 for 
men and 579.46 ± 91.76 min/day for women. Mean MVPA was 31.58 ± 20.62 min/day for men 
and 26.18 ± 17.03 min/day for women. Only 50% of participants met the recommended 
guidelines of 30 minutes of MVPA per day (26). TABLES 2, 3 and 4 show the standardized 
regression coefficients of CPM, MVPA, and ST with the cardio metabolic risk factors. 
Counts per minute 
TABLE 2 shows the standardized regression coefficients of CPM, with the cardio metabolic risk 
factors. After adjusting for age, sex, ethnicity, smoking, accelerometer wear time, intervention 
centre, sleep duration, body fat%, education level and household income, CPM had significant 
inverse associations with HOMA-IR, waist circumference, fasting insulin, 2-hour glucose, 
triglycerides and CRP and a positive association with HDL-cholesterol.  
TABLE 3 shows the standardized regression coefficients for MVPA with the cardio metabolic risk 
factors. In model 1, adjusted for age, sex, ethnicity, smoking, accelerometer wear time, 
intervention centre, sleep duration, body fat%, education level and household income, MVPA was 
significantly and negatively associated with HOMA-IR, waist circumference, fasting insulin, 2h 
glucose, triglycerides and CRP), and positively associated with HDL-cholesterol. After adjusting for 
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ST in model 2, the association with HDL-cholesterol was lost. Associations with other biochemical 
factors were slightly attenuated but all remained significant.  
TABLE 2 Standardized β coefficients for associations between total physical activity (counts·minute
-1
) 
and cardio metabolic risk factor 
Characteristics B 95% Confidence interval p R
2
 
Waist (cm) -0.179 (-0.224, -0.134) 
*** 
0.21 
Systolic BP (mmHg) -0.033 (-0.074, 0.007) 
 
0.19 
Diastolic BP (mmHg) -0.020 (-0.057, 0.017) 
 
0.34 
Fasting insulin (mU·l
-1
) -0.139 (-0.183, -0.096) 
*** 
0.13 
Fasting glucose (mmol·l
-1
) -0.028 (-0.074, 0.018) 
 
0.16 
2-h plasma glucose (mmol·l
-1
) -0.088 (-0.131, -0.045) 
*** 
0.11 
HbA1c (%) -0.049 (-0.098, -0.001) 
 
0.13 
HOMA-IR -0.151 (-0.194, -0.107) 
*** 
0.13 
Triglycerides (mmol·l
-1
) -0.117 (-0.162, -0.071) 
*** 
0.08 
Total cholesterol (mmol·l
-1
) -0.007 (-0.053, 0.038) 
 
0.10 
HDL (mmol·l
-1
) 0.088 (0.048, 0.129) 
*** 
0.19 
LDL (mmol·l
-1
) 0.002 -0.045, 0.049) 
 
0.06 
CRP (mg·l
-1
) -0.104 (-0.146, -0.062) 
*** 
0.21 
Adjusted for age, sex, ethnicity, smoking, household income, education level, body fat%, wear time, 
sleep time and intervention centre. *P<0.05; **P<0.01; ***P<0.001 
MVPA  
Sedentary time   
TABLE 4 shows the standardized regression coefficients for ST with the cardio metabolic risk 
factors. In model 1, adjusted for age, sex, ethnicity, smoking, accelerometer wear time, 
intervention centre, sleep duration, body fat%, education level and household income, ST was 
positively associated with waist circumference, systolic BP, diastolic BP, mean arterial pressure, 
fasting insulin, 2 h glucose, HOMA-IR, triglycerides and CRP, and negatively associated HDL. After 
adjusting for MVPA in model 2, associations with 2-hour plasma glucose were no longer 
significant. Fasting plasma glucose, total cholesterol and LDL-cholesterol were not associated with 
any of our exposure variables. Two-way interactions indicate that associations between MVPA and 
fasting insulin were greater in the older age group (table 3). We did not observe any significant 
sex, centre, or BMI interactions between measures of PA or ST and any cardio metabolic risk 
factors.  
CONCLUSIONS 
This study investigated the associations between objectively measured PA and ST and metabolic 
variables in a worldwide sample of overweight and obese adults (BMI >25 kg/m
2
) with pre-
diabetes
 
confirmed through an OGTT (27). To our knowledge this is the first international 
investigation of associations between objectively measured PA and ST with cardio-metabolic risk 
factors in a population that exclusively meet the criteria for pre-diabetes (IFG 5.6-6.9 or IGT 7.8-11 
(mmol·l
-1
). Previous studies conducted in high risk populations have included participants based 
on a risk score questionnaire (5), family history of type 2 diabetes (9,13) or participants with 
diabetes and pre-diabetes have been combined (14). Consequently, physical characteristics and 
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metabolic parameters reported in these studies varied substantially from the present study. In our 
population of participants with pre-diabetes, MVPA was negatively associated with HOMA-IR, 
waist circumference, fasting insulin, 2h glucose, triglycerides and CRP after accounting for 
potential confounders, sleep duration and sedentary time.  
TABLE 3 Standardized β-coefficients for associations between MVPA (min·day
-1
) and cardiometabolic 
risk factors 
Characteristics  B 95% Cl  p R
2
 
Model 1   
 
 
Waist (cm) -0.177 (-0.122, -0.134)
 ***
 0.20 
Systolic BP (mmHg) -0.005 (-0.047, 0.083)  0.19 
Diastolic BP (mmHg) -0.007 (-0.044, 0.031)  0.34 
Fasting insulin (mU·l
-1
) -0.115 (-0.158, -0.072) 
***
 0.12 
Fasting glucose (mmol·l
-1
) -0.028 (-0.072, 0.017)  0.16 
2 h plasma glucose (mmol·l
-1
) -0.069 (-0.112, -0.025) 
**
 0.11 
HbA1c (%) -0.046 (-0.096, 0.004)  0.13 
HOMA-IR -0.122 (-0.166, -0.078) 
***
 0.12 
Triglycerides (mmol·l
-1
) -0.091 (-0.138, -0.044) 
***
 0.08 
Total cholesterol (mmol·l
-1
) -0.010 (-0.056, 0.035)  0.10 
HDL (mmol·l
-1
) 0.055 (0.009, 0.101) 
*
 0.18 
LDL (mmol·l
-1
) 0.002 (-0.044, 0.048)   0.06 
CRP (mg·l
-1
) -0.086 (-0.127, -0.045) 
***
 0.26 
Model 2    
 
 
Waist (cm) -0.127 (-0.173, -0.081) 
*** 
0.22 
Systolic BP (mmHg) 0.020 (-0.026, 0.067) 
 
0.20 
Diastolic BP (mmHg) 0.011 (-0.03, 0.053) 
 
0.35 
Fasting insulin (mU·l
-1
) main effect -0.078 (-0.127, -0.03) 
** 
0.13 
25-45.9 years(reference)  - - - - 
46.0 -54.9 years 0.025 (-0.120, 0.170) 
 
0.13 
55.0 -71 years -0.098 (-0.195, -0.001) 
* 
0.13 
Fasting glucose (mmol·l
-1
) -0.014 (-0.063, 0.035) 
 
0.17 
2 h plasma glucose (mmol·l
-1
) -0.053 (-0.1, -0.006) 
* 
0.11 
HbA1c (%) -0.036 (-0.095, 0.023) 
 
0.13 
HOMA-IR -0.080 (-0.129, -0.031) 
** 
0.14 
Triglycerides (mmol·l
-1
) -0.067 (-0.117, -0.017) 
** 
0.08 
Total cholesterol (mmol·l
-1
) -0.013 (-0.064, 0.037) 
 
0.10 
HDL (mmol·l
-1
) 0.028 (-0.081, 0.383) 
 
0.19 
LDL (mmol·l
-1
) 0 (-0.053, 0.052) 
 
0.06 
CRP (mmol·l
-1
) -0.061 (-0.108, -0.015) 
** 
0.27 
Model 1 adjusted for age, sex, ethnicity, smoking, household income, education level, body fat%, wear 
time, sleep time, and intervention centre. Model 2 additionally adjusted for ST. *P<0.05; **P<0.01; 
***P<0.001 
Our study also demonstrated that total PA volume (counts·minute
-1
) at least as strongly 
associated with the aforementioned risk factors as MVPA. Before controlling for sedentary time in 
model 2, total PA volume also accounts for greater variance in cardio-metabolic risk factors than 
MVPA. Hence, it appears that in this population although both are significant, the accumulation of 
total PA over a day is a stronger indicator of insulin resistance and some related cardio metabolic 
risk factors than MVPA.  
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TABLE 4 Standardized β-coefficients for associations between ST (min·day
-1
) and cardiometabolic risk 
factors 
Characteristics  B 95% CI  p R2 
Model 1     
Waist (cm) 0.215 (0.146, 0.267)
 ***
 0.21 
Systolic BP (mmHg) 0.078 (0.026, 0.131) 
**
 0.20 
Diastolic BP (mmHg) 0.057 (0.007, 0.106) 
*
 0.35 
Fasting insulin (mU·l
-1
) 0.155 (0.092, 0.219) 
***
 0.13 
Fasting glucose (mmol·l
-1
) 0.052 -0.004, 0.108)  0.17 
2 h plasma glucose (mmol·l
-1
) 0.072 (0.015, 0.129) 
*
 0.11 
HbA1c (%) 0.047 (-0.022, 0.117)  0.13 
HOMA-IR 0.175 (0.114, 0.236) 
***
 0.13 
Triglycerides (mmol·l
-1
) 0.106 (0.052, 0.16) 
***
 0.08 
Total cholesterol (mmol·l
-1
) -0.006 (-0.062, 0.051)  0.10 
HDL (mmol·l
-1
) -0.103 (-0.165, -0.042 
***
 0.19 
LDL (mmol·l
-1
) -0.007 (-0.062, 0.048)  0.06 
CRP (mg·l
-1
) 0.106 (0.039, 0.172) 
**
 0.26 
Model 2      
Waist (cm) 0.165 (0.109, 0.221) 
*** 
0.22 
Systolic BP (mmHg) 0.086 (0.028, 0.143) 
** 
0.20 
Diastolic BP (mmHg) 0.061 (0.006, 0.116) 
* 
0.35 
Fasting insulin (mU·l
-1
) main effect 0.126 (0.055, 0.198) 
** 
0.13 
Fasting glucose (mmol·l
-1
) 0.047 (-0.014, 0.108) 
 
0.17 
2 h plasma glucose (mmol·l
-1
) 0.053 (-0.009, 0.114) 
 
0.11 
HbA1c (%) 0.034 (-0.045, 0.113) 
 
0.13 
HOMA-IR 0.145 (0.077, 0.213) 
*** 
0.14 
Triglycerides (mmol·l
-1
) 0.08 (0.023, 0.138) 
** 
0.08 
Total cholesterol (mmol·l
-1
) -0.011 (-0.074, 0.052) 
 
0.10 
HDL (mmol·l
-1
) -0.093 (-0.163, -0.022) 
* 
0.19 
LDL (mmol·l
-1
) -0.007 (-0.069, 0.055) 
 
0.06 
CRP (mmol·l
-1
) 0.083 (0.01, 0.156) 
* 
0.27 
Model 1 adjusted for age, sex, ethnicity, smoking, household income, education level, body fat%, wear 
time, sleep time, and intervention centre. Model 2 additionally adjusted for MVPA. *P<0.05; **P<0.01; 
***P<0.001 
Previous studies in populations with a family history of diabetes and newly diagnosed diabetes, 
have shown that total energy expenditure spent on PA (14), counts·minute
-1
 (13) and MVPA (9) 
were negatively associated with waist circumference, fasting serum triglycerides, systolic BP, 
fasting plasma glucose, fasting plasma insulin,  HOMA-IR and a clustered metabolic risk score. In 
agreement with our findings, Ekelund et al (13), reported that total counts·day-1 was more 
strongly associated with clustered risk and individual cardio metabolic risk factors than MVPA. In 
the general population, Balkau and colleagues (22) reported associations between MVPA and 
total PA with insulin resistance using the gold standard clamp technique for determining insulin 
sensitivity. However, after adjusting for total PA, associations with MVPA were lost (22). These 
findings, in keeping with the present study would support the hypothesis that the accumulation 
of total PA volume accounts for greater variance in insulin resistance and some related cardio 
metabolic risk factors than MVPA.   
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The present study also demonstrated that after controlling for confounders, ST is positively 
associated with waist circumference, systolic BP, diastolic BP, fasting insulin, HOMA-IR, 
triglycerides, CRP, and HDL-cholesterol independent of time spent in MVPA. In agreement with 
our findings, Henson et al (5) reported positive associations between ST, 2 hour plasma glucose, 
triglycerides and HDL-cholesterol, independent total PA in a population at risk of type 2 diabetes 
(5). Similarly, positive associations between ST, waist circumference, insulin, HOMA-IR, and HDL-
cholesterol were reported in an older sample with newly diagnosed type-2 diabetes (28). There is 
a lack of consensus on the role of ST in pathology of cardio metabolic risk factors. Some authors 
have reported that once total energy expenditure is taken into account the association between 
ST and cardio-metabolic health are lost. These findings suggest that ST reduces total energy 
expenditure by displacing other activities that are more energy costly (22,29). Other investigators 
have found that the mechanism linking ST to glucose metabolism and metabolic health differ 
from those of PA and may be related to static posture and unloading of large skeletal muscle 
groups when seated (7,30) Sedentary time is thought to affect glucose homeostasis and lipid 
metabolism by reducing muscle GLUT-4 content and insulin-stimulated glucose uptake (6) while 
also reducing  LPL activity leading to impaired triglyceride and HDL cholesterol metabolism (7).  
Further, light activity is associated with marked improvements in cardio-metabolic health (8) while 
interventions have shown that replacing ST with postural changes such as standing or light 
ambulatory activity can improve glycaemic control to a greater extent than structured exercise of 
the same energy cost (31). In the present analysis, sedentary time was associated with HDL 
cholesterol however, associations between MVPA and HDL cholesterol were lost after controlling 
for ST. Similarly, ST was positively associated with systolic and diastolic blood pressure 
independent of MVPA while no association was found between CPM or MVPA with either blood 
pressure variable. Associations between PA, ST and blood pressure variables reported by 
observation studies have been inconsistent (8,12,14). However, experimental studies in 
overweight/obese populations have suggested that a reduction of sedentary time and the 
interruption of prolonged sedentary bouts with light or moderate activity are associated with 
improved systolic and diastolic blood pressure (32).     
While physical activity guidelines continue to focus on participation in MVPA (26), our data 
demonstrated that in a population with pre-diabetes, total volume of PA was as strongly 
associated with cardio-metabolic health as MVPA. The implications of this finding may be 
important considering the levels of PA in this population. Light activity may be more readily 
adopted by individuals with pre-diabetes particularly if they are physically inactive, 
overweight/obese, or reluctant to engage in structured exercise (31).  
The lack of associations observed for all exposure variables with fasting glucose is consistent with 
previous research (5,8). This finding reflects the fact that the PA predominantly affects peripheral 
insulin sensitivity, which is responsible for lowering blood glucose levels after an OGTT when most 
of the glucose is taken up by skeletal muscle (33).  
The strengths of this study are the implementation of a 24h accelerometer wear time protocol 
that resulted in a greater mean waking wear time (15.5 hours) than many studies of a similar 
C
H
A
P
T
E
R
 3
 
 
 CHAPTER 3 
44 
nature (5,18,28). Longer monitoring duration provides greater reliability of average activity 
estimates. This approach also allowed an objective assessment of sleep time using an algorithm 
to detect sleep onset and wake time from a 24h waist worn accelerometer trace (19) This allowed 
the study team to control for the confounding effects of sleep on cardio metabolic risk factors 
(34).    
Type 2 diabetes is high on public health agendas with attention on the prevention or delay of 
diabetes onset and the management of cardio metabolic risk factors (35,36). National and 
international guidelines focus on first identifying high-risk individuals and second controlling 
modifiable risk factors such as body weight, diet, ST and PA, through targeted interventions 
(37,38). This study provides new evidence of associations between PA and ST with cardio 
metabolic markers in a population to which the results are most applicable.  
Whilst this study has numerous strengths it is also important to acknowledge its limitations. First, 
the cross-sectional design does not allow insight into the direction of causality between each 
exposure variable and markers of cardio metabolic health and, although we controlled for many 
potential confounding factors, we did not account for dietary intake or alcohol consumption 
which may have influenced our results. Secondly, although accelerometers offer more robust 
assessments of PA than self-report (39), they are not without limitation. Hip worn accelerometers 
capture most movement during locomotion, but cannot account for upper body movement,  
movement that occurs during activities such as cycling or weight lifting (40) or distinguish 
between light intensity activities such as sitting and standing. Furthermore, the accelerometer is 
removed during water-based activities and contact sports. Therefore, PA may be underestimated. 
Given the fixed nature of accelerometer-derived variables (sleep, light activity ST and MVPA) as 
proportions of wake time, time spent in behaviours within the day are inherently collinear; every 
increase in time spent in one behaviour unavoidably causes a decrease in the time spent in one or 
a combination of the other behaviours. Thus, it is not possible to include all subcomponents of 
the day (sleep, sedentary, light activity, MVPA) in a regression model without violating collinearity 
assumptions. Consequently, in the present study it is not possible to say with certainty that the 
positive associations observed between cardio-metabolic risk factors and ST are truly 
independent and not, in fact, negative associations with light activity. Finally, participants in this 
study were voluntary recruits to a lifestyle intervention from the 8 study sites worldwide with 
approximately 50% of the study sample were between 55-70 years. Whilst this may limit the 
applicability of the current findings to the older age-range, it is this group who are at greater risk 
of type 2 diabetes and are perhaps more likely to participate in such interventions given their 
greater availability of time to those still in employment.  
In conclusion, this study provides new evidence that in a large diverse population of adults with 
pre-diabetes, objective measures of PA and ST are associated with markers of cardio metabolic 
health. Furthermore, associations with total PA volume are stronger than MVPA. Taken together, 
these findings suggest that replacing ST with light activity may provide practical approach to 
improve cardio-metabolic health in a population with low engagement in MVPA.  
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ABSTRACT 
Dietary protein is effective for body-weight management, in that it promotes satiety, energy 
expenditure, and changes body-composition in favor of fat-free body mass. With respect to 
body-weight management, the effects of diets varying in protein differ according to energy 
balance. During energy restriction, sustaining protein intake at the level of requirement appears 
to be sufficient to aid body weight loss and fat loss. An additional increase of protein intake does 
not induce a larger loss of body weight, but can be effective to maintain a larger amount of fat-
free mass. Protein induced satiety is likely a combined expression with direct and indirect effects 
of elevated plasma amino acid and anorexigenic hormone concentrations, increased diet-induced 
thermogenesis, and ketogenic state, all feed-back on the central nervous system. The decline in 
energy expenditure and sleeping metabolic rate as a result of body weight loss is less on a high-
protein than on a medium-protein diet. In addition, higher rates of energy expenditure have been 
observed as acute responses to energy-balanced high-protein diets. In energy balance, high 
protein diets may be beneficial to prevent the development of a positive energy balance, whereas 
low-protein diets may facilitate this. High protein-low carbohydrate diets may be favorable for the 
control of IHTG in healthy humans, likely as a result of combined effects involving changes in 
protein and carbohydrate intake. Body weight loss and subsequent weight maintenance usually 
shows favorable effects in relation to insulin sensitivity, although some risks may be present. 
Promotion of insulin sensitivity beyond its effect on body-weight loss and subsequent body-
weight maintenance seems unlikely. In conclusion, higher-protein diets may reduce overweight 
and obesity, yet whether high-protein diets, beyond their effect on body-weight management, 
contribute to prevention of increases in NAFDL, type 2 diabetes and cardiovascular diseases is 
inconclusive. 
  
 Dietary protein and energy balance in relation to obesity and co-morbidities 
51 
INTRODUCTION  
The prevalence of obesity and its associated co-morbidities, such as non-alcoholic fatty liver 
disease (NAFLD), type 2 diabetes and cardiovascular diseases, has increased in a growing number 
of countries (1, 2). Energy intake exceeding energy expenditure results in a chronic positive 
energy balance, storage of excess energy and subsequent body weight gain (3). Treatment of 
obesity requires a negative energy balance, which most efficiently and effectively is achieved by 
applying an energy-restricted diet (4). However, this usually results in increased feelings of hunger 
and desire to eat, and in a decrease of the feeling of fullness, implying a risk for sustaining a lower 
energy intake. Body weight loss consists of loss of fat mass and of fat-free mass (FFM); the latter 
causes a reduction in energy expenditure and a decrease in energy requirement. This vicious cycle 
may counteract the negative energy balance induced by the energy-restricted diet. Consequently, 
body weight loss should be paralleled by a reduction in energy intake without changing appetite, 
and maintenance of energy expenditure by preserving FFM. Both goals can be achieved through 
an energy-restricted, relatively high-protein diet (5-8). In this review the mechanisms of protein-
induced appetite modulation, reward homeostasis, and energy expenditure are highlighted, 
including possible adverse effects of protein-diets. Finally, the relevance of relatively high-protein 
diets for treatment or prevention of NAFLD, cardiovascular diseases and type 2 diabetes apart 
from weight-loss and subsequent weight maintenance are discussed.  
SHORT-TERM DIETARY PROTEIN-INDUCED ENERGY HOMEOSTASIS - SATIETY  
Short-term intervention studies using energy-balanced diets with large contrasts in relative 
protein content have shown that high-protein diets are more satiating than diets lower in protein 
(9-15). Furthermore, subjects consumed less food during an ad libitum high-protein diet relative 
to baseline (16), while being similarly satiated and satisfied (16-18). Dietary proteins exert a high 
satiating effect via different pathways including stimulation of gut hormone secretion, digestion 
effects, circulating amino-acid levels, energy expenditure, a ketogenic state and possibly 
gluconeogenesis. Here the gut-brain axis, encompassing signaling from gastrointestinal 
hormones released in the blood and acting at their brain receptors, conducts signals to the brain 
deriving from the gastrointestinal system contributing to control of energy intake.  
AMINOSTATIC THEORY 
Elevated blood concentrations of amino acids may stimulate satiety signaling in the brain (13, 19-
23). According to the ‘aminostatic theory’, serum amino acids that cannot be channelled into 
protein synthesis directly serve as satiety signals (24). However, the aminostatic theory failed to 
gain strong support because fasting circulating amino acid levels do not correlate with appetitive 
sensations and there are non-congruent appetitive responses to protein sources varying in the 
rate of amino acid appearance. Indirectly, dietary amino acids may act on satiety signaling via 
receptors in the duodeno-intestinal and hepatoportal regions (25). Depending on the type of 
amino acid, they increase or decrease the activity of hepatic vagal afferent fibers, innervating 
satiety centers in the brain (25). The branched-chain amino acids leucine, isoleucine and valine 
reportedly contribute to satiety, following these mechanisms (13, 19-21, 23, 25).  
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ROLE OF ANOREXIGENIC AND OREXIGENIC GUT HORMONES  
The satiety-stimulating effect of protein is partly related to increases in anorexigenic gut 
hormones, produced in response to peripheral and central detection of amino acids (23, 26-30). 
They react to elevated protein intake and stimulate vagal activity in brain areas involved in the 
control of food intake (23, 31, 32). Concentrations of glucagon-like peptide 1 (GLP-1), 
cholecystokinin (CCK) and peptide YY (PYY) consistently increase in response to high protein 
intakes (23, 26-30). Apart from its effect on anorexigenic hormones, protein intake can also 
influence orexigenic tone. Therefore, dietary protein consumed in liquid preloads prolongs the 
postprandial suppression of ghrelin (33, 34). This response was not affected by the type of protein 
consumed (soy, whey, or gluten) and was similarly observed in lean and overweight subject. The 
ghrelin decrease was also shown during a whey-protein infusion intraduodenally administered 
with a dose dependent effect (35, 36).  Cortisol response has also been studied after protein 
ingestion with a significant decline of serum cortisol within 30 min after amino-acid ingestion (37). 
This underlines the general view that amino-acids also stimulate catabolic pathways. In addition, 
effects of protein on the orexigenic endocannabinoids have to be investigated (38). 
POSSIBLE RELATIONS OF CHANGES IN AMINO-ACID CONCENTRATIONS OR GUT 
HORMONES WITH SATIETY 
Acute amino acid-related effects on satiety, depending on the quality proteins, have been 
reported. The digestion of ‘fast’ proteins, such as whey, results in high and early rises of plasma 
amino acids and appetite hormones (23).  The slower digestion and absorption rates of casein 
result in more prolonged and maintained plasma amino acid and hormone concentrations than 
those of whey (13, 22, 39, 40). However, at high concentrations, no clear evidence exists for 
differences in satiating capacity between different types of protein, (11, 21-23, 28, 33, 41-43). The 
concentrations of certain amino acids have to be above a particular minimum threshold to 
promote a relatively stronger hunger suppression or greater fullness (23). Indispensible or 
complete proteins reach these thresholds at lower concentrations than other, dispensible or 
incomplete proteins.  Deficiency of essential amino-acids may lead to suppression of intake of 
food consisting of incomplete proteins (44). A chemosensor for essential amino acid deficiency is 
present in the anterior periform cortex (45), signaling brain areas that control food intake (44). 
Likewise, consumption of an incomplete protein may be detected and result in a signal to stop 
eating in humans (46). The signal of incomplete proteins is rather a signal of hunger suppression 
than of satiation or satiety (23, 46). 
PROTEIN-INDUCED SATIETY AND DIET-INDUCED THERMOGENESIS 
The relationship between protein-induced satiety and diet-induced thermogenesis, or DIT, is 
explained by increased energy expenditure at rest implying increases in oxygen consumption and 
body temperature. The feeling of oxygen deprivation is translated into satiety feelings (12, 47). A 
positive relationship between an increase in satiety and at the same time an increase in 24-h DIT 
has been observed with an energy-balanced high-protein diet (12, 48).  
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HIGH-PROTEIN LOW-CARBOHYDRATE INDUCED KETOGENIC EFFECT AND 
GLUCONEOGENESIS 
Fasting β-hydroxybutyrate concentrations increase in response to a ketogenic high-protein, ‘low-
carb’ diet compared with an isoenergetic medium-protein, medium-carbohydrate diet (49-51). 
Increased concentrations of β-hydroxybutyrate directly affected satiety in a 36h study (52). 
Gluconeogenesis and satiety were increased at a zero carbohydrate, high-protein diet, however, 
these were unrelated to each other, yet the increased concentration of β-hydroxybutyrate 
contributed to satiety in the high-protein diet (53). 
In general, in short-term experiments, ad libitum high-protein diets have been observed to 
sustain appetite at a level comparable to the original diet, despite a lower energy intake. Energy-
restricted, high-protein diets produce a sustained lower energy intake compared to diets with 
lower protein content, without altered appetite and satiety scores (17, 54). Consequently, 
individuals who consume a high-protein diet in combination with energy-restriction are more 
satiated and potentially less likely to consume additional calories from foods extraneous to 
dietary prescription (10).  
From short-term experiments we conclude that relatively high-protein diets have the potential to 
maintain a negative energy balance by sustaining satiety at the level of the original diet (9, 16). 
This strong satiety effect depends partly on the type of dietary protein, and is elicited by a mixture 
of gut-brain axis effects, such as anorexigenic gut hormones, digestion, amino-acids, ketogenesis, 
and the increase in diet-induced thermogenesis. Gluconeogenesis did not show a relation with 
satiety (53). 
SHORT-TERM DIETARY PROTEIN-INDUCED REWARD HOMEOSTASIS   
Although dietary protein-induced satiety affects energy intake, it may be dominated by reward-
driven eating behavior (20, 31, 55-57). Several brain areas that are involved in food reward link 
high-protein intake with reduced food wanting and thereby act as a mechanism involved in the 
reduced energy intake following high protein intake (20, 31, 55-57). A mechanism through which 
protein acts on brain reward centers involves direct effects of certain amino acids as precursors of 
the neuropeptides serotonin and dopamine (31, 55). A high-protein, low-carbohydrate breakfast 
vs. a medium-protein, high-carbohydrate breakfast led to reduced reward-related activation in 
the hippocampus and parahippocampus before dinner (20, 32). Furthermore, acute food-choice 
compensation changed the macronutrient composition of a subsequent meal to offset the protein 
intervention (56). A compensatory increase in carbohydrate intake was related to a decrease in 
liking and task-related signaling in the hypothalamus after a high-protein breakfast. After a lower-
protein breakfast, an increase in wanting and task-related signaling in the hypothalamus was 
related to a relative increase in protein intake in a subsequent meal (56). Protein intake may 
directly affect the rewarding value of this macronutrient (56, 58). Thus limited protein-induced 
food reward may affect compliance to a long-term protein-diet. 
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SHORT-TERM DIETARY PROTEIN-INDUCED ENERGY EXPENDITURE - EFFECTS AND 
MECHANISMS  
With respect to dietary protein-induced energy expenditure, short-term effects of energy-
balanced high-protein diets showed higher rates of energy expenditure, especially diet-induced 
thermogenesis (DIT) (59, 60). Mechanisms encompass the ATP required for the initial steps of 
metabolism, such as protein breakdown, synthesis and storage, and oxidation including urea 
synthesis. Also gluconeogenesis may take place. Protein storage capacity of the body is limited. 
Therefore readily metabolic processing is necessary. The magnitude of DIT is determined by the 
level of energy intake in relation to energy requirement and the type of protein, and is illustrated 
by the difference between the gross energy value of 22-25 kJ/g and the net metabolizable energy 
of 13 kJ/g. DIT values for separate proteins are 20 to 30% of energy intake from protein (61). 
Significantly higher dietary protein induced DIT (59), subsequently Sleeping Metabolic Rate (SMR) 
and Basal Metabolic Rate (BMR) (12, 60) was shown in 36h respiration chamber studies, in 
comparison to iso-energetic, iso-volumetric, dietary carbohydrate or fat, composed of normal 
food items and matched organoleptic properties. Short-term protein- induced increase in DIT is 
explained by the ATP required for the initial steps of metabolism and oxidation including urea 
synthesis, while subsequent protein induced increase of SMR is explained by stimulation of 
protein synthesis and protein turnover. The metabolic efficacy of protein oxidation largely 
depends on the amino acid composition of the protein (62). A well-balanced amino acid mixture 
produces a higher thermogenic response than does an amino acid mixture with a lower biological 
value, explaining why intake of plant proteins or incomplete proteins results in less protein 
synthesis than does intake of animal protein. Based upon the stoichiometry of amino acid 
catabolism and urea synthesis, the calculated energy expenditure to produce ATP is ranging from 
153 kJ/ATP for cysteine, to 99 kJ/ATP for glutamate (63). This relative metabolic inefficiency 
contributes to the higher diet-induced energy expenditure of a high protein meal, which, in turn, 
has shown to be related to subjective feelings of satiety (48). Gluconeogenesis, as a result of 
further postprandial amino-acid metabolism also contributes to the protein induced energy 
expenditure. De novo synthesis of glucose in the liver from gluconeogenic precursors including 
amino acids is stimulated by a high protein diet in the fed state (64, 65), and is an alternative 
biochemical pathway to cope with postprandial amino acid excess (66). When the protein content 
of the diet is increased, Phosphoenolpyruvate Carboxylase (PEPCK) that catalyzes the initial 
conversion of oxaloacetate to phosphoenolpyruvate is up-regulated either in the fasted and in 
the fed state, whereas glucose 6-phosphatase (G6Pase), that catalyzes the last step of 
gluconeogenesis is up-regulated in the fasted state and down-regulated in the fed state (64). 
Although hepatic glycogen stores as well as hepatic gluconeogenesis have been suggested to 
play a role in the regulation of satiety (67, 68), this was not confirmed by a study by Veldhorst et 
al. (49). However, they showed that gluconeogenesis strongly increased energy expenditure, in 
that forty-two percent of the increase in energy expenditure after the high-protein diet was 
explained by the increase in gluconeogenesis. The cost of gluconeogenesis was 33% of the 
energy content of the produced glucose (49). 
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PROTEIN TURNOVER, PROTEIN BREAKDOWN, AND PROTEIN SYNTHESIS 
Also protein turnover contributes to the high energetic costs of protein metabolism, and protein 
synthesis. The daily protein turnover of a healthy adult - defined as synthesis plus breakdown-, 
300 gram/day, depends on the type of protein, and age. It is high in children, and decreases with 
older age. Increasing protein intake increases protein turnover by increasing protein synthesis and 
protein breakdown, and does not necessarily affect protein balance (69, 70). Rapidly digested 
dietary protein results in a stronger increase in postprandial protein synthesis and amino acid 
oxidation than slowly digested protein (39, 40, 71).  
Acutely, high protein intake stimulates protein synthesis and turnover, and induces a small 
suppression of protein breakdown (72-74). Prolonged low protein intake may lead to muscle loss 
due to the lack of precursor amino acid availability for de novo muscle protein synthesis (75, 76). 
Hursel et al. (70) observed that protein turnover was significantly higher after a 12-week high-
protein vs. low-protein diet, with significant increases in protein synthesis, protein breakdown, 
and protein oxidation. Notably, in the fasted state net protein balance was less negative after the 
low-protein diet compared with the high-protein diet, while in the fed state, protein balance was 
positive with the high-protein diet, and negative with the low-protein diet (70). Thus protein 
turnover in the fasted state needs to be distinguished from that in the fed state. The role of 
protein synthesis and protein breakdown in FFM accretion was discussed by Deutz and Wolfe (77) 
and Symons et al. (76). The observed maximum response of protein synthesis after a single 
serving of 20-30 g of dietary protein suggests that additional effects of protein intake on FFM 
accretion are accounted for by the inhibition of protein breakdown. However, a beneficial 
reduction of protein breakdown only occurs with acute ingestion of protein (70, 76, 78-80). The 
positive protein balance observed at a high-protein diet is due to acute postprandial responses, 
rather than to the postabsorptive state.  
Consumption of a low-protein diet for 12 weeks was not detrimental to young healthy individuals 
who might have the ability to adapt acutely to this condition (70). The Adaptive Demands model 
developed by Millward may provide an explanation for the observation that the human body is 
able to show physiological adaptations to changes in protein intake (81). The model proposes 
that the metabolic demand for amino acids comprises a fixed component and a variable adaptive 
component (81). Short-term changes in protein intake are likely within the adaptive range. 
Adaptations in protein and amino acid metabolism to changes in protein intake largely occur via 
changes in whole-body protein turnover and amino acid oxidation (82). Changes in amino acid 
oxidation were reflected as decreased and increased nitrogen excretion in response to the low- 
and high-protein diets respectively. The activity of enzymes that regulate: 1) transamination, 2) 
the disposal of the carbon skeletons in intermediary metabolism, and 3) the disposal of nitrogen 
through the urea cycle increased in response to high protein intake (83, 84). Nevertheless, a 
positive nitrogen balance following high protein intake (69, 82, 85, 86) does not automatically 
reflect an increase in protein anabolism (87). The capacity of the body to increase amino acid 
anabolism through an increase in lean body mass is limited (87). Only interventions using diets 
high in specific indispensable amino acids, such as leucine, might be able to stimulate protein 
synthesis in specific target groups (73, 88). Therefore, transient retention or loss of body nitrogen 
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because of a labile pool of body nitrogen may contribute to adaptations in amino acid 
metabolism in response to changes in protein intake (89). Transient adaptive mechanisms may be 
distinguished from mechanisms that maintain homeostasis in the body in the longer-term.  
LONG-TERM DIETARY PROTEIN EFFECTS DURING ENERGY RESTRICTION, BODY-WEIGHT 
LOSS AND BODY-WEIGHT MAINTENANCE 
Most long-term studies comparing energy-restricted diets with a relatively high protein content 
and diets with a normal protein content, within a large range of fat contents, showed independent 
effects of a high protein intake on body weight reduction (7, 90-93, 93-110), while in other studies 
the opposite has been observed (111-121). From these studies, a larger reduction in fat mass 
following relatively high-protein diets was reported by Wycherly et al. (7), Soenen et al. (90), 
Brinkworth et al, (93) Brinkworth et al. (94), Due et al. (96), Das et al. (112), Foster et al. (107), 
Frisch et al. (97), Gardner et al. (98), Jesudason et al. (101), Keogh et al. (121), Krebs et al. (119),  
Layman et al. (102), Mcauley et al. (104), while less reduction in fat mass was reported by 
Delbridge et al. (113). An energy-restricted high-protein diet in combination with exercise can 
even increase muscle mass (124). The main reason behind the differences in outcomes of the 
studies cited, is the difference in dosage of dietary protein (125). If the control, implying an 
adequate protein intake is sufficiently high, then no differences in body weight effects are 
expected. If the relatively high protein diet is higher than 1,2 g/kg body weight daily, then a fat 
free mass sparing effect can be expected. 
Conclusions from long-term studies comparing relatively high-protein with normal-protein diets 
differ from those testing relatively high-protein and low-protein diets (5). In the following studies 
compliance was monitored and confirmed with a quantitative biomarker, such as urinary nitrogen 
(5, 7, 91). A relatively high protein diet (in % of energy) implies a restriction in carbohydrate and 
fat intake, but no restriction of protein intake (in g/d), thus a protein intake comparable to the 
original diet. During energy restriction, sustaining protein intake at the level of the minimal 
requirement (0.66 g/kg body weight daily) appears not to hinder body weight loss and fat loss (7, 
91, 126). An additional increase of protein intake may not induce a larger loss of body weight, but 
can be effective to maintain a larger amount of FFM (7, 91, 126) and limits the reduction of energy 
expenditure through sparing of FFM (91, 127). For example, a 6-month energy restricted diet with 
a daily protein intake just above the minimal requirement (0.8 g/kg body weight daily) induced a 
comparable reduction in body weight to an energy-restricted diet with a daily protein intake well 
above the minimal requirement (1.2 g/kg body weight daily) (91). Interestingly, a protein intake of 
1.2 g/kg body weight daily resulted in a stronger decrease in fat mass and preservation of FFM 
(91). Dietary protein intake below requirements could lead to less weight loss and a higher risk for 
body weight regain (6).  Increasing the relative protein content of a diet automatically results in a 
decrease in the relative content of carbohydrate and/or fat, which theoretically could be a factor 
in triggering the described effects. However, a study by Soenen et al. demonstrated that the 
effects of a relatively high protein intake on body weight loss and weight maintenance were 
present independent of a low carbohydrate intake (90), and that low carbohydrate alone, without 
high protein did not trigger the described effects.  
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However, protein diets could have resulted in stronger effects with respect to body weight 
management, if compliance would have been larger (see section 4). To counteract poor 
compliance, dietary restraint is necessary (128). In several long term clinical trials with dietary 
protein, cognitive dietary restraint had increased, implying greater conscious control over food 
intake (68, 90, 91). Post hoc analysis of those data shows that the change in the cognitive dietary 
restraint score was inversely related to the change in body weight. Dietary restraint is associated 
with brain signaling for reward, indicating a greater control over food intake and implying a 
greater control over reward as well (129). In general dietary restraint is associated with long-term 
weight maintenance (130, 131).    
Taken together, Clifton et al. (125) conclude from a recent meta-analysis that the short-term 
benefit of higher protein diets persists to a small degree over the long term, depending on 
dietary compliance. 
BODY COMPOSITION   
Older studies, in the perspective of composing meal replacers to be used as energy restricted 
diets showed strong energy restriction effects on body composition, in relation to the percentage 
from dietary protein. The protein content of a formula diet was varied from 0 to 50 g/d resulting 
in a protein loss of between 1202 to 91 grams, respectively, over 28 days (132). Loss of fat mass 
(FM) as a percentage of body weight loss was 43% with 0 g/d protein, and up to 79% with 50 g/d 
protein (20), indicating a change in body composition including sparing of fat free mass (FFM), 
due to the amount of protein intake. Similarly, during weight maintenance following weight loss, 
FFM was preserved, while FM was reduced. Since weight maintenance after weight loss usually 
implies a slight weight regain, Stock’s model can be applied (133). The greatest metabolic 
efficiency of weight gain is shown when protein intake is 10-15% of energy and inefficiency is 
shown with <5% and > 20% of energy from protein. The latter metabolic inefficiency is related to 
body composition. For 1 kg of body mass with 60% FM and 40% FFM, an additional 30 MJ needs 
to be ingested, whereas for 1 kg of only FFM, an additional 50-70 MJ is needed (133, 134). This 
metabolic inefficiency, partly due to sparing FFM promotes dietary protein induced weight 
maintenance. In addition, preserving FFM, being the main determinant of basal energy 
expenditure, limits a possible reduction in energy expenditure during weight maintenance. 
Whitehead et al. showed that during energy-restriction, the decline in total energy expenditure 
and SMR as a result of body weight loss is less on a high-protein than on a medium-protein diet 
(135). Even an increase in FFM during a high-protein diet in negative energy balance has been 
observed (124), although these changes may partly be ascribed to a high protein intake combined 
with physical activity.  
PREVENTION OF OVERWEIGHT: ROLE OF DIETARY PROTEIN IN NEUTRAL ENERGY BALANCE 
If the protein-induced effects on appetite and energy expenditure observed during energy 
restriction also hold under non-restricted conditions, then, increasing protein intake with a usual 
diet may prevent overweight and obesity. A 12-week intervention study was performed 
comparing high-protein (30% of energy from protein) and low-protein (5% of energy from 
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protein) diets, in weight stable individuals (136). In this controlled situation, participants were able 
to sustain the high- and low-protein diets. The low-protein diet facilitated the development of 
positive energy balance, while the high-protein diet was beneficial to prevent this (136). 
Correspondingly, small increases in fullness and satiety ratings were observed as acute responses 
to a high-protein diet in neutral energy balance (1136). In this situation, translation into large 
changes in energy intake was not possible, because subjects had to maintain their body weight. In 
the longer term, appetite ratings were returned to the level of the original diet, which suggests 
that the human body habituates to the satiating effects of high protein intake (136). FFM showed 
small increases and decreases after a 12-week intervention with high-protein and low-protein 
diets in energy balance (136). As a consequence, SMR, DIT and total energy expenditure was 
maintained at the high-protein diet, while it was significantly decreased at the low protein diet. 
Thus, at a constant body weight, a high-protein diet may protect against the development of a 
positive energy balance. The consumption of a low-protein diet may increase the risk for the 
development of a positive energy balance through adaptive thermogenesis (136).  
DIETARY PROTEIN AND OVERWEIGHT RELATED CO-MORBIDITIES  
Humans with overweight or obesity may show co-morbidities, such as a nonalcoholic fatty liver 
disease, type 2 diabetes, or cardiovascular diseases. Whether a high-protein diet may be 
protective against these co-morbidities, independent of, or in addition to effects of weight loss is 
still under debate.  
NONALCOHOLIC FATTY LIVER DISEASE  
In general, weight loss improves metabolic function (6, 7), yet a high protein intake may modulate 
intrahepatic triglyceride (IHTG) content as well (137-139). In short-term studies, protein 
supplementation was shown to be associated with reduced hepatic fat (137-139). High ectopic 
lipid content, especially IHTG content, and not visceral adipose tissue (VAT) volume, is an 
independent risk factor for these metabolic disturbances (140-142). A 12-week intervention study 
showed that effects of high- and low-protein diets on IHTG content in weight-stable individuals 
tended to lower IHTG content after the high protein-low carbohydrate diet compared with the 
low protein-high carbohydrate diet (127). This suggests that high protein-low carbohydrate diets 
may be favorable for the control of IHTG in healthy humans. High protein intake stimulates 
hepatic lipid oxidation due to the high energetic demand for amino acid catabolism and 
ketogenesis (5, 49). Furthermore, hepatic lipid oxidation may be stimulated by an increased bile 
acid production, a process that may also inhibit lipogenesis (143). Protein-induced glucagon 
secretion inhibits de novo lipogenesis and stimulates hepatic ketogenesis (144, 145). High protein 
intake may blunt the increase of very low density lipoprotein (VLDL)-TG concentrations induced 
by carbohydrate intake (146-148). High VLDL-TG concentrations may increase hepatic TG, and 
subsequently IHTG content (148). The observed trend for a difference in IHTG content between 
the diets likely is the result of combined effects involving changes in protein and carbohydrate 
intake.  
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TYPE 2 DIABETES                                                                                                                       
Relevant diets possibly contributing to the management of type 2 diabetes are low-carbohydrate 
diets. Those diets often are high-protein diets. A recent systematic review explored the 
interpretation and effectiveness of a low-carbohydrate diet in the management of type 2 diabetes 
(149). They suggest that low-carbohydrate diets may improve HbA1c, HDL cholesterol and 
triglyceride levels. The meta-analyses confirmed statistically significant superiority of the low-
carbohydrate intervention arm in improving HbA1c, HDL cholesterol, triglyceride and systolic 
blood pressure levels at 1 year. Reducing carbohydrate intake demonstrated a strong superiority 
over control diets in reducing diabetes medication, which may have diminished the observed 
effects of a reduced-carbohydrate intake on HbA1c. This review concludes that reducing 
carbohydrate intake may promote favourable health outcomes in the management of type 2 
diabetes in the context of a healthy diet (149). The relation between high-protein intake and type 
2 diabetes is still under debate, and results differ depending on study duration and source of 
protein. Short-term studies have reported favorable effects on glucose homeostasis (21, 150, 151), 
while an epidemiological and a long-term study reported an increased risk for type 2 diabetes 
with increased protein intake (152-154). The increased risk may be dependent on the source of 
protein. Tian et al. conducted a systematic review and meta-analysis of cohort studies to 
investigate the association between protein consumption and the risk for type 2 diabetes (155). In 
this review, they reported an increased relative risk of type 2 diabetes for total protein and animal 
protein in men and women and a reduced relative risk for plant protein in women.  
However, high-protein diets may have some risk regarding insulin sensitivity. An increase in 
Branched-Chain Amino Acids (BCAAs) seems to be a marker of type 2 diabetes (156, 157).  
Newgard et al. observed in rodents that in the context of a dietary pattern that includes high fat 
consumption BCAA contributes to the development of obesity-associated insulin resistance. 
Moreover, Pedersen et al. (158) showed that the serum metabolome of insulin-resistant 
individuals is characterized by increased levels of BCAAs, which correlate with a human gut 
microbiome that has an enriched biosynthetic potential for BCAA.  
Taken together, when protein diets are applied during energy restriction aiming at weight loss 
and subsequent weight maintenance, the latter usually shows favorable effects in relation to 
insulin sensitivity, although some risks may be present. That a higher protein diet would promote 
insulin sensitivity beyond its effect on body-weight loss and subsequent body-weight 
maintenance seems unlikely.  
CARDIOVASCULAR DISEASES 
Parameters that indicate cardiovascular risks usually change in a favorable direction during body 
weight loss. The question remains whether the type of diet, especially a protein diet, would affect 
favorable changes in cardiovascular parameters. Atherosclerosis lies at the root of cardiovascular 
complications, and the main indicators are the HDL- and LDL cholesterol. Certain proteins may 
exert a greater effect on blood cholesterol levels than other (159). Possible different effects from 
vegetable vs animal proteins have been tested. Sacks et al. (160) compared diets enriched in 
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casein for 20 days with diets enriched in soy for 20 days. They did not observe significant 
differences in LDL or HDL cholesterol, neither between lipid profiles or lipid proteins. Other 
studies, comparing casein and soy diets, did find significant reductions in LDL with the soy diet, 
compared to the casein diets (161, 162), however this did not appear in volunteers with already 
high cholesterol concentrations (163). In long term weight loss and subsequent weight 
maintenance studies, it was shown that individuals consuming soy meal replacements showed 
favorable effects in their cardiovascular profile, e.g. lowering LDL, TG, visceral fat, and systolic 
blood pressure (164). With respect to blood pressure, a study by Teunissen-Beekman et al. (165) 
compared postprandial blood pressure-related responses to the ingestion of pea protein, milk 
protein and egg-white protein. They concluded that lower postprandial blood pressure is not 
necessarily accompanied by higher NOx, insulin, glucagon or GLP-1 responses, and that dietary 
protein, especially egg-white protein, may induce a risk for elevated blood pressure (165). Yet, it 
has been reported that effects of dietary protein depend on age. Tielemans et al. (166) showed 
that intake of plant protein, but not animal protein, was inversely associated with 5-year changes 
in blood pressure level in elderly men. A critical evaluation of the evidence for the effects of milk 
proteins and their associated peptides on blood pressure and vascular dysfunction, showed that 
results are inconclusive, while one study clearly reported that main intact milk proteins reduced 
blood pressure, and whey protein improved measures of arterial stiffness (167). Some 
epidemiological studies based upon large community cohorts report no overall relationship 
between protein type and dietary protein sources on coronary heart diseases (168), while another 
epidemiological study indicated that high red meat intake increases risk for coronary heart 
disease and stroke, and that poultry, fish and nuts reduced these risks (169, 170). A general 
systematic review on health effects of protein intake in healthy adults reported that results are 
inconclusive for a relationship between protein intake and cardiovascular diseases (171), while a 
recent systematic review concluded that low-carbohydrate diets, that often are high-protein diets 
may improve HDL cholesterol and triglyceride levels and systolic blood pressure levels at 1 year 
(149). Taken together, more accurately designed randomized control trials on dietary protein 
quality and quantity and possible relations with cardiovascular risks are required. 
ADVERSE EFFECTS OF PROTEIN-DIETS 
There is a long-held view that high-protein intake might interfere with calcium homeostasis by 
increasing the acid load. It is hypothesized that this could be partially buffered by bone, 
subsequently resulting in bone resorption and hypercalciuria (172). In general, protein is a 
necessary nutrient for bone health (173). Nitrogen intake seems to have a positive effect on 
calcium balance and consequent preservation of bone mineral content (174). With respect to 
renal issues, only patients with pre-existing dysfunction appeared to have an increased risk for the 
development of kidney stones and renal diseases (172). In addition, Jesudason et al. (101) showed 
that both a medium or higher protein energy restriction diet, inducing body weight loss, 
normalized renal function in individuals with hyperfiltration.  Similarly, Møller et al. (175) showed 
in a study in volunteers with overweight or obesity and pre-diabetes on a higher protein diet, a 
significant increase in urinary urea/creatinine ratio and serum urea after one year. There were no 
associations between increased protein intake and creatinine clearance, estimated glomerular 
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filtration rate, urinary albumin/creatinine ratio, or serum creatinine. They found no indication of 
impaired kidney function after one year with a higher protein intake in pre-diabetic older adults. 
In the elderly, beneficial health effects of higher-protein intake might outweigh the adverse 
effects possibly because of the changes in protein metabolism with ageing. In contrast, persistent 
total protein and amino acid intake below requirements impairs bodily functions leading to 
higher disease and mortality risks across the lifespan (176, 177). Taken together, application of 
relatively high-protein diets, whereby protein intake is sustained at the original level, does not 
seem to have any adverse effects in healthy individuals. Although no clear recommendation exists 
that defines the safe upper limit of protein intake, consumption of up to 1.66 g/kg BW daily has 
not been associated with increased health risks (87, 122). This means that sustaining or slightly 
increasing protein intake during energy restriction likely poses no adverse effects in healthy 
individuals. However, protein intake can exceed the suggested safe upper limit. The question 
arises whether and how and over which time-frame these high intakes of protein would 
negatively affect health. Recent studies applying medium-term, high-protein interventions in 
neutral or positive energy balance did not report any adverse effects (136, 178). However, the 
limits of adaptation to high protein intake over the longer term remain to be investigated.  
DISCUSSION  
With respect to body-weight management, the effects of diets varying in protein differ according 
to energy balance. During energy restriction, sustaining protein intake at the level of requirement 
appears to be sufficient to aid body weight loss and fat loss (FIGURE 1). An additional increase of 
protein intake does not induce a larger loss of body weight, but can be effective to maintain a 
larger amount of FFM (FIGURE 1). Protein induced satiety is likely a combined expression with 
direct and indirect effects of elevated plasma amino acid and anorexigenic hormone 
concentrations, increased DIT, and a ketogenic state, which all feed- back on the central nervous 
system (FIGURE 1). Changes in appetite appear most clearly as short-term response to changes in 
dietary protein content; the human body may habituate to the satiating effects of protein intake 
in the longer-term. The decline in energy expenditure and sleeping metabolic rate as a result of 
body weight loss is less on a high-protein than on a normal-protein diet. In addition, higher rates 
of energy expenditure have been observed as acute responses to energy-balanced high-protein 
diets (FIGURE 1). In energy balance, high protein diets may be beneficial to prevent the 
development of a positive energy balance, whereas low-protein diets may facilitate this. 
Furthermore, high protein, low carbohydrate diets may be favorable for the prevention of 
metabolic disturbances. During positive energy balance, excess energy intake alone may account 
for the increase in fat mass. Increases in energy expenditure and FFM may largely be predicted by 
protein intake.  
Whether high-protein diets, beyond their effect on body-weight management, contribute to 
prevention of increases in NAFDL, type 2 diabetes and cardiovascular diseases is inconclusive 
(FIGURE 1). High protein-low carbohydrate diets may be favorable for the control of IHTG in 
healthy humans, likely as a result of combined effects involving changes in protein and 
carbohydrate intake. When protein diets are applied during energy restriction aiming at weight 
loss and subsequent weight maintenance, the latter usually shows favorable effects in relation to 
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insulin sensitivity, although some risks may be present. That a higher protein diet would promote 
insulin sensitivity beyond its effect on body-weight loss and subsequent body-weight 
maintenance seems unlikely. At least high-protein diets do not seem to have adverse effects on 
these co-morbidities. In conclusion, higher-protein diets may reduce overweight and obesity, yet 
whether high-protein diets, beyond their effect on body-weight management, contribute to 
prevention of increases in NAFDL, type 2 diabetes and cardiovascular diseases is inconclusive. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FIGURE 1. Summary of the observations on relatively high protein diets applied during energy 
restriction or weight maintenance (WM) thereafter. EB, energy balance; T2D, type 2 Diabetes; NAFLD, 
non-alcoholic fatty liver disease; CV, cardiovascular diseases. 
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ABSTRACT 
Background 
Obesity and type-2 diabetes have been linked to alterations in food reward processing, which 
may be linked to insulin resistance.  
Objective  
In this clinical study, we investigated the respective contribution of insulin resistance, 
anthropometry, and behavioral factors to brain reward activation in response to visual stimuli. 
Design 
Food reward-related brain reward activation was assessed with functional magnetic resonance 
imaging in 39 overweight/obese individuals with impaired fasting glucose and/or impaired 
glucose tolerance (22 women, 17 men; insulin sensitivity index (ISI): 2.7±1.3; body mass index 
(BMI): 32.3±3.7 kg/m
2
; body-fat percentage: 40.5±7.9 %; fasting glucose: 6.3±0.6 mmol/l). Food 
and non-food images were shown in a randomized block design. Brain activation (food vs non-
food images) was correlated with anthropometric and behavioral variables. Behavioral variables 
included eating behavior (TFEQ) and habitual physical activity (Baecke). Glucose and insulin 
concentrations, determined during an oral glucose challenge, were used to assess the 
homeostatic model assessment for insulin resistance (HOMA-IR) and Matsuda insulin sensitivity 
index (ISI). 
Results 
Food>non-food brain activation was positively associated HOMA-IR in the nucleus accumbens, 
right/left insula and right cingulate gyrus (p<0.005, corrected for multiple comparisons). TFEQ 
factor 2 was positively related to food>non-food brain activation in the supramarginal gyrus 
(p<0.005, corrected for multiple comparisons). Habitual physical activity during leisure time was 
negatively associated with food>non-food brain activation in multiple regions associated with the 
attention and reward network (p<0.005, corrected for multiple comparisons).   
Conclusions 
Individuals with increased insulin resistance and emotional eating/disinhibition showed higher 
brain reactivity to food cues, which may imply changes in food preference and hyperphagia. 
Individuals with higher habitual physical activity showed less food reward related brain activation.  
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INTRODUCTION 
Insulin resistance is one of the most important factors linking obesity with chronic disease risk, 
including type-2 diabetes (T2D) and cardiovascular disease (1). While consequences of increased 
body fat and systemic insulin resistance have been investigated for the periphery, consideration 
of the brain as an insulin sensitive tissue is comparatively recent. Both, obesity and T2D were 
shown to be associated with altered brain signaling in areas relevant for food intake motivation 
and food reward (2-4). However, due to the frequent co-occurrence of both, it is difficult to 
discern whether their contribution to alterations in neural, cue-initiated responses is individual or 
synergistic in nature. Not only does insulin relay information of peripheral energy status for 
homeostatic control to the hypothalamus, insulin receptors also densely populate brain regions 
associated with motivated behaviors and reward processing (5). Furthermore, insulin is thought to 
play a role in brain reward regulation through its pivotal role for dopamine release and re-uptake 
(5). Uninhibited brain reward received from food intake may be one of the mechanisms 
underlying continued overeating in obese individuals. In healthy and lean participants studies 
utilizing intranasal insulin administration showed an attenuation of brain activation in response to 
food pictures (6) and reduced food intake (7). Two studies in children with overweight showed 
brain activation in response to food images to be inversely associated with either insulin 
sensitivity or waist circumference (8, 9). Those results corroborated studies suggesting the co-
occurrence of peripheral and central insulin resistance, an idea further supported by studies 
utilizing magneto-encephalography (10).  
Additionally, behavioral factors were shown to play a role in the modulation of brain reward 
signaling in people with obesity or T2D. Eating behavior (11) and physical activity (12) affect food 
reward, yet it is not clear whether their impact is direct or rather indirect through their 
relationship with either obesity or insulin resistance. In order to identify primary intervention 
targets, it is vital to discern the relative contribution of weight, insulin, and behavioral factors to 
the observed alterations in brain reward signaling, especially for people at risk for T2D. Almost all 
the insulin in the brain is derived from the periphery (13), posing peripheral insulin resistance as a 
particularly interesting target to tackle the mechanisms underlying altered brain responses in 
individuals at risk. Research participants from the PREVIEW intervention study deliver an ideal 
research population. The PREVIEW study is a multicentre study which aims to find the most 
effective lifestyle components for the prevention of T2D in overweight/ obese individuals with 
impaired fasting glucose (IFG) and/or impaired glucose tolerance (IGT). The aim of the current 
study was to investigate the respective association of insulin resistance, weight status, and 
behavioral factors with brain reward activation in response to visual food cues on a whole brain 
level and specifically for the nucleus accumbens, a central region of the dopaminergic reward 
system. Given the evidence so far it was our hypothesis that brain reward signaling would be 
primarily associated with insulin resistance, rather than weight status or behavioral variables. 
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SUBJECTS AND METHODS 
Participants  
Forty participants were recruited from the cohort of the PREVIEW study (PREVIEW - Prevention of 
Diabetes through lifestyle intervention and population studies in Europe and around the world, 
EU 7
th
 Framework Programme, grant agreement no. 312057, www.previewstudy.com (14)) at 
Maastricht University. One participant lacked valid functional imaging data and was excluded 
from analysis (see TABLE 1 for participant characteristics). Inclusion criteria were: age 25-70 years, 
BMI ≥25 kg/m2, fasting plasma glucose of 5.6 – 6.9 mmol/l and/or plasma glucose concentration 
of 7.8 – 11.0 mmol/l at 2h after an oral glucose tolerance test (OGTT), and willingness to undergo 
MRI procedures. Exclusion criteria included T2D, left-handedness, claustrophobia and history of 
neurological disorders in addition to the general PREVIEW exclusion criteria (ClinicalTrials.gov 
NCT01777893). All participants gave written informed consent for participation. The study was 
approved by the Medical Ethical Committee of Maastricht University Medical Center and in 
accordance with guidelines of the Declaration of Helsinki. 
TABLE 1. Participant characteristics 
No. participants (female/male) 39 (17/22)  
Age (years) 53 ± 11.3 25.0 - 68.0 
BMI (kg/m
2
) 32.3 ± 3.7 25.7 - 40.7 
Fat mass (kg) 38.9 ± 10.2 18.5 - 59.8 
Body-fat (%) 40.5 ± 7.9 22.9 - 55.2 
Fasting glucose (mmol/l) 6.3 ± 0.6 5.4 - 8.3 
Fasting insulin (mU/l) 13.6 ± 6.3 1.1 - 30.0 
HOMA-IR 3.9 ± 1.9 0.3 - 9.2 
ISI 2.7 ± 1.3 0.9 - 5.8 
ISI (log) 0.38 ± 0.22 -0.03 - 0.76 
Baecke work index 2.6 ± 0.8 1.3 - 4.3 
Baecke sport index 2.6 ± 0.7 1.0 - 4.0 
Baecke leisure index 2.9 ± 0.7 1.5 - 4.4 
TFEQ factor 1 8.5 ± 4.7 1.0 - 17.0 
TFEQ factor 2 8.1 ± 3.7 2.0 - 15.0 
TFEQ factor 3 5.6 ± 3.5 0.0 - 12.0 
Notes: Data are mean ± SD and range. HOMA-IR, homeostatic model assessment for insulin 
resistance; ISI, insulin sensitivity index; log, log transformed; TFEQ, three factor eating questionnaire 
Body weight and composition  
Body weight was measured using a calibrated scale (Life Measurement Corporation, Inc, Concord, 
CA, USA) and body composition was determined using Siri’s equation  based on body density 
measured via air-displacement plethysmography with the BodPod System (Life Measurement 
Corporation, Inc, Concord, CA, USA) (15). Height was measured using a wall-mounted stadiometer 
to the nearest 0.1 cm (Seca, model 222, Seca, Hamburg, Germany).  
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OGTT  
Participants underwent a 2 hour 75-gram OGTT after an overnight fast >10 hours. Blood samples 
to determine glucose and insulin concentrations were taken prior to and 30, 60, 90 and 120 
minutes after receiving the glucose load.  
Blood samples  
Blood samples were drawn from an antecubital vein and stored locally at -80°C. Samples were 
transported and analysed centrally at the National Institution for Health and Welfare in Helsinki, 
Finland. Plasma glucose was measured by enzymatic hexokinase method and insulin was 
measured using chemiluminescent microparticle immunoassay. The homeostatic model 
assessment for insulin resistance (HOMA-IR) was used to assess insulin resistance and was 
calculated as follows: fasting glucose x fasting insulin / 22.5 (16). Insulin sensitivity was calculated 
with the Matsuda index: Insulin sensitivity index derived from OGTT (ISI) =10,000/√(fasting 
glucose x fasting insulin) x (mean glucose x mean insulin during OGTT) (17). Insulin data during 
the OGTT was missing for four participants. Therefore, all analyses with ISI were performed with 
35 participants. HbA1c was measured using enzymatic assay. Laboratory measurements are 
performed on Architect ci8200 analyzer (Abbott Laboratories, Abbott Park, IL, USA). 
Brain imaging paradigm 
Participants arrived at the university after an overnight fast of >10 hours. They underwent 
functional magnetic resonance imaging to obtain blood oxygen level-dependent (BOLD) data. 
During scanning, nine blocks of ten images each were presented in a randomized order. Blocks 
contained high-calorie food, low-calorie food or non-food images. The food images were shown 
in a randomized order. Each participant viewed the same set of images. The images were selected 
from various Web sites and from the IAPS as it has been used in previous studies (8, 9, 18, 19). 
High-calorie images included items such as fries, mac-and-cheese, hamburgers, donuts etc. Low-
calorie images included items such as fruit salad, cucumbers, carrots, broccoli etc. 
Food images were randomly chosen from sixty different images in order to avoid preference and 
learning effects. Images were shown for 2 seconds each. Between the blocks, a fixation cross was 
shown for 10 seconds. During the presentation participants received the instruction to focus on 
how much they liked the images. 
Image acquisition 
Scanning was performed on a 3 Tesla scanner (Magnetom, Siemens, Erlangen, Germany) using a 
64-channel head coil. First, a T1 weighted scout scan was used to confirm the participant was 
correctly placed in the scanner. Functional runs were collected using a T2*-weighted protocol 
(TR=2.0s, TE=30.0ms, FOV=216x216, matrix size=72x72, voxel size, 3x3x3 mm
3
). Each volume 
consisted of 34 slices. The slice acquisition order was interleaved ascending. In each session, 
anatomical images were acquired with a high-resolution T1 weighted scan.  
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Image processing 
Functional data preprocessing included slice scan time correction, 3D motion correction temporal 
high-pas filtering with 4 cycles. Anatomical data was corrected for intensity inhomogeneities. To 
achieve brain normalization, the anatomical scan of each participant was transformed into 
Montreal Neurological Institute (MNI) space. After preprocessing, both functional and anatomical 
scans were aligned based on starting position and boundary-based registration. The resulting 
volume-time-courses were spatially smoothed by applying a Gaussian filter (FWHM=6) to 
increase signal-to-noise ratio. For each participant, food reward-related brain activation predictors 
for the three stimuli blocks (high-calorie food images, low-calorie food images and neutral 
images) were applied in generalized linear model (GLM) analyses and the hemodynamic-response 
was taken into account by adding a two gamma hemodynamic response function. Additionally, 
three-dimensional motion correction parameters were added as confounding predictors. The 
individual brain responses were subsequently used for whole brain analysis. To specifically 
investigate the activation in the nucleus accumbens, two spherical regions of interest (ROI) were 
drawn on the left and right nucleus accumbens (MNI coordinates ±9,6,-4 (20)). Beta values in 
these ROIs were calculated and extracted for each participant individually. 
Behavioral questionnaires 
Behavioral factors were assessed using validated questionnaires in native language. Eating 
Behavior was assessed using the Three Factor Eating Questionnaire (TFEQ), which consists of 51 
questions (21). The three factors it measures are cognitive restraint (TFEQ factor 1), emotional 
eating and disinhibition (TFEQ factor 2) and feelings of hunger (TFEQ factor 3). Habitual physical 
activity was assessed using the Baecke questionnaire. It consists of 17 questions to measure 
physical activity during work, sport and leisure time (22).  
Statistical analysis  
Power calculations were based on a study by Jastreboff et al. (23) which reported a correlation 
coefficient of 0.52 between HOMA-IR and brain activation to food cues, yielding a minimum of 27 
participants. Since in general no significant differences in brain activation during the high-calorie 
food images and low-calorie images were observed, food images were taken together and 
contrasted with the neutral images as a ‘non-food’ condition. Whole brain contrast map for 
food>non-food is available as supplemental figure 2. Whole brain correlation analyses was used 
to test the correlation between the food>non-food activation and the different anthropometric 
and behavioral parameters. For the whole brain analyses, Monte Carlo simulations were 
performed in BrainVoyager to identify cluster extent thresholds. A cluster alpha of 0.005 was used 
to correct for multiple comparisons. Monte Carlo simulations were performed with 1000 iterations 
with an independent voxel threshold of p<0.001. For the ROI analysis in the nucleus accumbens, 
food>non-food activation was averaged and extracted from the left and right ROI and used in 
pearson’s correlation analyses to determine the relation with anthropometric and behavioral 
parameters. A p<0.005 was considered significant, to correct for multiple comparisons. Partial 
correlation analysis was used to determine the relationship between extracted brain activation in 
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the significant clusters and ROIs with HOMA-IR or behavioral variables, adjusted for BMI and age. 
Data are expressed as mean ± SD. Analyses were performed using BrainVoyager 20.6 (Brain 
Innovation B.V., Maastricht, The Netherlands) and SPSS 23 (IBM corp., Armonk NY, USA). 
RESULTS 
Food reward-related brain activation and anthropometric or behavioral variables 
BMI was positively associated with HOMA-IR (r=0.40; p=0.012) and inversely with ISI (r=-0.43; 
p=0.009). HOMA-IR and ISI were negatively related (r=-0.92; p<0.001). Activity in response to 
viewing food images was contrasted with non-food images and the association with 
anthropometric or behavioral parameters was assessed using whole brain analysis. 
Anthropometric parameters included BMI, body-fat percentage and HOMA-IR. Results showed a 
positive association between food>non food activation and HOMA-IR in the right (r= 0.53) and 
left insula (r= 0.55) and right cingulate gyrus (r=0.53) (FIGURE 1) (TABLE 2). There were no 
significant associations between food>non-food activation and BMI or body-fat percentage. After 
adjusting for BMI and age, the correlation coefficient between HOMA-IR and food>non-food 
activation remained significant (Table 2). Food>non-food brain activation was positively related to 
TFEQ factor 2 (emotional eating and disinhibiton) in the right supramarginal gyrus (r=0.55), which 
remained significant after adjusting for BMI and age (Table 2). Food>non-food brain activation 
was not related to TFEQ factor 1 (cognitive restraint) or factor 3 (feelings of hunger). Food>non-
food brain activation was negatively related to Baecke leisure index in multiple regions associated 
with reward, attention and memory. After adjusting for BMI and age, the correlation coefficients 
of these relationships were reduced (Table 2). Food>non-food brain activation was positively 
related to Baecke work index (r=0.53). This relationship disappeared after adjusting for BMI and 
age. Food>non-food brain activation was not related to Baecke sport index. 
Food reward-related brain activation in the nucleus accumbens and anthropometric and 
behavioral variables 
Activation in the right nucleus accumbens was significantly associated with HOMA-IR (r=0.46; 
p=0.003). While the association between HOMA-IR and food>non-food activation in the right 
nucleus accumbens became non significant after correction for BMI and age (r=0.33; p=0.046), 
activation in the left nucleus accumbens remained significantly associated with HOMA-IR (r=0.47; 
p=0.003) after correction for BMI and age. Food>non-food brain activation was not associated 
with the other variables. 
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FIGURE 1. Whole brain contrast map. Brain regions with significant associations between food reward-
related brain activation and HOMA-IR are shown in orange (p<0.005, corrected for muliple 
comparisons). Scatter plots of HOMA-IR and extracted food>non-food BOLD response are shown on 
the right. 
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TABLE 2 Summary of whole brain analysis correlating food>non-food brain activation with anthropometric and behavioral variables 
Variable 
cluster threshold 
(mm
3
) 
AAL x y z 
cluster size 
(mm
3
) 
r r* p* 
HOMA-IR 432 Insula R 40 15 0 1557 0.53 0.53 <0.001 
  Middle Cingulate gyrus R 3 22 33 478 0.53 0.46 0.004 
  Insula L -36 9 5 1040 0.55 0.48 0.003 
TFEQ factor 2 351 supramarginal gyrus R 58 -32 45 841 0.55 0.56 <0.001 
Baecke leisure index 513 no label 32 -1 26 708 -0.54 -0.44 0.008 
  Thalamus R 16 -10 7 554 -0.54 -0.34 0.048 
  Middle cingulate gyrus L -2 -35 39 1934 -0.55 -0.33 0.050 
  Precuneus R 2 -53 25 1170 -0.55 -0.47 0.005 
  Putamen L -26 1 8 557 -0.55 -0.29 0.094 
  no label -35 -46 17 771 -0.54 -0.43 0.010 
  Angular gyrus L -38 -54 35 910 -0.55 -0.29 0.091 
Baecke work index 378 no label 22 30 18 633 0.53 0.11 0.569 
          
Notes: Cluster extent threshold was determined by Monte Carlo simulation with a voxel threshold of p<0.001 and cluster alpha of 0.005. Centre-of-gravity 
coordinates of each cluster are given in MNI space and the automated anatomical labeling atlas was consulted to obtain corresponding anatomical labels. 
Correlation coefficients (r) present average correlation coefficients of the significant clusters determined with BrainVoyager. * adjusted for BMI and age 
Abbreviations: AAL, automated anatomical labeling; HOMA-IR, homeostatic model assessment for insulin resistance; TFEQ, three-factor eating questionnaire; 
R, right hemisphere; L, left hemisphere 
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DISCUSSION  
The present study investigated the respective association of body weight, insulin sensitivity and 
behavioral factors with brain activation contrasting food images to non-food images in 
overweight and obese individuals with IFG and/or IGT. Food reward-related brain activation was 
positively associated with insulin resistance during the anticipation of food reward, specifically in 
the nucleus accumbens, left/right insula and right cingulate gyrus, independently of BMI. High 
calorie food images were previously shown to increase activity in these regions that are known for 
playing a central role in food reward processing, and are connected through the dopaminergic 
pathway originating in the ventral tegmental area (24). Generally, but especially in people with IFG 
or IGT, disturbance of food reward processing may be an important accelerator for the transition 
to T2D through overeating. The catabolic action of insulin in the brain is an important signal to 
the homeostatic circuit, but also relevant to the termination of reward experience from 
pleasurable behaviors, including food intake. Taking the brakes off reward perception may 
consequentially support hyperphagia (25). Several studies have shown that diminished sensitivity 
of insulin receptors impairs inhibitory effects of insulin on brain signaling. Mechanistically, the 
close link between insulin and dopamine in the brain may explain the effect of insulin on reward 
perception. It has been shown that insulin sensitivity was positively associated with dopamine 
levels at the dopamine D2/3 receptor (26) and negatively related to dopamine D2/3 receptor 
availability in the ventral striatum (27). Insulin is thought to activate the PI3K/Akt/mTOR pathway 
stimulating the synthesis of the dopamine transporter for dopamine reuptake (28). Reduced 
reuptake of dopamine as a result of brain insulin resistance might lead to increased activation or 
prolonged action of synaptic dopamine (29), which in turn could lead to oversensitivity to food 
cues and subsequent hyperphagia. In line with this mechanism, Labouebé and colleagues showed 
that injection of insulin in the ventral tegmental area of mice led to a reduction in synaptic 
transmission of ventral tegmental area dopamine neurons (30). Blockage of the PI3k/Akt/mTOR 
pathway prevented this reduction. Central administration of insulin also led to decreased 
anticipatory activity and conditioned place preference (30). It should be noted that the interaction 
between insulin and dopamine is contentious and study results are quite diverse. Peripheral 
insulin administration had no effects on brain activation in healthy, presumably insulin sensitive, 
non-obese individuals in response to visual food cues (31).  
Findings from our study are in accordance with other studies demonstrating positive associations 
between insulin resistance and neural activation in the mesolimbic reward system in overweight 
girls and obese individuals (8, 23).  More support for the role of insulin resistance rather than 
weight status is given by studies demonstrating a robust effect on prefrontal cortex blood 
perfusion in lean, but not overweight/obese men, after elevating brain insulin concentrations 
through intranasal insulin administration (32). Changes were inversely related to insulin sensitivity, 
even after adjustment for BMI, with nasal insulin administration leading to a decrease in 
prefrontal blood flow in lean, but not in overweight and obese men (32). Studies that measured 
brain activation during a glucose challenge showed reduced activation in response to food 
pictures after glucose ingestion (33-35). The reduction in brain response to food cues was 
associated with increases in plasma insulin levels during the glucose challenge (33). However, this 
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reduction in brain response was only seen in insulin-sensitive but not insulin-resistant participants 
(34, 35). Similar to our study, the degree of insulin resistance correlated positively with the BOLD 
response to food images in reward regions.  
With respect to habitual physical activity and food reward-related brain signaling, we found an 
inverse relationship between habitual activity during leisure time and food-reward related brain 
activation in multiple regions associated with the attention network and reward network.  
Accordingly, another study suggested that brain activation to food pictures is affected by physical 
activity with physical exercise attenuating food reward-related brain activation (36). Furthermore, 
leisure-time physical activity, assessed with the Baecke questionnaire in a large cohort of adults, 
was also shown to be negatively associated with BMI and body fat and positively associated with 
eating fruits and vegetables (37). Based on the results it may be conceivable that habitual physical 
activity could potentially diminish anticipated food reward and lead to healthier eating habits. 
Eating behavior and overeating is an important component in the association of obesity and T2D 
(38) and may come forward as a result to changes in food reward-related brain signaling (39). We 
found a positive association between food reward-related brain activation and emotional 
eating/disinhibiton in the right supramarginal gyrus. The supramarginal gyrus has been previously 
associated with reward, motivation and drug abuse (40, 41). A study in adolescents reported 
increased BOLD-response during inhibitions versus non-inhibition trials in the supramarginal 
gyrus and participants that showed highest activation also progressed to the highest levels of 
substance use within the next 18 months (40).  
While our research participants presented with a fairly large range in BMI and insulin resistance, 
we did not include healthy participants or participants with T2D in this study. Since brain response 
in the nucleus accumbens to food images may not show a linear relation with insulin sensitivity 
(42) we cannot generalize the results for the whole population.  
Furthermore, it is known that menstrual cycle and sex hormones influence reward-related brain 
activation (43-45). Since we did not collect data on markers of menopausal stage or menstrual 
stage, we were not able to take this into account. Another limitation poses the use of cross-
sectional data only. However, as part of the overall PREVIEW study, these observations will be 
followed by assessing effects of changes in body weight, insulin resistance and behavioral factors 
on food reward-related brain signaling, induced by an 8-weeks weight loss period followed by up 
to 3-years weight maintenance.  
In conclusion, in participants with overweight/obesity and limited insulin sensitivity, insulin 
resistance was positively associated with brain reactivity to food cues in the nucleus accumbens, 
insula and cingulate gyrus and emotional eating/disinhibition was posivitely associated with brain 
reactivity to food cues in the supramarginal gyrus, which may lead to changes in food preference 
and hyperphagia. The results are especially relevant for individuals with increased risk for the 
development of T2D. The lifestyle factor physical activity was inversely associated with food 
reward related brain signaling, posing as a potentially protective factor to counteract the effects 
of insulin resistance on brain reactivity to food cues. In addition to the well known peripheral 
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benefits of physical activity, the results corroborate an additional route for physical activity in the 
prevention of T2D and obesity. 
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SUPPLEMENTAL FIGURE 1. Participant flowchart 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
SUPPLEMENTAL FIGURE 2. Visual representation of neural response to food>non-food images. 
Increased brain response to food images compared to non-food images is shown in orange (T>3.57). 
  
Assessed for eligibility (n=106) 
Excluded  (n= 66) 
▪ Not meeting inclusion criteria (n=36) 
   Declined to participate (n=30) 
 
Enrolled in study (n=40) 
Excluded  (n=1) 
▪ No valid functional imaging data 
available 
Analysed  (n=39) 
▪ Functional imaging data (n= 39) 
▪ Fasting blood samples (n=39) 
▪ Blood samples during oral glucose tolerance test (n=35) 
Behavioral questionnaire data (n=39)  
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SUPPLEMENTAL FIGURE 3. Whole brain correlation map. Brain region with positive association 
between food reward-related brain activation and TFEQ disinhibition is shown in orange (r=0.55; 
P<0.005, corrected for multiple comparisons). The scatter plot of TFEQ disinhibition and extracted 
food>non-food BOLD response is shown on the right.  
 
SUPPLEMENTAL FIGURE 4. Whole brain correlation map. Brain regions with significant inverse 
associations between food reward-related brain activation and Baecke leisure index are shown in blue 
(r=0.55; P<0.005, corrected for multiple comparisons).  
 
SUPPLEMENTAL FIGURE 5. Whole brain correlation map. Brain region with significant positive 
associations between food reward-related brain activation and Baecke sport index is shown in orange 
(r=0.55; P<0.005, corrected for multiple comparisons). 
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ABSTRACT  
Aims 
The PREVIEW lifestyle intervention study is to date the largest, multinational study for  type-2 
diabetes prevention. We hypothesized that the initial, fixed low-energy diet (LED) would induce 
different metabolic outcomes in men vs women. 
Materials and methods 
All participants followed a LED [3.4 MJ/810 kcal/daily] for 8 weeks (Cambridge Weight Plan®). 
Participants were recruited from eight sites in Europe, Australia, and New Zealand. Those eligible for 
inclusion were overweight (BMI ≥ 25 kg/m2) individuals with pre-diabetes according to ADA-criteria. 
Outcomes of interest included changes in insulin resistance, fat mass, fat-free mass and metabolic 
syndrome Z-score. 
Results 
In total, 2,224 (1,504 women; 720 men) individuals attended the baseline visit and 2,020 (90.8%) 
completed the follow-up visit. Following the LED, weight loss was 16% greater in men than women 
(11.8% vs 10.3% respectively) but improvements in insulin resistance were similar. HOMA-IR 
decreased by 1.50 ± 0.15 in men and 1.35 ± 0.15 in women (ns). After adjusting for differences in 
weight loss, men had larger reductions in metabolic syndrome Z-score, C-peptide, fat mass and 
heart rate, whilst women had larger reductions in HDL-cholesterol, fat free mass (FFM), hip 
circumference and pulse pressure. Following the LED, 35% of the participants of both genders had 
reverted to normo-glycaemia. 
Conclusions:  
An 8-week LED induced different effects in women than men. These findings are clinically important 
and suggest gender-specific changes after weight loss. It is of importance to investigate whether the 
greater falls in FFM, hip circumference and HDL-cholesterol in women after rapid weight loss 
compromise weight loss maintenance and future cardiovascular health. 
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INTRODUCTION 
Type 2 diabetes mellitus is one of the fastest growing chronic diseases worldwide (1). We are aware 
of the major risk factors, including being overweight or obese, and know that achieving weight loss 
'prevents diabetes' in the sense that onset of new cases is delayed. The most recent paper exploring 
the dose-response effect of weight loss shows that more than 4.3% weight loss is needed to prevent 
diabetes, for 3 years, in Japanese men (2). The PREVIEW intervention study (PREVention of diabetes 
through lifestyle Intervention and population studies in Europe and around the World; 
www.previewstudy.com) is to date the largest, multinational study which aims to prevent type 2 
diabetes in overweight individuals with pre-diabetes. Diet and physical activity are utilized with 
changes being reinforced by behavior modification techniques (3). The study is an ongoing 3-year 
multicenter, 2-by-2 factorial, randomized controlled trial, in which eligible adult participants initially 
followed an 8-week low-energy diet (LED). The aim was to induce a weight loss of at least 8%, in 
order to qualify for inclusion in the randomized intervention, where the focus is on long-term weight 
loss maintenance (4).  
The majority of individuals who use weight loss programmes, including bariatric surgery, are women 
(5,6). Investigating whether there are differences in outcomes between men and women is of 
importance in order to develop gender-specific treatment programmes, if required (6–12). 
Differences in outcomes after weight loss have been reported previously with men commonly losing 
more body weight and fat than women (13). This difference is mainly due to the concept of LED’s. 
Thus, a fixed daily energy intake is provided to both genders, despite men and women having 
significantly different energy requirements due to men characteristically having a greater body mass. 
Notably however, during weight loss, men may mobilize more intra-abdominal fat than women, 
whereas women may lose more subcutaneous fat (14,15). The greater reduction in intra-abdominal 
fat in men is accompanied by a more pronounced improvement in the metabolic risk profile. 
Therefore, greater improvement of risk factors in men is not only related to a greater negative 
energy balance, but also to a gender-specific effect (16,17). 
Of interest are the differences in glycaemia between overweight men and women. The prevalence of 
pre-diabetes has been reported to be significantly higher in men than in women (18). Impaired 
fasting glucose (IFG), which is indicative of hepatic insulin resistance (IR), is also more common in 
men (typically 1.5–3 times higher) (19). Conversely, the prevalence of impaired glucose tolerance 
(IGT), which is indicative of skeletal muscle IR, has been reported to be higher in women than men in 
almost all age groups (16). 
In this study, we aimed to compare the effects of an 8 week LED-induced weight loss on metabolic 
outcomes in a large group of men and women. The study included data from adult participants aged 
25-70 years who were enrolled into the PREVIEW diabetes prevention study. 
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MATERIALS AND METHODS 
Adult participants were recruited to the PREVIEW study between August 2013 and March 2015 from 
eight different intervention sites. The study sites were University of Copenhagen (UCPH), Denmark; 
University of Helsinki (HEL), Finland; University of Nottingham (UNOTT), United Kingdom; University 
of Maastricht (UM), The Netherlands; University of Navarra (UNAV), Spain; Medical University of Sofia 
(MU), Bulgaria; University of Auckland (UOA), New Zealand and University of Sydney (UNSYD), 
Australia. Overweight men and women with pre-diabetes were eligible for inclusion. Participants 
were recruited by advertisements in newspapers, newsletters, radio and television 
advertisements/interviews, and by contacting primary and occupational health care providers. 
Interested individuals were pre-screened for eligibility by using the Finnish Diabetes Risk Score 
(20,21) as well as the inclusion and exclusion criteria listed in the Online Supplemental Materiel 
(Appendix 1). Potentially eligible participants were then invited to an information meeting, where 
written and oral information was provided. Before continuing to the laboratory screening session, 
written informed consent was obtained. Criteria for assessing pre-diabetes were those recommended 
by the American Diabetes Association (ADA) (22), namely: fasting venous plasma glucose 
concentration 5.6 - 6.9 mmol/l (IFG) and/or venous plasma glucose concentration of 7.8 - 11.0 
mmol/l at 2 h (IGT) after oral administration of 75 g glucose at an oral glucose tolerance test (OGTT), 
with fasting plasma glucose (FPG) less than 7.0 mmol/l. HbA1c was not used to determine eligibility. 
Other inclusion criteria for adult participants were 25-70 years of age and body mass index (BMI) ≥ 
25 kg/m
2
. Prior to screening and recruitment, the study protocol was approved by the Ethical 
Committees of the participating countries. The PREVIEW study is registered at clinicaltrials.gov with 
Identifier: [NCT01777893]. 
Interventions  
The PREVIEW study comprises of two intervention phases. Phase 1 is an 8 week, weight loss phase 
using a formula LED (3.4 MJ/day) intended to induce weight loss of ≥ 8% in order to qualify for the 
next phase. The second phase of the study is an ongoing 148-week randomised lifestyle intervention 
which focuses on diet, physical activity and behaviour modification for weight loss maintenance. The 
LED was implemented by using a range of Cambridge Weight Plan® (Northants, UK) formula 
products. All intervention sites used the standard assortment from the Cambridge Weight Plan that 
was available in the United Kingdom, to ensure that the nutritional content of the sachets were 
identical. The sachets were provided to the participants without any charge and included soups, 
shakes and porridges. The participants were instructed to consume four sachets (4 x 40 g) per day. 
Of these, 3 sachets were to be dissolved in milk (3 x 250 ml low fat milk = total 750 ml/day) and 1 
sachet in 250 ml of water. The fat content of the milk was ≤0.5 g/100 ml and the energy content 
≤170 kJ (40 kcal)/100 ml. Participants with a BMI > 40 kg/m2 were encouraged to dissolve all 4 
sachets in milk in order to increase the intake of protein. 
 In total, the LED provided an estimated 3.4 
MJ/day (810 kcal/day),   85 g of protein,   5 g of essential fatty acids and the daily requirement for 
vitamins and minerals (23,24).  
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The macronutrient composition was as follows: 43.7 total energy % from protein, 41.2 total energy % 
from carbohydrate and 15.1 total energy % from fat. The fiber content of the LED was relatively low 
at 13.3 g/day. In order to avoid any gastrointestinal side effects, the participants were recommended 
to use psyllium fibers and to drink sufficient water to remain hydrated. In addition to the sachets and 
milk, the participants were permitted to consume 375 g of low-starch vegetables, such as tomatoes, 
cucumber and lettuce per day. Replacement of these additional foods by alternatives was not 
permitted. During the LED intervention, participants attended group visits at the intervention sites at 
weeks 2, 4, 6 and 8, where they were guided in the use of the LED by experienced dietitians or 
counsellors. Further information about the LED is available in the Online Supplemental Material 
(Appendix 2).  
Outcomes 
All outcomes were measured before and after the 8 weeks intervention at clinical investigation days 
(CIDs), which participants attended in the fasting state (10-12 hours). The main outcome of interest 
in this analysis was change in insulin resistance (IR) calculated by the Homeostasis Model for 
Assessment (HOMA). The equation used was (FSI * FPG)/22.5, where FSI is fasting serum insulin 
concentration (mU/l) and FPG is fasting plasma glucose (mmol/l) (25). Other outcomes included were 
changes in FPG, hemoglobin A1c (HbA1c), fasting insulin, C-peptide, total-, high density lipoprotein 
(HDL)- and low density lipoprotein (LDL)-cholesterol, triglycerides (TG), C-reactive protein (CRP) and 
liver enzymes, alanine aminotransferase (ALT) and aspartate aminotransferase (AST).  
The blood samples were drawn from the antecubital vein. Serum and whole blood samples were 
initially stored at –80°C at the individual intervention sites, after which they were transported to a 
laboratory in Finland for central batch analyses (National Institute for Health and Welfare, Helsinki, 
Finland). Laboratory measurements were performed on Architect ci8200 integrated system (Abbott 
Laboratories, Abbott Park, IL, USA). The laboratory (T077) has been accredited by the Finnish 
Accreditation Service and fulfils the requirements of the standard SFS-EN ISO/IEC 17025:2005. The 
scope of accreditation covers all analyses except AST and C-Peptide. Other outcomes were change in 
body weight, measured in the fasting state, with an empty bladder and wearing underwear (or other 
light clothing). Two measurements were taken to the nearest 0.1 kg and the mean calculated. For 
measurement of height, the participants were required to remove shoes, and stand with their heels, 
buttocks and upper part of the back in contact with a wall-mounted stadiometer. Height was 
measured to the nearest 0.5 cm and the mean of two measurements was calculated. Waist-, hip- and 
thigh circumference were measured to the nearest 0.5 cm with a non-stretch tape with the 
participant standing. Two measurements were recorded and the mean was calculated. Waist 
circumference (WC) was measured midway between the bottom of the rib cage (last floating rib) and 
the top of the iliac crest, at the end of expiration. Hip circumference was measured at the widest 
point between the hips and buttocks, following the same directions as for the waist measurement. 
Mid-thigh circumference was measured on the right side of the body. The measuring tape was 
placed horizontally around the thigh at midway between the midpoint of the inguinal crease and the 
proximal border of the patella.  
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Measurements of body composition were performed by different methods at the intervention sites 
(see Appendix 3). Fertile women were tested for pregnancy before DXA. The outcomes of interest 
were fat mass (FM), fat free mass (FFM), bone mineral content (BMC) and bone mineral density 
(BMD). 
Systolic (SBP) and diastolic blood pressure (DBP) and heart rate were measured using a validated 
automatic device on the right arm after 5-10 min in a resting position. The measurements were 
performed three times with a 1 minute rest between each recording and mean value was reported. 
Pulse pressure was calculated by using the formula SBP minus DBP. Mean arterial pressure (MAP) 
was calculated by using the formula 0.42 x SBP + 0.58 x DBP (26). 
FIGURE 1. Trial flow chart. Pre-screening, screening, individuals starting initial weight-loss phase and 
follow-up of study participants. 
Men and women respond differently to rapid weight loss: Metabolic outcomes of a multi-centre 
intervention study after a low-energy diet in 2500 overweigth individuals with pre-diabetes 
93 
 
The metabolic syndrome (MS) was evaluated using a MS Z-score, which is a continuous score of the 
5 MS variables as reported previously (27). Gender-specific Z-scores were used to account for 
variations in the criterion between men and women. The equations used were: MS Z-score = [(50-
HDL)/14.1]+ [(TG-150)/81.0] + [(FPG-100)/11.3] + [(WC-88)/9.0] + [(MAP-100)/9.1] for women, and 
Z-score = [(40-HDL)/9.0] + [(TG-150)/81.0] + [(FPG-100)/11.3] + [(WC-102)/7.7] + [(MAP-100)/9.1] 
for men (27).  
At all visits to the intervention sites, the participants were asked whether they had experienced any 
adverse events. Any such adverse event (AE) was noted on a related AE form, which captured onset, 
end, intensity, causality, action taken and outcome of the AE. 
Statistical methods 
Descriptive characteristics at CID1 and CID2 are summarized as mean ± SD. Differences between 
men and women were analyzed using a linear mixed model including intervention site as random 
effect. The estimate of mean difference at baseline is presented as mean ± SEM. All analyses were 
carried out as complete-case analyses, (i.e., data from all participants that attended both baseline 
visit (CID1) and the visit at week 8 (CID2), independent of the amount of weight loss). Count data, 
such as number of participants dropping out or achieving a successful weight loss were analysed for 
group differences by simple 2x2 contingency tables and Chi-square. For continuous outcomes, the 
mean gender difference was estimated using ANCOVA-type linear mixed models, adjusting for fixed 
effects of baseline, age, and including centers as random effects. As the weight loss intervention 
provided 3.4 MJ/day (810 kcal/day), we anticipated that men would experience a larger energy 
deficit than women during the intervention, and therefor lose more weight. In order to adjust for 
weight loss difference between men and women, the same ANCOVA-type linear model was applied 
for all outcome variables, whilst adjusting for weight loss percentage (%) as well. All statistical 
analyses and calculations were performed with the statistical program “R – version 3.3.2” and 
“RStudio – version 0.98.1028”. A p-value of <0.05 was considered significant.    
RESULTS 
The flow of participants is shown in the Flow Chart FIGURE 1. A total of, 2,224 individuals (1,504 
women; 720 men) participated in the baseline visit (CID1) and began the LED phase. The majority of 
participants described themselves as Caucasians (1.949; 87.6%), whereas the remainder were 
Polynesians (92; 4.1%), Asians (59; 2.7%), Hispanics (44; 2.0%) and Black (38; 1.7%). A total of 42 
(1.9%) were classified as “other”, where most were of mixed origin. On average, the age of the 
included individuals was 51.6 ± 11.6 years, body weight 100.1 ± 21.4 kg, BMI 35.4 ± 6.6 kg/m
2,
 
HOMA-IR 3.75 ± 2.43, and FPG 6.2 ± 0.7 mmol/L. Baseline characteristics are shown in TABLE 1.  
Changes after the LED are shown in TABLE 2. A total of 2,020 participants attended the CID2 visit, 
with a dropout rate during the 8 weeks of 9.2% (204 participants; 152 women; 52 men). The 
proportion of dropouts varied amongst the centers (UCPH: 2.5%, HEL: 5.8%, UM: 7.4%, UNAV: 9.0%, 
UNSYD: 10.1%, MU: 12.1%, UOA: 12.7%, UNOTT: 14.4%).  
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TABLE 1. Anthropometrical, metabolic and clinical characteristics of the participants at the baseline visit (CID1) and following 8 weeks (CID2).  
Variable CID1 – all (N = 2,224) 
 CID1 - 
women 
(N = 1,504) 
CID1 - men 
(N = 720) 
Mean difference 
between men and 
women
a
 
CID2 - all 
(N = 2,020) 
CID2 - 
women 
(N = 1,352) 
CID2 - men 
(N = 668) 
Mean difference 
between men and 
women
a
 
Age, years 51.6 ± 11.6 (25.0 - 70.0) 51.0 ± 11.6 52.9 ± 11.6 1.1 ± 0.5 - - - - 
Weight, kg 100.1 ± 21.4 (58.4 - 238.0) 95.6 ± 19.8 109.4 ± 21.6 14.9 ± 0.9*** 88.9 ± 19.2 85.2 ± 17.5 96.4 ± 20.2 12.3 ± 0.8*** 
Height, cm 168.0 ± 9.4 (139.0 - 198.0) 163.5 ± 6.7 177.4 ± 6.9 13.7 ± 2.9*** - - - - 
BMI, kg/m
2
 35.4 ± 6.6 (24.7 - 77.3) 35.7 ± 6.7 34.7 ± 6.3 -0.5 ± 0.3 31.4 ± 6.0 31.8 ± 6.0 30.6 ± 5.9 -0.8 ± 0.3** 
Primary outcome         
HOMA-IR
b
 3.75 ± 2.43 (0.23 - 31.37) 3.5 ± 2.2 4.24 ± 2.82 0.73  ± 0.11*** 2.28 ±  1.61 2.26 ± 1.45 2.31 ± 1.90 0.12 ± 0.08 
Secondary outcomes         
Metabolic syndrome  
Z-score
c
 2.6 ± 3.2 (-7.5 - 18.2) 
2.4 ± 3.2 
(-7.5-18.2) 
2.9 ± 3.3 
(-5.9-14.0) 0.5 ± 0.1*** 0.1 ± 3.1 0.4 ± 2.9 -0.6 ± 3.3 -0.9 ± 0.1*** 
Fasting glucose, mmol/L 6.2 ± 0.7 (3.4 - 13.6) 6.1 ± 0.7 6.3 ±  0.7 0.2 ± 0.03*** 5.8 ± 0.6 5.7 ± 0.6 5.8 ± 0.6 0.1 ± 0.03 
HbA1c, mmol/mol 36.7 ± 4.1 (23.0 - 79.0) 36.7 ± 3.9 36.8 ± 4.4 0.2 ± 0.2 34.6 ± 3.4 34.7 ± 3.3 34.3 ± 3.6 -0.3 ± 0.2  
HbA1c, % 5.5 ± 0.4 (4.3 - 9.4) 5.5 ± 0.4 5.5 ± 0.4 0.02 ± 0.02 5.3 ± 0.3 5.3 ± 0.3  5.3 ± 0.3 -0.03 ± 0.01* 
Insulin, mU/L 13.5 ± 8.0 (1.0 - 97.5) 12.8 ± 7.4 14.8 ± 8.9 2.1 ± 0.4*** 8.7 ± 5.5 8.7 ± 5.0 8.8 ± 6.4 0.3 ± 0.3 
C-peptide, pmol/L 923.6 ± 349.3 (177.0-3234.0) 888.8±328.2 996.3 ± 379.7 115.1 ± 15.7*** 706.6 ± 302.4 713.4 ± 290.1 693.0 ± 325.3 -7.9 ± 14.0 
Total Cholesterol, mmol/L 5.2 ± 1.0 (2.0 - 10.3) 5.3 ± 1.0 5.0 ± 1.0 -0.2 ± 0.04*** 4.3 ± 1.0 4.4 ± 0.9 4.1 ± 1.0 -0.3 ± 0.04*** 
LDL Cholesterol, mmol/L 3.2 ± 0.8 (0.7 - 7.2) 3.3 ± 0.8 3.2 ± 0.9 -0.1 ± 0.04** 2.6 ± 0.8 2.7 ± 0.8 2.5 ± 0.8 -0.2 ± 0.04*** 
HDL Cholesterol, mmol/L 1.3 ± 0.3 (0.6 - 2.6) 1.3 ± 0.3 1.1 ± 0.2 -0.2 ± 0.01*** 1.2 ± 0.2 1.2 ± 0.2 1.1 ± 0.2 -0.1 ± 0.01*** 
Triglycerides, mmol/L 1.5 ± 0.8 (0.23 - 11.5) 1.4 ± 0.8 1.6 ± 0.8 0.2 ± 0.04*** 1.1 ± 0.5 1.1 ± 0.5 1.1 ± 0.7 0.03 ± 0.02 
C-reactive protein, mg/L 5.4 ± 7.0 (0.1 - 144.5) 5.9 ± 7.3 4.3 ± 6.2 -1.4 ± 0.3*** 4.4 ± 6.4 4.5 ±  6.0 4.1 ± 7.1 -0.3 ± 0.3 
ALT, U/L 27.9 ± 16.3 (6.0 - 182.0) 25.1 ± 13.9 33.8 ± 19.2 9.6 ± 0.7*** 35.7 ± 26.9 36.7 ± 28.9 33.6 ±  22.1 -3.3 ± 1.3* 
AST, U/L 27.7 ± 10.7 (10.0 - 140.0) 26.4 ± 9.8 30.5 ± 11.9 4.4 ± 0.5*** 28.6 ± 13.0 28.5 ± 14.2 28.7 ± 10.2 0.01 ± 0.6 
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TABLE 1. continued  
Variable CID1 – all (N = 2,224) 
 CID1 - women 
(N = 1,504) 
CID1 - men 
(N = 720) 
Mean difference 
between men 
and women
a
 
CID2 - all 
(N = 2,020) 
CID2 - 
women 
(N = 1,352) 
CID2 - men 
(N = 668) 
Mean difference 
between men and 
women
a
 
Anthropometry, body composition and blood pressure      
Waist circumference, cm 110.4 ± 14.7 (71.0 -210.0) 107.5 ± 14.0 116.7 ± 14.3 9.8 ± 0.6*** 100.6 ± 13.7 98.2 ± 13.0 105.3 ± 13.8 7.5 ± 0.6*** 
Hip circumference, cm 118.5 ± 13.8 (80.5 -202.0) 120.5 ± 14.1 114.2 ± 12.1 -5.5 ± 0.6*** 110.9 ±  12.7 112.7 ± 13.0 107.1 ± 11.2 -4.8 ± 0.6*** 
Thigh circumference, cm 60.4 ± 7.3 (40.5 - 99.0) 61.0 ± 7.6 59.1 ± 6.6 -1.8 ± 0.3*** 56.6 ±  6.6 57.1 ± 6.9 55.5 ± 5.9 -1.7 ± 0.3*** 
Fat free mass, kg 56.5 ± 12.0 (32.8 - 138.4) 50.8 ± 7.7 68.6 ± 10.3 18.7 ± 0.4*** 53.6 ±  11.1 48.1 ± 6.9 65.0 ± 9.4 17.7 ± 0.4*** 
Fat mass, kg 43.0 ± 13.7 (7.7 - 128.3)  44.3 ± 13.1 40.3 ± 14.4 -3.7 ± 0.6*** 34.7 ± 12.9 36.7 ± 12.2 30.7 ± 13.5 -5.5 ± 0.6*** 
Fat % 43.3 ± 7.6 (11.1 - 61.3) 46.4 ± 5.8 36.8 ± 6.6 -10.0 ± 0.3*** 39.3 ± 9.0 42.9 ± 6.9 31.7 ± 8.0 -11.4 ± 0.3*** 
Bone mineral content, g 2877 ± 572 (1442 - 5500) 2631 ± 399 3424 ± 518 811 ± 21*** 2826 ± 567 2579 ± 403 3366 ± 495 793 ± 23*** 
Bone mineral density, g/cm
2
  1.3 ± 0.1 (0.9 - 1.7) 1.2 ± 0.1 1.3 ± 0.1 0.09 ± 0.007*** 1.3 ± 0.1 1.2 ± 0.1 1.3  ± 0.1 0.1 ± 0.007*** 
SBP, mmHg 129.1 ± 15.9  (80.7- 85.3) 127.1 ± 16.0 133.2 ± 14.7 6.0 ± 0.7*** 122.0 ± 15.8 120.8 ± 15.7 124.3 ± 15.6 3.4 ± 0.7*** 
DBP, mmHg 78.1 ± 11.1 (38.0 - 117.3) 76.8 ± 11.4 80.9 ± 9.9 3.7 ± 0.4*** 75.0 ± 9.9 74.7 ± 10.0 75.5 ± 9.6 0.6 ± 0.4 
Pulse pressure, mmHG 50.9 ± 12.4 (19.0 - 100.3) 50.3 ± 12.8 52.3 ± 11.2 2.3 ± 0.5* 47.0 ± 11.4 46.2 ± 11.6 48.8 ±  10.8 2.8 ± 0.5*** 
MAP, mmHG
d
 99.5 ± 11.8 (56.6 - 137.1) 97.9 ± 12.0 102.9 ± 10.8 4.6 ± 0.5*** 94.7 ± 11.3 94.0 ± 11.3 96.0 ± 11.2 1.8 ± 0.5*** 
Heart rate, bpm 71.3 ± 10. 6 (35.0 - 119.3) 71.9 ± 10.3 70.0 ± 11.0 -1.3 ± 0.5* 65.8 ± 10.9 66.9 ± 10.6 63.6 ± 11.2 -2.3 ± 0.5*** 
Abbreviations: ALT, Alanine aminotransferase; AST, Aspartate aminotransferase; BMI, Body mass index; CID, Clinical investigation day; DBP, Diastolic 
blood pressure; HDL, High-density lipoprotein; HOMA-IR, Homeostasis model of assessment insulin resistance; LDL, Low-density lipoprotein; MAP, Mean 
arterial pressure; SBP, Systolic blood pressure; SD, Standard deviation. Data for all, men and women are presented as mean ± SD (min – max).  
a 
For difference between men and women the estimate is mean difference ± SEM adjusted for site; *P<0.05, ** P<0.01, ***P<0.001. 
b
 The formula to calculate the HOMA-IR was: fasting insulin(mU/L) * fasting glucose (mmol/L) / 22.5 [25]. 
c
 The metabolic syndrome was calculated as a Z score [27]. 
d
 The formula used to calculate MAP was 0.42 x SBP + 0.58 x DBP (26). 
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TABLE 2. Changes in Anthropometry, HOMA-IR and Blood Markers in Participants meeting at the Clinical Investigation Day after the LED (CID2). 
Variable 
All
a 
(N = 2,020)  P-value
 a
 
Women
b 
(N = 1,352) 
Men
b 
(N = 668) 
Mean difference 
between men 
and women
b
 P-value
b
 
Mean difference 
between men and 
women
c
 P-value
c
  
Primary outcome         
∆Weight, kg -10.7 ± 0.4 <0.001 -10.2 ± 0.4 -11.8 ± 0.5 -1.6 ± 0.1 <0.001 - - 
Weight loss (%) 10.8 ± 3.1 - 10.3 ± 2.8 11.8 ± 3.4 1.3 ± 0.1 <0.001 - - 
∆HOMA-IR
d
 -1.42 ± 0.15 <0.001 -1.35 ± 0.15 -1.50 ± 0.15 -0.15 ± 0.06 n.s. 0.01 ± 0.06 n.s. 
Secondary outcomes         
Metabolic syndrome  Z-score
e
 -2.5 ± 0.2 <0.001 -2.1 ± 0.2 -3.4 ± 0.2 -1.3 ± 0.1 <0.001 -0.9 ± 0.1 <0.001 
∆Fasting glucose, mmol/L -0.44 ± 0.07 <0.001 -0.42 ± 0.07 -0.46 ± 0.07 -0.04 ± 0.02 n.s. 0.02 ± 0.02 n.s. 
∆HbA1c, mmol/mol -2.1 ± 0.2 <0.001 -1.93 ± 0.15 -2.35 ± 0.16 -0.42 ± 0.10 <0.001 -0.25 ± 0.10 n.s. 
∆HbA1c, % -0.19 ± 0.02 <0.001 -0.17 ± 0.01 -0.22 ± 0.01 -0.05 ± 0.01 <0.001 -0.03 ± 0.01 <0.05 
∆Insulin, mU/L -4.51 ± 0.44 <0.001 -4.28 ± 0.44 -4.83 ± 0.46 -0.55 ± 0.21 <0.05 -0.03 ± 0.21 n.s. 
∆C-peptide, pmol/L -210.4 ±  18.7 <0.001 -183.7 ± 22.6 -259.7 ± 23.4 -76.0 ± 10.5 <0.001 -48.6 ± 10.3 <0.001 
∆Total Cholesterol, mmol/L -0.93 ± 0.08 <0.001 -0.89 ± 0.09 -1.02 ± 0.09 -0.13 ± 0.03 <0.001 -0.04 ± 0.03 n.s. 
∆LDL Cholesterol, mmol/L -0.64 ± 0.06 <0.001 -0.60 ± 0.07 -0.72 ± 0.07 -0.11 ± 0.03 <0.001 -0.04 ± 0.03 n.s. 
∆HDL Cholesterol, mmol/L -0.12 ± 0.02 <0.001 -0.12 ± 0.02 -0.10 ± 0.02 0.02 ± 0.01 <0.05 0.03 ± 0.01 <0.01 
∆Triglycerides, mmol/L -0.40 ± 0.04 <0.001 -0.39 ± 0.04 -0.42 ± 0.04 -0.02 ± 0.02 n.s. 0.02 ± 0.02 n.s. 
∆C-reactive protein, mg/L -0.89 ± 0.17 <0.001 -0.97 ± 0.27 -0.77 ± 0.31 0.20 ± 0.29 n.s. 0.38 ± 0.29 n.s. 
∆ALT, U/L 7.6 ± 1.7 <0.001 10.0 ± 2.3 2.2 ± 2.4 -7.8 ± 1.3 <0.001  -8.3 ± 1.3 <0.001 
∆AST, U/L 1.0 ± 0.6 n.s. 1.5 ± 0.7 -0.1 ± 0.8 -1.6 ± 0.6 <0.05 -1.8 ± 0.6 <0.05 
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TABLE 2. continued 
Variable 
All
a 
(N = 2,020)  P-value
 a
 
Women
b 
(N = 1,352) 
Men
b 
(N = 668) 
Mean difference 
between men 
and women
b
 P-value
b
 
Mean difference 
between men and 
women
c
 P-value
c
  
Anthropometry, body composition and blood pressure      
∆Waist circumference, cm -9.6 ± 0.4 <0.001 -9.2 ± 0.4 -10.5 ± 0.4 -1.4 ± 0.3 <0.001 -0.2 ± 0.2 n.s. 
∆Hip circumference, cm -7.1 ± 0.3 < 0.001 -7.1 ± 0.2 -7.2 ± 0. 3 -0.04 ± 0.2 n.s. 0.7 ± 0.2 <0.001 
∆Thigh circumference, cm -3.7 ± 0.1 <0.001 -3.7 ± 0.1 -3.9 ± 0.1 -0.2 ± 0.2 n.s. 0.2 ± 0.2 n.s. 
∆Fat free mass, kg -2.74 ± 0.37 <0.001 -3.17 ± 0.38 -1.90 ± 0.40 1.26 ± 0.18 <0.001 1.58 ± 0.17  <0.001 
∆Fat mass, kg -7.80 ± 0.39 <0.001 -7.09 ± 0.40 -9.33 ± 0.41 -2.23 ± 0.15 <0.001 -1.30 ± 0.12 <0.001 
∆Fat % -3.9 ± 0.5 <0.001 -3.7 ± 0.4 -4.3 ± 0.4 -0.6 ± 0.2 <0.01 -0.2 ± 0.2 n.s. 
∆Bone mineral content, g -45.3 ± 20.0 <0.05 -57.1 ± 19.4 -8.6 ± 20.3 48.4 ± 9.3 <0.001 53.8 ± 9.5 <0.001 
∆Bone mineral density, g/cm
2
  0.004 ± 0.005 n.s. 0.001 ± 0.004 0.007 ± 0.004 0.006 ± 0.002 <0.05 0.005 ± 0.002 n.s. 
∆SBP, mmHg -7.5 ± 0.7 <0.001 -7.7 ± 1.3 -7.8 ± 1.3 -0.2 ± 0.6 n.s. 0.6 ± 0.6 n.s. 
∆DBP, mmHg -3.5 ± 0.8 <0.001 -3.2 ± 0.9 -4.5 ± 0.9 -1.3 ± 0.4 0.001 -0.8 ± 0.4  n.s. 
∆Pulse pressure, mmHG -4.0 ± 0.9 <0.001 -4.5 ± 0.9 -3.2 ± 0.9 1.4 ± 0.4 <0.01 1.6 ± 0.4  <0.001 
∆MAP, mmHG
f
 -5.2 ± 0.6 <0.001 -5.1 ± 0.9 -5.9 ± 1.0 -0.8 ± 0.4 n.s. -0.2 ± 0.4 n.s. 
∆Heart rate, bpm -5.4 ± 0.8 <0.001 -4.9 ± 1.1 -6.3 ± 1.1 -1.4 ± 0.4 <0.001 -1.1 ± 0.4 <0.05 
Data are mean change ± SEM. Abbreviations: CID, Clinical investigation day; HOMA-IR, Homeostasis model of assessment insulin resistance; BMI, Body 
mass index; LDL, Low-density lipoprotein; HDL, High-density lipoprotein; ALT, Alanine aminotransferase; AST, Aspartate aminotransferase; SBP, Systolic 
blood pressure; DBP, Diastolic blood pressure; MAP, Mean arterial pressure; SE, Standard error.  
a
The ANCOVA models includes adjustment for intervention site. 
b
The ANCOVA models includes adjustment for site, age, gender and baseline.  
c
ANCOVA models included adjustment for site, age, gender, baseline and weight loss percentage. 
d
 The formula to calculate the HOMA-IR was: fasting insulin(mU/L) * fasting glucose (mmol/L) / 22.5 [25]. 
e
 The metabolic syndrome was calculated as a Z score [27]. 
f
 The formula used to calculate MAP was 0.42 x SBP + 0.58 x DBP [26]. 
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Proportionally, more women (10.1%) than men (7.2%) dropped out, leaving a risk difference of -
2.9% points (95% confidence interval (CI): -0.5 to -5.6% points, P=0.01). 1857 (83.5%) of the 
participants who began the LED phase, successfully achieved the target of ≥ 8% weight loss at 8 
weeks. Fewer women (82%) than men (86.5%) achieved the target weight loss (difference of 4.5% 
points, 95% CI: 1.4% - 7.7% points, P=0.02) The mean LED weight loss (± SEM) in all participants 
was 10.7 ± 0.4 kg (10.8%; P <0.001) with women losing 16% less weight than men (10.2 ± 0.4 kg 
(10.3%) vs 11.8 ± 0.5 kg (11.8%) respectively, P <0.001). On average, HOMA-IR decreased by 1.42 
± 0.15 units (P <0.001) in all participants and was similar in women to men (1.35 ± 0.15 vs 1.50 ± 
0.15 respectively, P = n.s.). The overall change in the metabolic syndrome Z-score was -2.5 ± 0.2 
(P <0.001), but the improvement was smaller in women than men (-2.1 ± 0.2 vs -3.4 ± 0.2 
respectively) with a mean difference of -1.3 ± 0.1 (P <0.001). The difference remained highly 
significant after adjusting for differences in weight loss (%) (P<0.001). 
Of the 2,224 participants who completed the baseline visit, 1,429 participants (64.3%) had isolated 
IFG, 283 participants (12.7%) had isolated IGT, and 512 participants (23.0%) had both IFG and IGT 
at the screening visit. Following the 8-week LED weight loss, 694 participants (35.8%) had reverted 
to normo-glycaemia based on FPG alone. This number increased to 40.2% amongst participants 
who met the target weight loss (i.e. ≥8% of initial body weight).   
Following the LED, fat free mass (FFM) decreased more in women than men (3.2 ± 0.4 kg vs 1.9 ± 
0.4 kg respectively (mean difference of 1.3 ± 0.2 kg, P<0.001). Conversely, fat mass (FM) 
decreased less in women than men (7.1 ± 0.4 kg vs 9.3 ± 0.4 kg respectively (mean difference of -
2.2 ± 0.2 kg, P<0.001). For both outcomes, the difference in changes between women and men 
remained highly significant after adjusting for weight loss (%).  
A separate analysis of the changes in anthropometry, HOMA-IR and blood markers in the female 
participants in different age groups is shown in Appendix 5. The younger age group (<45.9 years) 
experienced statistically different changes in HOMA-IR, HbA1c, insulin, HDL-cholesterol, ALT, 
thigh circumference, BMC, BMD and heart rate compared to the two older age groups (46-54 
years and >55 years). Between the older age groups, changes in HbA1c, ALT, thigh circumference 
and BMD were statistically significantly different after the LED weight loss.     
During the LED weight loss period, 961 adverse events were reported across all sites. Of these 10 
events were reported as serious adverse events (SAE). However all SAE’s were evaluated as 
unlikely to be related, or unrelated to the study intervention and the LED weight loss. As shown in 
TABLE 3, women reported significantly more adverse events than men. The main events were 
constipation, having a cold/influenza and muscular weakness and pain. 
DISCUSSION 
In this worldwide intervention study, participants lost an average of 11% of their body weight and 
showed significant improvements in insulin resistance (change in HOMA-IR -1.4, P<0.001) after an 
8-week LED.  There were differences in other metabolic outcomes by gender, in that men 
appeared to benefit more than women. Men lost significantly more body weight than women, 
and had larger reductions in the metabolic syndrome Z-score, C-peptide, FM and heart rate, even 
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after adjusting for differences in weight loss (%). In contrast, women had larger reductions in 
HDL-cholesterol, hip circumference, FFM and pulse pressure than men, again after adjustment for 
the differences in weight loss (%). Since declines in HDL-cholesterol, BMC and lean mass are 
generally not supportive of long term health, it is of general interest whether rapid weight loss on 
a LED compromises the health of some women. Therefore it is of importance to investigate if the 
long-term effects of rapid weight loss are indeed more beneficial for men than women with 
regard to the prevention of both type-2 diabetes and cardiovascular disease. 
TABLE 3. Adverse effects reported by the PREVIEW participants during and immediately after the 
weight loss period at the intervention sites. 
Symptoms 
All 
(n=2224) 
Women 
(n=1504) Men (n=720) 
Risk difference  
(95% CI) * P<0.05 
Constipation 169 (7.6%) 129 (8.6%) 40 (5.6%) 0.030* (0.008; 0.052) 
Diarrhea  34 (1.5%) 26 (1.7%) 8 (1.1%) 0.006 (-0.004; 0.016) 
Other gastrointestinal symptoms 
including feeling nausea, having 
pain, flatulence and vomiting 84 (3.8%) 67 (4.5%) 17 (2.4%) 0.021* (0.006; 0.036) 
Having a cold/influenza 121 (5.4%) 85 (5.7%) 36 (5.0%) 0.007 (-0.013; 0.026) 
Sore throat 10 (0.4%) 6 (0.4%) 4 (0.6%) -0.002 (-0.008; 0.005) 
Dizziness 44 (2.0%) 27 (1.8%) 17 (2.4%) -0.006 (-0.019; 0.007) 
Headaches and migraines 66 (3.0%) 56 (3.7%) 10 (1.4%) 0.023* (0.011; 0.036) 
Muscular weakness and pain 113 (5.0%) 77 (5.1%) 36 (5.0%) 0.001 (-0.018; 0.021) 
Allergic reaction 8 (0.4%) 6 (0.4%) 2 (0.3%) 0.001 (-0.004; 0.006) 
Hair loss 19 (0.9%) 18 (1.2%) 1 (0.1%) 0.011* (0.004; 0.017) 
Changes in menstrual symptoms,  
-cycle or postmenstrual symptoms 15 (0.7%) 15 (1.0%) -  
Various infections 74 (3.3%) 61 (4.1%) 13 (1.8%) 0.023* (0.009; 0.036) 
Dry skin. eczema and other effects on 
skin 23 (1.0%) 17 (1.1%) 6 (0.8%) 0.003 (-0.006; 0.011) 
Gout 6 (0.3%) 0 (0.0%) 6 (0.8%) 
-0.008* (-0.015; -
0.002) 
Other 175 (7.9%) 122 (8.1%) 53 (7.4%) 0.008 (-0.016; 0.031) 
Total 961 (43.2%) 712 (47.3%) 249 (34.6%) 0.128* (0.085; 0.171) 
Abbreviations: CI, confidence interval. Data are presented as numbers and proportions. no. (%); mean 
difference between women and men is estimated via the risk difference. *Analyzed using chi-square; 
P<0.05. 
Previous studies have reported that gender differences in metabolic outcomes occur because 
men mobilize more intra-abdominal fat than women during weight loss, and that this is 
accompanied by a more pronounced improvement in the metabolic risk profile (12,14,15). In the 
present study, we found important differences when comparing outcomes between women and 
men, both before and after adjusting for the differences in weight loss (%). This suggests intrinsic 
differences in how men and women adapt to dietary energy deficits.  
Following the LED weight loss, the loss of FFM was on average 25% of total weight loss. Changes 
in FFM of this magnitude are considered normal during LED weight loss (28,29). Interestingly, 
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however, women lost twice as much FFM as men (31.4% vs. 16.1%), which is striking as men had a 
larger energy deficit during LED-phase. It would be expected that the men would have a larger 
requirement for dietary protein as their FFM was much larger than that of the womens at baseline. 
From the most recent Joint FAO/WHO/UNU Expert Consultation on Human Energy Requirements 
(30), it is possible to estimate the daily energy requirement of an average male PREVIEW 
participant (body weight 109.4 kg) with a low daily physical activity level (PAL: 1.45) as 13 MJ 
(3,086 kcal). In comparison, a female participant (body weight 95.6 kg) with a similar activity level 
would have a daily energy requirement of only approximately 10 MJ (2,353 kcal). However, 
despite this large difference in energy requirement, men managed to preserve more of their FFM 
during the LED than women. When looking at this from a compliance perspective, the daily 
provision of 3.4 MJ/day from the LED would leave men with an energy deficit of 9.6 MJ/day, and 
women with a 6.5 MJ/day deficit. Following 8 weeks, these energy deficits should yield a weight 
loss of 18.3 kg for men and of 12.4 kg for women according to Westerterp et al (32). Considering 
the actual weight losses achieved of 11.8 kg for men and 10.2 kg for women, there is reason to 
believe that women were closer to their theoretically achievable weight loss (82.2%) than men 
(64.5%). If we then evaluate and make the reverse calculation of the achieved weight losses, it 
appears that the mean of the energy intake in men must have been 6.1 MJ/d, and the mean 
energy intake of women must have been 4.55 MJ/d. This suggests that women were more 
compliant with the diet than men. Similar observations were made by Camps SG et al (31). It 
would be interesting to investigate differences in compliance and adaptation to the LED-phase 
between men and women as it may help explain the differences found in this analysis.   
Physical activity (PA) and exercise training are associated with numerous health benefits (33). In 
the PREVIEW study, we did not measure the level of physical activity during or immediately after 
the LED weight loss phase. Differences in the physical activity level between participants could 
have impacted on some of the results presented in this paper; however, the strict inclusion 
criterion (not high PA) have led to a narrower between-person variance in PA, which has 
decreased the likelihood that one could find an association between PA, weight loss and the 
related outcomes. The included participants were (more or less) physically inactive and no 
guidance on PA was given during the LED-phase. Although we do not have the direct evidence, it 
is unlikely that any major changes in PA occurred during the LED. 
In the PREVIEW study different equipment was used to measure body composition at the 
intervention sites (see Appendix 3), however the same equipment was always used to measure the 
same participant during the intervention. There are many body composition methods available to 
estimate different body compartments (34,35). The more practical and acceptable methods that 
are frequently used for the estimation of body composition include Dual-energy X-ray 
absorptiometry (DXA) and bioimpedance analysis (BIA).  These were mostly used in the current 
study. The validity of DXA and BIA has been debated previously, where it is described that their 
accuracy can vary according to age, adiposity etc. (34,36). In this study, using different equipment 
at the various sites may have introduced some variability in the data.  However as the same 
equipment was always used for a participant, and adjustments were made for the site in the 
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analyses, we believe that we have limited the bias to the greatest extent possible. However, not 
using the same equipment across all sites is a weakness of the trial. 
Additionally, 87.6 % of the study participants described themselves as Caucasians and the 
remaining participants were either Polynesians, Asians, Hispanics, Black or of mixed origin. 
Therefore, the ethnic diversity of the PREVIEW participants does not allow generalization of the 
results presented to all ethnic groups, but primarily to Caucasians. 
The dropout rates during the LED were generally low, but varied across centers from 2.5% to 
14.4%. The lower drop-out rate in men might be explained by the greater, early success 
experienced by the men on the LED. There can be many reasons for the differences in drop-outs 
across sites. In some sites, the participants were not as familiar with using formula LEDs for weight 
loss as in other centers, so the cultural and social challenges varied. Differences in compliance and 
efficacy of a LED in different settings have also been reported in an earlier large-scale study (37). 
As outlined in this discussion many aspects could have contributed to the gender-specific effects 
that we found. The regional fat distribution is indeed different between men and women, and as 
described earlier, men may mobilize more intra-abdominal fat than women, whereas women may 
lose more subcutaneous fat during weight loss (14,15). However, our aim with these analyses was 
not to attempt to disentangle the various contributors to the gender-specific effect (i.e. the 
gender-specific hormones, behavior and compliance during the LED etc).  Our aim was to assess 
the gender-specific effect as a whole. A future analysis of our data could explore what constitutes 
the gender-specific effects. 
In the separate analysis investigating differences between the age groups within the female 
population, we found several significant findings. Whether these findings are clinically important 
or just statistically significant findings is hard to interpret.     
Generally, weight loss is known to be associated with improvements in liver transaminases once 
weight stability has been achieved (39). However, our current study is consistent with the existing 
literature by showing that transient mild increases in liver enzymes can be observed in some 
individuals immediately after a LED period (39). The increments were significantly larger in the 
women than in the men. From previous studies it has been reported that the values return to 
normal within a few weeks (24). The consequences of the changes are believed to be benign if the 
enzyme elevation is transient (39).  
An important strength of our study is the large sample size and the wide age span, in all sites, in 
Europe, Australia and New Zealand. In addition, criteria for identifying pre-diabetes were 
consistent from site to site as the ADA criteria (IFG = 5.6-6.9 mmol/l) (22 ,40) were used. The 
range for identifying IFG according to the World Health Organization is narrower (6.1-6.9 mmol/l ) 
(40). However, in the present study, following LED weight loss, more than 35% of the men and 
women with IFG at screening reverted to normo-glycaemia. A recent systematic review and meta-
analysis concluded the risk of cardiovascular disease was increased in people with FPG as low as 
5.6 mmol/l.  When considering participants with IFG, according to the WHO criteria (41) (>6.1 
mmol/l), n = 790), 442 participants (55.9%) were no longer classified with pre-diabetes after the 
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LED weight loss. This number increased to 62.6%, when including only those participants with a 
successful weight loss (i.e. ≥ 8% of initial body weight).  
The results presented in this analysis only provide data on short-term changes. Indeed 
maintaining weight loss and the accompanying improvements is challenging (42, 43). Whether 
the PREVIEW participants are able to maintain the weight loss and achieved metabolic responses; 
and whether changes between genders persist in the long-term will be apparent once the trial is 
completed.  However, the 8 week LED, in individuals with pre-diabetes, did results in the initial 
10% weight loss needed to achieve major metabolic improvement in the first phase of a diabetes 
prevention programme. 
CONCLUSION 
In conclusion, an 8-week LED was accompanied by significant improvements in anthropometry, 
blood pressure and metabolic profile in overweight, women and men with pre-diabetes. Whilst 
HOMA-IR improved in all participants, (regardless of gender), men lost significantly more body 
weight than women, and had larger reductions in the metabolic syndrome Z-score, C-peptide and 
fat mass, even after adjusting for differences in weight loss (%). In contrast, women had larger 
reductions in HDL-cholesterol, fat free mass and BMC that could be considered undesirable. 
These findings are clinically important and suggest gender-specific changes in men and women 
after weight loss. It is of importance to investigate whether the greater reductions in FFM, hip 
circumference and HDL-cholesterol in women after a rapid weight loss is indeed beneficial or on 
the contrary might compromise weight loss maintenance and future optimal / good 
cardiovascular health. 
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ABSTRACT  
Aims 
To assess the effects of a weight maintenance period comprising two diets differing in protein 
intake, after weight loss, on intrahepatic lipid content and implications for insulin sensitivity.  
Materials and methods 
 A total of 25 participants (BMI: 31.1±3.5 kg/m2; intrahepatic lipid (IHL): 8.7±8.3%; fasting glucose: 
6.4±0.6 mmol/l; HOMA-IR: 3.7±1.6; Matsuda index: 3.4±2.9) started an 8-week low energy diet 
followed by a 2-year weight maintenance period with either high protein (HP) or medium protein 
(MP) dietary guidelines. At baseline, after 6 months and after 2 years, IHL, visceral adipose tissue 
(VAT) and subcutaneous adipose tissue (SAT) were determined by magnetic resonance 
spectroscopy/imaging. Glucose and insulin concentrations, determined during an oral glucose 
challenge, were used to assess the HOMA-IR and Matsuda insulin sensitivity index (ISI). Protein 
intake was measured with 24-h urinary nitrogen excretion. 
Results 
Protein intake, BMI, IHL, VAT, SAT, HOMA-IR and ISI did not change differently between the 
groups during the intervention. In the whole group, BMI, IHL, VAT, SAT, HOMA-IR, and ISI were 
favourably changed at 6 months and 2 years compared to baseline (p<0.05). Mixed model 
analysis showed that independent of BMI, protein intake (g·d
-1
) at 6 months was inversely related 
to IHL (coefficient:-0.04; p<0.05) and VAT (coefficient:-0.01; p<0.05). Overall, IHL was positively 
related to HOMA-IR (coefficient: 0.10; p<0.01) and inversely related to ISI (coefficient: -0.17; 
p<0.01), independent of BMI. 
Conclusion 
A 2-year medium- to high-protein energy restricted diet reduced IHL and VAT. Independently of 
changes in BMI, IHL was inversely related to insulin sensitivity.   
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INTRODUCTION 
The increase in obesity and type 2 diabetes is paralleled by an alarming increase in nonalcoholic 
fatty liver disease (NAFLD) with NAFLD being defined as intrahepatic lipid content exceeding 5% 
of liver weight (1). Reasons for intrahepatic lipid accumulation in NAFLD can be manifold, but 
most are associated with the metabolic consequences of excess body fat accumulation (2). Long-
term excessive storage of free fatty acids (FFA) as triglycerides in subcutaneous adipose tissue 
depots eventually exceeds the functionally normal storage capacity of the subcutaneous adipose 
tissue depots, leading to spill over of FFA to other ectopic tissues, including the liver (3, 4).  
Ectopic fat accumulation and increased de novo lipogenesis in individuals with NAFLD are 
associated with the development of systemic insulin resistance. The prevalence of NAFLD in the 
general population is estimated to be about 20-30%, prevalence of NAFLD in type 2 diabetic 
individuals is estimated to be around 70% (5). While NAFLD is often perceived as a pathway to 
insulin resistance (6), there is also evidence for the perspective of NAFLD being a consequence of 
adiposity induced metabolic dysfunction (7).  
To elucidate the role of NAFLD for metabolic disease it is of particular interest to differentiate the 
role of intrahepatic lipid accumulation relative to other adipose tissue compartments for 
metabolic consequences. Even though hepatic fat has been associated with visceral fat 
accumulation (8), there is also research showing that their respective impact on metabolic risk 
may be independent (9). The latter perspective is supported by data showing no increase in 
metabolic dysfunction with concomitantly increased whole body adiposity, if the amount of liver 
fat was not affected (10). The specific importance for intrahepatic fat relative to visceral and 
subcutaneous fat for metabolic health finds further support in results showing that weight loss 
induced a decrease in liver fat content and the associated improvements in insulin sensitivity 
remained throughout a 2-year follow-up period, in spite of weight and fat mass regain (11). The 
role of weight loss as a primary intervention for NAFLD seems to be pivotal (12). The addition of 
physical activity to a dietary intervention was shown to further promote reductions in intrahepatic 
fat (13) and in people with and without NAFLD, exercise training lead to a reduction in 
intrahepatic fat (14).  
While there is research assessing the effect of dietary fat and carbohydrate intake on liver fat 
accumulation (15), studies investigating the effect of protein intake are relatively sparse. Protein 
supplementation was shown to be associated with reduced hepatic fat in short-term studies (16-
18), but data on longer-term effects of increased protein intake is lacking.  
The goal of the current study was to investigate long-term effects of weight maintenance with 
increased protein intake, after weight loss, on intrahepatic lipid content (IHL) and its implication 
for insulin sensitivity. Considering the evidence from short term studies we hypothesized that 
participants with higher protein intake during weight maintenance after weight loss would have 
reduced IHL and increased insulin sensitivity compared to participants with moderate protein 
intake during weight maintenance after weight loss. 
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RESEARCH DESIGN AND METHODS 
Participants  
Twenty-five participants were recruited from the PREVIEW cohort at Maastricht University. The 
PREVIEW study (Prevention of Diabetes through lifestyle intervention and population studies in 
Europe and around the World, EU 7th Framework Programme, grant agreement no. 312057, 
ClinicalTrials.gov NCT01777893) has been initiated to find the most effective lifestyle (diet and 
physical activity) for the prevention of type 2 diabetes in overweight and obese participants with 
increased risk for type 2 diabetes (www.previewstudy.com) (19). Inclusion criteria were: age 25-70 
years, BMI >25 kg/m
2
, pre-diabetes using the American Diabetes Association criteria (20):  fasting 
plasma glucose of 5.6 – 6.9 mmol/l and/or plasma glucose concentration of 7.8 – 11.0 mmol/l at 
2h after an oral glucose tolerance test (OGTT) with fasting plasma glucose <7.0 mmol/l, and 
willingness to undergo MRI procedures. All participants provided written informed consent for 
participation. The study was approved by the Medical Research Ethics Committee of Maastricht 
University Medical Center and in accordance with guidelines of the Declaration of Helsinki.  
Study design 
The intervention consisted of two phases: a two-month period of rapid weight reduction using a 
low energy diet (LED), followed by a weight maintenance period with instructions to follow dietary 
guidelines in two groups, a moderate protein (MP) and high protein (HP) group. Measurements 
were performed at baseline, after 6 months and after 2 years after an overnight >10h fasting 
period. Measurements included body weight and anthropometrics, proton magnetic resonance 
spectroscopy (
1
H-MRS) for quantification of IHL, MRI to determine subcutaneous and visceral 
adipose tissue, blood sampling before and during an OGTT. Prior to the investigation day, 
participants collected 24-hour urine to determine nitrogen excretion as a marker for protein 
intake.  
Weight loss period 
After the baseline measurements, participants started with an eight-week low energy LED period 
with the aim to lose at least 8% of their body weight. The LED provided 3.4 MJ (35-40 percentage 
of energy (En%) protein, 45-50 En% carbohydrate, 15-20 En% fat) per day with four sachets of the 
Cambridge Weight Plan
®
, 3 of which were dissolved in 250 mL low fat milk and one in 250 mL 
water. Additionally, energy-free drinks and <400 gram per day of non-starchy, low-carbohydrate 
vegetables (e.g. lettuce, asparagus, broccoli, celery, cucumber, mushrooms, radish, tomato, and 
watercress) were allowed.  
Weight maintenance period  
Participants were randomized into two dietary intervention groups at the start of the study. 
Participants received no information regarding their intervention group until after the LED phase. 
Both diets were consumed ad libitum with respect to energy, but with the instruction to maintain 
the achieved body weight. Additional weight loss was allowed. Dietary intervention groups 
comprised a moderate protein (MP) group with 15 En% of energy from protein, 55 En% of 
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carbohydrates, 30 En% of fat and a moderate dietary glycaemic index (GI) (≥56), and a high 
protein (HP) group with 25 En% of energy from protein, 45 En% of carbohydrates, 30 En% of fat, 
with a low dietary GI (≤50). Participants were given examples of daily eating plans according to 
the macronutrient and GI requirements of the two intervention groups. Furthermore they 
received cooking books that were created for their dietary group. Participants were instructed 
about controlling portion sizes of specific food types in order to achieve the macronutrient 
and GI prescriptions, and in self-monitoring and adjustment of portion sizes in general, in 
order to maintain their body weight loss. They were encouraged to follow a regular meal 
pattern. More detailed information on the dietary guidelines and of the intervention groups has 
been reported before (19). 
Body weight and anthropometrics  
Body weight was measured using a calibrated scale (Life Measurement Corporation, Inc, Concord, 
CA, USA) and body composition was determined based on body density measured via air-
displacement plethysmography with the BodPod System (Life Measurement Corporation, Inc, 
Concord, CA, USA) (21), utilizing Siri’s equation for body density (22). Height was measured using 
a wall-mounted stadiometer to the nearest 0.1 cm (Seca, model 222, Seca, Hamburg, Germany).  
Regional fat deposition; IHL, VAT, SAT 
IHL was quantified with 1H-MRS on a 3.0-T whole-body scanner (Achieva 3Tx; Philips Healthcare, 
Best, The Netherlands) and a 32-element sense cardiac/torso coil. 
1
H-MR spectra were obtained 
from a 20x20x20 mm
3
 volume of interest (VOI) placed centrally in the right lobe of the liver by 
using point-resolved spectroscopy volume selection (PRESS) with a repetition time (TR) of 4000 
ms and echo time (TE) of 32.5 ms and NSA = 64. The water resonance was suppressed by using a 
chemical shift selective water suppression technique. Shimming was performed by using second-
order FASTMAP (fast, automatic shimming technique by mapping along projections)–based 
shimming. A water reference spectrum was acquired with NSA = 8. Special care was taken to 
ensure that the VOI was placed at the same location during the two measurements.  
The participants were instructed to breathe at a 4s-rhythm, which was monitored with a pressure-
sensitive sensor on the belly. Signals were acquired during the expired breathing phase. Spectra 
were analyzed using a MATLAB (version 7, The Mathworks Inc.) script, which phased and aligned 
all the spectra individually. Spectra with a full width at half maximum or peak height 1.5 SD above 
or below the mean of all acquired spectra were removed. Lipid-methylene (CH2) and water peaks 
were fitted using a combination of Gaussian and Lorentzian line shape (50/50%). T2 relaxation 
times of 60 ms for the methylene peak and 26 ms for the water peak were used for quantification 
of IHL (23, 24). 
Visceral adipose tissue (VAT) and subcutaneous adipose tissue (SAT) were determined during the 
same scanning session as the IHL. T1-weighted TSE imaging at the L5 vertebral body was used to 
obtain a two-dimensional transversal image (Repetition time= 500 ms Echo time= 15 ms). Images 
were analyzed using OsiriX (version 3.9.2, Pixmea SARL, Switzerland). Regions of interest (ROI) 
were manually drawn following the skin and the abdominal wall. SAT was calculated by 
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subtracting the area of the abdominal wall ROI from the area of the skin ROI. VAT was quantified 
within the abdominal wall ROI based on intensity segmentation, with a lower intensity threshold 
of 450. 
Oral Glucose Tolerance Test  
Participants underwent a 2-hour 75-gram OGTT after an overnight fast >10 hours. Blood samples 
to determine glucose and insulin concentrations were taken prior to, as well as 30, 60, 90 and 120 
minutes after receiving a glucose load. 
Blood samples and insulin sensitivity  
Blood samples were drawn from an antecubital vein and stored at -80°C. Samples were analysed 
at the National Institution for Health and Welfare in Helsinki, Finland. Plasma glucose was 
measured by enzymatic hexokinase method and insulin and C-peptide concentrations were 
measured using chemiluminescent microparticle immunoassay. Laboratory measurements are 
performed on Architect ci8200 analyzer (Abbott Laboratories, Abbott Park, IL, USA). The 
homeostatic model assessment (HOMA-IR) was used to assess insulin resistance and was 
calculated as follows: fasting glucose x fasting insulin / 22.5 (25). Insulin sensitivity was calculated 
with the Matsuda index: Insulin sensitivity index derived from OGTT (ISI) =10,000 / √(fasting 
glucose x fasting insulin) x (mean glucose x mean insulin during OGTT) (26).  
Urinary nitrogen 
Nitrogen excretion was measured from 24-hour urine collections, as a marker of protein intake. 
Urine was collected in 2 L urine bottles that contained 10 mL 4M hydrochloric acid to prevent 
nitrogen loss. Nitrogen concentration was measured with a nitrogen analyzer (CHO-O-Rapid; 
Hereaus) and multiplied with the total volume to determine nitrogen excretion per day. Nitrogen 
excretion per day was multiplied by 6.25 and divided by the body weight to determine daily 
oxidation per kilogram body weight. 
Physical activity 
Physical activity was assessed using the ActiSleep+ accelerometer (Actigraph LLC, Pensacola, FL). 
Participants wore the accelerometer for seven consecutive days on the right side of an elastic belt 
around the waist. Data was collected at 100 Hertz and aggregated to 60 second epochs. After 
removal of sleep episodes, average counts per minute (CPM) were calculated. 
Statistical analysis 
Data were expressed as mean ± SD. Values of non-normally distributed variables were 
logarithmically transformed. Factorial ANOVA was used to assess differences between groups at 
baseline. Pearson’s correlations were used to identify correlations between parameters at 
baseline. Two-way repeated measures ANOVA was used to test differences between groups and 
gender over time. Repeated-measures ANOVA was used to test differences over time for the 
whole group. Mixed model regression analysis was used to determine the relation between 
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protein intake and regional fat deposition, physical activity and regional fat deposition and 
regional fat deposition and indices of insulin sensitivity, independent of BMI. Two-tailed P values 
<0.05 were considered statistically significant. Statistical analyses were performed using the 
Statistical Package for the Social Sciences (SPSS, IBM Corp., IBM SPSS Statistics, V23, Armonk, NY, 
USA). 
RESULTS 
Characteristics of the two groups during the intervention period  
Characteristics of the two intervention groups are presented in TABLE 1. Alanine 
aminotransferase (ALT) and aspartate aminotransferase (AST) were lower in the HP group 
compared to the MP group at baseline. No other parameters were significantly different between 
groups at baseline. There were no differences between the groups or between men and women 
regarding changes in regional fat deposition, anthropometry or blood parameters over time, 
throughout the intervention period.  
Nitrogen excretion and protein oxidation  
Protein intake, determined by nitrogen excretion (g·d
-1
)
 
and protein oxidation (g·kg
-1
·d
-1
) in the 
two groups are shown in TABLE 2. Nitrogen excretion and protein oxidation did not change 
differently between groups. Therefore, both groups were combined and further analysis was 
performed in the total group of participants. 
Regional fat deposition, anthropometry, and blood parameters at baseline for all participants 
together  
With respect to anthropometrics, baseline IHL (r=0.55; p<0.01), VAT (r=0.72; p<0.01) and SAT 
(r=0.61; p<0.01) were positively related to BMI. Regarding indices of insulin sensitivity, IHL was 
positively associated with fasting concentrations of insulin (r=0.48, p<0.05), C-peptide (r=0.50, 
p<0.05) and HOMA-IR (r=0.58, p<0.01). Neither VAT nor SAT was related to indices of insulin 
sensitivity. Regarding liver enzymes, IHL was positively associated with ALT (r=0.69, p<0.01) and 
AST (r=0.49, p<0.05). 
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TABLE 1. Participant characteristics in the MP and HP group 
 
Total group (n=25) MP (n=13) HP (n=12) 
 
Baseline 6 months 2 years Baseline 6 months 2 years Baseline 6 months 2 years 
Sex 11w/13m   5w/7m 
  
6w/6m 
  Age (yr) 56.0±11.1   54.3±13.1 
  
57.9±8.6 
  Weight (kg) 92.8±16.3 81.4±13.0* 85.2±14.8*# 94.0±14.5 81.9±10.5* 84.6±11.1*# 91.7±16.5 80.9±15.7* 85.9±18.3*# 
BMI (kg/m
2
) 31.1±3.5 27.4±3.63* 28.7±3.8*# 31.4±3.1 27.5±2.4* 28.3±2.6*# 30.9±4.0 27.3±4.0* 29.0±4.8*# 
Body-fat (%) 41.0±6.5 32.9±8.3* 37.2±8.5*# 41.3±7.3 33.2±7.8* 36.5±8.5*# 40.6±6.0 32.7±9.1* 37.8±8.9*# 
IHL (%) 8.7±8.3 2.4±3.0* 3.9±3.5*# 11.3±9.9 3.0±3.2* 4.8±3.7* 5.8±5.1 1.7±2.7* 3.0±3.3*# 
IHL (log) 0.68±0.56 0.10±0.50* 0.34±0.57*# 0.83±0.57 0.26±0.48* 0.46±0.56* 0.52±0.54 -0.09±0.49* 0.20±0.57*# 
SAT (cm
2
) 344.2±72.1 271.4±86.2* 304.7±82.3*# 360.5±73.7 285.0±99.3* 302.9±97.5* 324.3±69.0 254.8±68.9* 306.9±64.9# 
SAT (log) 2.5±0.1 2.4±0.1* 2.5±0.1*# 2.5±0.1 2.4±0.2* 2.5±0.2* 2.5±0.1 2.4±0.1* 2.5±0.1# 
VAT (cm
2
) 311.8±79.4 192.1±55.1* 229.4±93.7*# 316.4±74.9 202.0±51.4* 228.1±85.1* 306.1±88.8 180.0±60.0* 231.0±108.7# 
VAT (log) 2.5±0.1 2.3±0.1* 2.3±0.2*# 2.5±0.1 2.3±0.1* 2.3±0.2* 2.5±0.1 2.2±0.2* 2.3±0.2*# 
Insulin (mU/l) 13.4±5.6 8.8±3.1* 9.5±3.5* 14.8±6.0 9.4±3.5* 10.4±3.7* 11.9±4.9 8.1±2.6* 8.6±3.2* 
Glucose (mmol/l) 6.4±0.6 6.0±0.4* 6.0±0.5* 6.2±0.5 5.9±0.3 5.9±0.5 6.6±0.6 6.1±0.5* 6.1±0.5* 
C-peptide (pmol/l) 931.3±264.1 645.6±136.5* 724.5±188.2*# 1010.4±264.6 678.1±109.2* 755.1±154.4* 852.1±250.4 613.2±157.7* 693.9±66.4* 
HOMA-IR 3.7±1.6 2.2±0.7* 2.4±0.8* 4.1±1.7 2.4±0.9* 2.7±0.9* 3.2±1.3 2.0±0.4* 2.1±0.7* 
HOMA-IR (log) 0.5±0.2 0.3±0.1* 0.4±0.2* 0.56±0.25 0.36±0.15* 0.40±0.16* 0.48±0.19 0.29±0.09* 0.30±0.15* 
ISI 3.4±2.9 5.2±2.1* 4.8±2.1* 3.3±3.9 4.7±2.3 4.7±2.2 3.5±1.4 5.7±1.8* 5.0±2.1* 
ISI (l) 0.44±0.26 0.68±0.18* 0.65±0.19* 0.38±0.32 0.63±0.22* 0.62±0.21* 0.51±0.19 0.74±0.13* 0.67±0.17* 
HbA1c (%) 5.4±0.3 5.2±0.3* 5.4±0.3# 5.3±0.22 5.1±0.2* 5.2±0.2# 5.5±0.3 5.3±0.3* 5.5±0.4# 
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TABLE 1. continued 
 Total group (n=25) MP (n=13) HP (n=12) 
 Baseline 6 months 2 years Baseline 6 months 2 years Baseline 6 months 2 years 
ALT  19.3±10.3 13.9±3.8* 13.7±5.0* 23.3±11.2† 13.9±3.4* 14.4±4.3* 15.4±7.9 13.9±4.2 13.1±5.8 
ALT (log) 1.23±0.23 1.13±0.12 1.11±0.15* 1.32±0.23† 1.13±0.10* 1.14±0.12* 1.14±0.20 1.12±0.14 1.08±0.18 
AST 28.9±9.2 24.1±4.3* 23.9±3.4* 33.5±11.1† 24.7±2.9* 25.0±3.2* 24.2±2.7 23.5±5.4 22.7±3.4 
AST (log) 1.44±0.13 1.38±0.08* 1.37±0.06* 1.50±0.16† 1.40±0.05* 1.39±0.06* 1.38±0.05 1.36±0.10 1.35±0.06 
CPM 322.7±119.2 361.1±152.3 325.9±95.8 361.0±132.1 432.0±190.0 336.3±112.4 293.9±95.3 308.0±67.7 318.1±77.2 
HDL (mmol/l) 1.31±0.25 1.43±0.31* 1.37±0.30*# 1.31±0.3 1.47±0.38* 1.39±0.38 1.32±0.18 1.39±0.24 1.35±0.19 
LDL (mmol/l) 3.80±0.89 3.45±0.86 3.74±0.77# 3.70±1.12 3.49±0.95 3.78±1.00# 3.89±0.66 3.42±0.80* 3.70±0.59* 
TG (mmol/l) 1.43±0.69 1.21±0.59* 1.40±1.09 1.55±0.85 1.27±0.66* 1.61±1.46 1.30±0.49 1.15±0.53 1.19±0.54 
Data are presented as mean ± standard deviation. Baseline difference between groups were assessed by means of factorial ANOVA, † P<0.05. Differences over 
time between MP and HP were assessed by means of factorial repeated-measures ANOVA; none were found. Changes over time within groups were 
determined using repeated-measures ANOVA, * P<0.05 significantly different from baseline, #P<0.05, significantly different from 6 months. MP = moderate 
protein; HP = high protein; IHL = intrahepatic lipid; VAT = visceral adipose tissue; SAT = subcutaneous adipose tissue; HOMA-IR = homeostatic model 
assessment for insulin resistance; ISI= insulin sensitivity index; HbA1c= glycated hemoglobin; ALT = alanine aminotransferase; AST = Aspartate 
aminotransferase; (log) = log-transformed; CPM =counts-per-minute; HDL = high-density lipoprotein; LDL= low-density lipoprotein; TG = triglyceride 
 
TABLE 2.  Protein oxidation was not different between the MP and HP group 
MP (n=13) Baseline 6 months 2 years 
Nitrogen excretion (g·d
-1
) 12.3±4.0 13.7±2.9 14.5±4.6 
Protein oxidation (g·kg
-1
·d
-1
) 0.81±0.2 1.03±0.2 1.10±0.5 
HP (n=12)    
Nitrogen excretion (g·d
-1
) 12.8±5.2 14.6±5.3 12.6±4.1 
Protein oxidation (g·kg
-1
·d
-1
) 0.86±0.2 1.12±0.3 0.95±0.3 
Data are presented as mean ± standard deviation. Baseline difference between MP and HP groups were assessed by means of factorial ANOVA, * P<0.05. 
Differences over time between MP and HP were assessed by means of two-way repeated-measures ANOVA; none were found. MP = moderate protein; HP = 
high protein 
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Changes in regional fat deposition, anthropometry, activity and blood parameters during the 
intervention period  
For the whole group, BMI, body-fat percentage (BF%), IHL, VAT, SAT, and C-peptide were 
significantly lower at 6 months and 2 years compared to baseline (Table 1). BMI (42.0±40.5% of 
amount lost), BF% (71.2±56.3% of amount lost), IHL (24.0±72.0% of amount lost), VAT 
(39.0±48.5% of amount lost) and SAT (73.9±122.7% of amount lost) increased again from 6 
months to 2 years. Activity (CPM) did not change during the intervention period. Glucose, insulin, 
HOMA-IR, ALT and AST were lower at 6 months and remained on that level during 2 years 
compared to baseline. ISI increased from baseline to 6 months and remained at that level during 
2 years. HbA1c decreased from baseline to 6 months and increased again from 6 months to 2 
years. HDL was significantly higher at 6 months and 2 years compared to baseline, and lower at 2 
years compared to 6 months. LDL was significantly higher at 2 years compared to 6 months. 
Triglyceride concentration was significantly lower at 6 months compared to baseline. The number 
of participants with NAFLD, as defined by IHL exceeding 5%, decreased from 15 participants at 
baseline to 3 participants at 6 months, and increased to 7 participants at 2 years.  
Effect of protein intake assessed by urinary nitrogen and physical activity on regional fat 
deposition during the intervention period 
The effect of nitrogen excretion on IHL, VAT or SAT during the intervention period, adjusted for 
BMI, was assessed using repeated measures mixed model regression analysis (TABLE 3). There 
was a significant time*nitrogen excretion effect throughout the whole study period (p<0.001) for 
IHL and VAT, with a significant inverse relation between nitrogen excretion and IHL and VAT at 6 
months but not at baseline or after two years. There was no significant effect of nitrogen 
excretion on SAT. There was no significant effect of physical activity (CPM) on IHL, VAT or SAT. 
Effect of regional fat deposition on indices of insulin sensitivity and blood parameters during the 
intervention 
There was an overall effect of IHL (%, log transformed) on HOMA-IR (log transformed; estimate= 
0.10; lower 95% CI: 0.01; upper 95% CI: 0.19; p<0.05), ISI (log transformed; estimate= -0.16, lower 
95% CI: -0.25; upper 95% CI: -0.06; p<0.01), and C-peptide (pmol/l; estimate= 102.2, lower 95% CI: 
18.7; upper 95% CI: 185.7; p<0.05), adjusted for BMI. There was no significant effect of IHL on 
fasting insulin or fasting glucose. There were no significant effects of VAT and SAT on indices of 
insulin sensitivity or blood parameters.  
DISCUSSION 
We assessed effects of increased daily protein intake from 0.82±0.2 g/kg to 1.05±0.3 g/kg, on 
regional fat deposition and insulin sensitivity in men and women at risk for T2D, during a weight 
loss and weight maintenance intervention. We did not find differences in changes in regional fat 
deposition between the MP and HP group, which is most likely explained by the fact that groups 
did not differ in protein intake. Lack of a significant difference in protein intake at 6 months and 2 
years between the two groups could in part be explained by a large dispersion of the data. The 
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sub-group of 25 subjects did not have the power to result in two groups with statistically 
significant protein intakes. Nevertheless, in the whole group, protein intake at 6 months was 
inversely associated with IHL, independent of BMI. Furthermore, the close relationship between 
IHL and insulin resistance was evidenced by the positive association between IHL and HOMA-IR at 
baseline as well as by the positive association between IHL and HOMA-IR and negative 
association between IHL and ISI during the intervention. There were no changes in activity (CPM) 
and CPM were not related IHL, VAT, SAT or indices of insulin sensitivity during the intervention. 
TABLE 3. Effect of protein intake, determined by nitrogen excretion on IHL, VAT and SAT during the 
intervention 
Dependent variable Time Estimate Lower 95% CI Upper 95% CI p 
IHL Baseline -0.01 -0.03 0.00 0.117 
 6 months -0.04 -0.05 -0.02 0.000 
 2 years 0.01 -0.01 0.02 0.320 
      
VAT Baseline 0.00 -0.01 0.01 0.560 
 6 months -0.01 -0.02 -0.00 0.001 
 2 years 0.00 -0.00 0.02 0.153 
      
SAT Baseline -0.00 -0.01 0.00 0.093 
 6 months 0.00 -0.01 0.01 0.163 
 2 years -0.00 -0.01 0.00 0.295 
Mixed modeling analysis was used to determine the effect of protein intake, determined by nitrogen 
excretion (g·d
-1
), on IHL (%, log transformed), VAT (mm
2
, log transformed) and SAT (mm
2
, log 
transformed), adjusted for BMI. There was a significant time*nitrogen excretion effect (p<0.001) in the 
models for IHL and VAT. IHL = intrahepatic lipid; VAT = visceral adipose tissue; SAT = subcutaneous 
adipose tissue 
Diets with higher protein content have been shown to change body composition by sparing fat 
free mass and reducing fat mass, and to promote metabolic health, especially during weight 
maintenance after weight loss (28, 46). While evidence of long-term effects of protein intake on 
IHL is lacking, short-term hyper- and isocaloric studies with protein supplementation showed 
reductions of IHL in healthy participants, participants with obesity and participants with type 2 
diabetes (16-18,). We found that protein intake at 6 months was inversely associated with IHL, 
independent of BMI. With regard to long-term metabolic impact, it is known that total amount of 
protein intake, rather than changes in protein intake is the significant factor to consider (29). 
Protein intake has also been shown to prevent lipid accumulation during weight (re)gain (11, 30, 
31) and hence may facilitate long-term metabolic benefits of weight loss, despite weight regain in 
at risk participants. 
Rodent data have shown that increased protein intake leads to decreases in IHL due to 
downregulation of lipogenesis as well as increased hepatic lipid oxidation and utilization (31, 32). 
Another explanation for the effects of protein intake on IHL may be decreased carbohydrate or fat 
intake in exchange for increased protein intake. Both, increased carbohydrate, especially fructose, 
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and increased fat intake have been linked to hepatic lipid accumulation in animals and humans 
(33), but mechanisms by which either may induce hepatic lipid accumulation may be different 
(34). In humans with overweight and obesity, a hypocaloric diet low in carbohydrates and a 
hypocaloric diet low in fat with equal protein content led to similar reductions in intrahepatic 
lipids (35).  
The weight change induced by the 8 week weight loss and weight maintenance intervention led 
to reductions in regional fat deposition and BF%. This was accompanied by favorable changes in 
indices of insulin sensitivity and blood parameters. The number of participants with NAFLD 
decreased from 15 to 7 after 2 years, which is especially relevant in our study population with 
increased risk for the development of diabetes. NAFLD has been shown to be an independent risk 
factor for the development of type 2 diabetes, with studies reporting up to 5.5 higher risk ratio 
(36, 37). We found a positive association between changes in IHL and insulin resistance (HOMA-
IR) and a negative association with insulin sensitivity (ISI), independent of changes in BMI. Similar 
relations between IHL and hepatic, skeletal and adipose tissue insulin sensitivity have been 
reported, with insulin sensitivity being measured using a euglycemic-hyperinsulinemic clamp 
procedure (38, 39). Reductions in hepatic insulin resistance along with a reduction in IHL have 
been shown to occur within days while increases in whole body insulin sensitivity are less rapid 
(40). Many authors have shown the close relation between liver fat accumulation and insulin 
resistance and it is suggested that the two reciprocally aggravate each other (41, 42). Intrahepatic 
lipid impairs insulin signaling and disrupts inhibitory effect of insulin on gluconeogenesis and 
stimulatory effects on glycogen synthesis. Especially increased diacylglycerol concentrations in the 
liver has been associated with hepatic insulin resistance 43). Increased diacylglycerol has been 
shown to activate protein kinase Cε which then reduces the phosphorylation of insulin receptor 
substrate-2. This impairs the activity of Akt2, leading to reduced glycogen synthesis and increased 
gluconeogenesis. In relation to this pathway, hepatic diaclyglycerol and protein kinase Cε activity 
was shown to be the strongest predictor of insulin resistance in humans with obesity (44, 45).  
Insulin resistance in adipose tissue leads to increased lipolysis, increasing non-esterified fatty 
acids in the circulation, which will be taken up by the liver (46). In accordance with those previous 
findings we found that IHL was positively related to fasting insulin and C-peptide concentrations 
at baseline and changes were also closely related to changes in C-peptide concentrations. The 
close link between increased IHL and hyperinsulinemia may be explained by reduced hepatic 
insulin clearance and/or increased pancreatic insulin secretion (47, 48). Hyperinsulinemia and 
increased C-peptide have been postulated as both a consequence and cause of insulin resistance 
(49, 50). 
To our knowledge, the present study is the first to assess long-term effects of weight loss and 
subsequent increased protein intake on IHL. Our study population consisted of people with 
overweight/obesity and IFG/IGT. The participants presented with increased and large ranges in 
IHL, BMI and insulin resistance. While our two groups did not statistically differ in protein intake, 
we were able to relate protein intake, measured by nitrogen excretion in the urine at 6 months of 
the intervention, with IHL.  
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In conclusion, a 2 year relatively high- or medium protein energy restricted diet reduced IHL and 
VAT and increased insulin sensitivity. The reduction in IHL was inversely related to insulin 
sensitivity, independent of BMI. These findings stress the clinical implications and potential 
benefits of increased protein intake after weight loss for people with NAFLD at risk to develop 
diabetes.  
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ABSTRACT  
The objective was to assess the effects of a weight loss and subsequent weight maintenance 
period comprising two diets differing in protein intake, on brain reward reactivity to visual food 
cues. Brain reward reactivity was assessed with functional magnetic resonance imaging in 27 
overweight/obese individuals with impaired fasting glucose and/or impaired glucose tolerance 
(HOMA-IR: 3.7 ± 1.7; BMI: 31.8 ± 3.2 kg/m
2
; fasting glucose: 6.4 ± 0.6 mmol/L) before and after an 
8-week low energy diet followed by a 2-year weight maintenance period, with either high protein 
(HP) or medium protein (MP) dietary guidelines. Brain reactivity and possible relationships with 
protein intake, anthropometrics, insulin resistance and eating behaviour were assessed. Brain 
reactivity, BMI, HOMA-IR and protein intake did not change differently between the groups 
during the intervention. In the whole group, protein intake during weight maintenance was 
negatively related to changes in high calorie images>low calorie images (H > L) brain activation in 
the superior/middle frontal gyrus and the inferior temporal gyrus (p < 0.005, corrected for 
multiple comparisons). H > L brain activation was positively associated with changes in body 
weight and body-fat percentage and inversely associated with changes in dietary restraint in 
multiple reward, gustatory and processing regions (p < 0.005, corrected for multiple 
comparisons). In conclusion, changes in food reward-related brain activation were inversely 
associated with protein intake and dietary restraint during weight maintenance after weight loss 
and positively associated with changes in body weight and body-fat percentage. 
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INTRODUCTION 
Overweight and obesity are established risk factors for the development of type 2 diabetes (T2D) 
(1) and insulin resistance (2). Both, obesity and T2D have been associated with neuronal 
alterations in areas associated with reward processing (3-5). Comparing obese and normal-weight 
individuals, functional neuroimaging studies have reported increased anticipatory brain activation 
in response to visual food cues in gustatory and reward regions (including the striatum, insula, 
amygdala, orbitofrontal cortex and hippocampus) (6). In response to food consumption however, 
obese individuals showed reduced activation of brain reward circuits compared to normal-weight 
individuals, suggesting decreased inhibitory control (4).  
Along similar lines, patients with T2D showed increased brain activation in response to viewing 
food images in the insula, caudate and orbitofrontal cortex (5) and a lack of inhibition of 
hypothalamic neuronal activity after glucose ingestion (7) compared to healthy controls. Central 
insulin resistance was suggested to possibly play a role in the altered brain activation in both, 
obesity and T2D. In a study measuring cerebral blood flow, a blunted response in the prefrontal 
cortex was observed after intranasal insulin administration in obese men, which was inversely 
related to peripheral insulin sensitivity, independently of BMI (8). Further evidence comes from 
studies finding an inverse relationship between markers of peripheral insulin sensitivity and brain 
activation in response to food cues in brain reward regions (9, 10). In line with these findings, we 
previously reported positive associations between insulin resistance and reactivity to food cues in 
the insula, anterior cingulate gyrus and nucleus accumbens in overweight and obese individuals 
with impaired fasting glucose and/or impaired glucose tolerance (11). Given that insulin binds to 
receptors expressed on neurons in areas of reward processing (12), central insulin resistance may 
contribute to impaired reward signalling, and a reduction in insulin resistance may help to 
normalize the reward response. 
One of the most potent strategies to reduce insulin resistance is body weight loss. It has been 
shown that food-cue reactivity of reward regions was also suppressed along with extended caloric 
restriction (13). Patients with T2D who underwent bariatric surgery showed decreased reward 
activation along with a normalization in glycaemic control, compared to T2D patients without 
surgery and impaired glycaemic control (14). Besides surgery, lifestyle intervention is a tool to 
reduce weight and increase insulin sensitivity. The intervention requires profound changes in 
eating behavior, but it remains unclear how changes in aspects of eating behavior, such as 
cognitive restraint, relate to changes in neuronal activation.  
Considering the well established effect of protein on satiety, diet induced thermogenesis, and the 
preservation of fat free mass during weight loss, it seems to be the intuitive macronutrient in the 
nutritional component of a lifestyle intervention. While largely unknown, the beneficial effects of 
protein for weight loss and weight maintenance may in part be mediated through an effect on 
reward signalling (15). In the rat, brain signalling was reduced in the amygdala after infusion of an 
intragastric protein load (16). Human short-term studies also reported a reduction in brain 
activation to food cues and subsequent reductions in energy (17, 18) or changes in food 
preference (19) after protein ingestion. 
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The aim of the current study was to investigate the effects of weight loss and subsequent weight 
maintenance with higher protein intake versus moderate protein intake on brain reward activity in 
response to visual food cues in participants of the PREVIEW study (Prevention of diabetes through 
lifestyle intervention in population studies in Europe and around the World). The PREVIEW study 
aims to find the most effective lifestyle for the prevention of T2D in overweight and obese 
participants with increased risk for type 2 diabetes (www.previewstudy.com). We hypothesized 
that participants with higher protein intake had reduced brain reactivity to food cues after 2 years 
compared to participants with moderate protein intake. 
MATERIALS AND METHODS 
Participants  
Forty participants were recruited from the PREVIEW-cohort at Maastricht University and a total of 
twenty-seven participants completed both fMRI measurements. Inclusion criteria were: age 25-70 
years, BMI ≥25 kg/m2, fasting plasma glucose of 5.6 – 6.9 mmol/l and/or plasma glucose 
concentration of 7.8 – 11.0 mmol/l at 2h after an oral glucose tolerance test (OGTT), and 
willingness to undergo MRI procedures. Exclusion criteria included T2D, left-handedness, 
claustrophobia and history of neurological disorders in addition to the general PREVIEW exclusion 
criteria (ClinicalTrials.gov NCT01777893). The study was approved by the Medical Research Ethics 
Committee of Maastricht University Medical Center and in accordance with guidelines of the 
Declaration of Helsinki. All participants provided written informed consent for participation. 
Participants started with 8 weeks on a low energy diet (LED), followed by a weight maintenance 
period with instructions to follow dietary guidelines in two groups, a moderate protein (MP) and 
high protein (HP) group. Only participants that reached at least 8% weight loss with the LED were 
allowed to continue in the weight maintenance period. Five participants dropped-out during the 
LED period, seven participants were lost to follow-up during the weight maintenance period. One 
participant lacked valid functional imaging data and had to be excluded from analysis. After this, 
twelve participants completed the study in the MP group and fifteen in the HP group 
(Supplemental figure 1). 
Measurements 
Measurements included functional magnetic resonance imaging (fMRI), body composition, blood 
sampling before and during an oral glucose tolerance test (OGTT) and behavioral questionnaires. 
Prior to the investigation days, participants collected 24-hour to determine nitrogen excretion as 
a marker for protein intake. Accelerometers were worn for 7 days to calculate physical activity. At 
baseline and after 2 years, measurements were performed after an overnight >10h fasting period. 
Study design 
The LED provided 3.4 MJ (35-40 E% protein, 45-50 E% carbohydrate, 15-20 E% fat) per day with 
four sachets of the Cambridge Weight Plan
®
, 3 of which were dissolved in 250 mL low fat milk 
and one in 250 mL water. Additionally, energy-free drinks and <400 gram per day of non-starchy, 
low-CHO vegetables were allowed. Participants were randomized into two dietary intervention 
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groups at the start of the study, but received no information regarding their intervention group 
until after the LED phase. Dietary intervention groups comprised a moderate protein (MP) group 
with 15/55/30% of energy from protein/carbohydrate/fat and a moderate dietary glycaemic index 
(GI) (≥56), and a high protein (HP) group with 25/45/30% of energy from 
protein/carbohydrate/fat, with a low dietary GI (≤50). Both diets were consumed ad libitum with 
respect to energy, but with the instruction to maintain the achieved body weight. Additional 
weight loss was allowed. Participants were given examples of daily eating plans according to the 
macronutrient and GI requirements of the two intervention groups. More detailed information on 
the dietary guidelines and of the intervention groups has been reported before (20). 
Brain imaging paradigm and acquisition 
Participants underwent functional magnetic resonance imaging to obtain blood-oxygen level-
dependent (BOLD) data. Scanning was performed on a 3 Tesla scanner (Magnetom, Siemens, 
Erlangen, Germany) using a 64-channel head coil. Nine randomized blocks of ten images were 
presented during scanning and blocks contained images of high-calorie foods, low-calorie foods 
or non-food objects. Images were chosen from the International Affective Picture System (21) and 
various web sites, which has been described previously (11). High-calorie images included items 
such as fries, mac-and-cheese, hamburgers, donuts etc. Low-calorie images included items suchs 
as fruit salad, cucumbers, carrots, broccoli etc. Food images were randomly shown from sixty 
different images in order to avoid preference and learning effects. Images were shown for 2 
seconds each. Between the blocks, a fixation cross was shown for 10 seconds. Participants 
received the instruction to focus on how much they liked the images. Functional runs were 
collected using a T2*-weighted protocol (TR=2.0s, TE=30.0ms, FOV=216x216, matrix size=72x72, 
voxel size, 3x3x3 mm
3
). Each volume consisted of 34 slices, acquired in interleaved ascending 
order. In each session, anatomical images were acquired with a high-resolution T1 weighted scan. 
Image processing 
Analysis of the fMRI data was performed with BrainVoyager 20.6 (Brain Innovation B.V, Maastricht, 
The Netherlands). Preprocessing of the functional images included slice scan time correction with 
cubic spline interpolation, 3D motion correction and temporal high-pas filtering with 4 cycles. 
Anatomical data was corrected for intensity inhomogeneities. The anatomical scan of each 
participant was transformed into Montreal Neurological Institute (MNI) space. After 
preprocessing, both functional and anatomical scans were aligned based on starting position and 
boundary-based registration. The volume-time-courses were spatially smoothed by applying a 
Gaussian filter (FWHM=6) to increase signal-to-noise ratio. For each participant, food reward-
related brain activation predictors for the three stimuli blocks (high-calorie food images, low-
calorie food images and neutral images) were applied in Generalized Linear Model (GLM) analyses 
and the hemodynamic-response was taken into account by adding a Two Gamma Hemodynamic 
Response Function and movement parameters were modeled as confounding predictors. To 
investigate the two scan sessions dummy coding was applied with the BVA-Predictor Tool 
software (BVA-Predictor Tool, J.M. Born, Maastricht, The Netherlands).  Region of interest (ROI) 
analysis was used to specifically investigate the activation in the right and left nucleus accumbens, 
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the right anterior cingulate gyrus and right insula. Regions were selected based upon previous 
research, which identified food reward related brain activation in these regions to be correlated 
with insulin resistance (11). See supplemental figure 2 for a visualization of the ROIs.  
Body weight and composition  
Body weight was measured using a calibrated scale (Life Measurement Corporation, Inc, Concord, 
CA, USA) and body composition was determined using the BodPod System (Life Measurement 
Corporation, Inc, Concord, CA, USA) (22). Height was measured using a wall-mounted stadiometer 
to the nearest 0.1 cm (Seca, model 222, Seca, Hamburg, Germany). 
Blood samples and urinary nitrogen excretion 
Blood samples were taken to determine fasting glucose and insulin concentrations. The 
homeostatic model assessment for insulin resistance (HOMA-IR) was used to assess insulin 
resistance and was calculated as follows: fasting glucose x fasting insulin / 22.5 (23). Blood 
samples were analysed at the National Institution for Health and Welfare in Helsinki, Finland. 
Plasma glucose was measured by enzymatic hexokinase method and insulin was measured using 
chemiluminescent microparticle immunoassay.  
Nitrogen excretion was measured from 24-hour urine collections, as a marker of protein intake. 
Urine was collected in 2 L urine bottles that contained 10 mL 4M hydrochloric acid to prevent 
nitrogen loss. Nitrogen concentration was measured with a nitrogen analyzer (CHO-O-Rapid; 
Hereaus) and multiplied with the total volume to determine nitrogen excretion per day. Nitrogen 
excretion per day was multiplied by 6.25 and divided by the body weight to determine daily 
oxidation per kilogram body weight. 24-hour urine was collected at baseline, after 6 months, after 
1 year and after 2 years. Averages of the 6 month, 1 year and 2 year samples were used as a 
representation of protein intake during the weight maintenance period.  
Physical activity 
Physical activity was assessed using the ActiSleep+ accelerometer (Actigraph LLC, Pensacola, FL). 
Participant wore the accelerometer for seven consecutive days on the right side of an elastic belt 
around the waist. Data was collected at 100 Hertz and aggregated to 60 second epochs. After 
removal of sleep episodes, average counts per minute (CPM) were calculated.   
Eating behavior 
Eating Behavior was assessed using the Three Factor Eating Questionnaire (TFEQ), which consists 
of 51 questions (24). The three factors it measures are cognitive restraint (TFEQ factor 1), 
emotional eating and disinhibition (TFEQ factor 2) and feelings of hunger (TFEQ factor 3).  
Statistical analysis  
Data are expressed as mean ± SD SPSS 23 (IBM corp., Armonk NY, USA). Variables were tested for 
normality and log-transformed if applicable. Factorial ANOVA was used to assess differences 
between groups at baseline. Two-way repeated measures ANOVA was used to test differences 
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between groups over time. Repeated-measures ANOVA was used to test differences over time for 
the whole group. Two-tailed P values <0.05 were considered statistically significant. For the fMRI 
data, contrasts of interest from single-subject analysis were tested in GLM analyses and then 
submitted to second-level whole brain random effect analysis to compare groups at baseline or 
changes between groups. Contrasts included food (high calorie images + low calorie images) 
versus non-food (neutral images) (F>nF) and high calorie images versus low calorie images (H>L). 
Whole brain correlation analyses was used to test the correlation between changes in F>nF or 
H>L reactivity and changes in anthropometric and behavioral parameters over the intervention 
period in the whole group of participants. Monte Carlo simulations were performed in 
BrainVoyager to identify cluster-extent thresholds with a cluster alpha of 0.005, to correct for 
multiple comparisons. Simulations were performed with 1000 iterations and an independent voxel 
threshold of p<0.001. Regarding the ROI analysis, average parameter estimates within each ROI 
were extracted and exported to SPSS to compare differences between groups. Pearson’s 
correlation analysis was used to determine the relation between brain reactivity within significant 
clusters or ROIs and anthropometric and behavioral parameters. Partial correlation analysis was 
used to determine the relationship between anthropometric and behavioral parameters and 
extracted brain activation in the significant clusters or ROIs adjusted for changes in BMI. There 
were no differences in changes in brain activation between men and women. A p<0.005 was 
considered significant to correct for multiple comparisons. Analyses were performed using 
BrainVoyager 20.6 (Brain Innovation B.V., Maastricht, The Netherlands) and the Statistical Package 
for the Social Sciences (SPSS, IBM Corp., IBM SPSS Statistics, V23, Armonk, NY, USA). 
RESULTS  
Characteristics of the participants in the two groups are shown in TABLE 1. Regarding 
anthropometrics, insulin resistance, protein intake and physical activity (CPM), no differences were 
observed at baseline, nor in changes during the intervention between the groups. All 
anthropometric parameters decreased significantly (see TABLE 1) in the whole group during the 
intervention period (P<0.001). Fasting insulin, glucose, c-peptide, HbA1c concentrations and 
HOMA-IR significantly decreased (p<0.05). Physical activity (CPM) did not significantly change 
during the intervention. During the intervention TFEQ restraint increased for the whole group. 
TFEQ hunger significantly decreased in the whole group of participants (TABLE 1).  
No differences in brain activity between MP and HP groups 
There were no differences in brain activation in response to viewing food versus non-food images 
(F>nF) or to high-calorie versus low-calorie images (H>L) between the groups at baseline. 
Differences in brain activation over the intervention period were compared between the two 
groups using whole brain analysis. There were no differences in changes for the contrasts F>nF or 
H>L between the groups. Furthermore, extracted brain activation in the a priori defined ROIs did 
not differently change between the groups for the contrasts F>nF or H>L.  
During the intervention, daily nitrogen excretion or daily protein intake were not different 
between the groups. Therefore, both groups were taken together for further analyses. In the 
whole group of participants, daily nitrogen excretion (12.1±4.1 g to 13.8±4.4 g) and daily protein 
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intake 0.82±0.23 g/kg to 1.04±0.25 g/kg) were increased at 2 years compared to baseline 
(p<0.05). During the weight maintenance period, average daily nitrogen excretion was 14.2±3.9 g 
and average protein intake was 1.06±0.24 g/kg.  
TABLE 1. Participant characteristics 
 
MP (n=12) 
 
HP (n=15) 
 
Total (n=27) 
 
 
Baseline 2 years Baseline 2 years Baseline 2 years 
Age 54.7 (10.6) 
 
52.7 (10.3) 
 
53.6 (10.3) 
 Height 1.74 (0.1) 
 
1.69 (0.12) 
 
1.71 (0.12) 
 Weight (kg) 99.4 (17.4) 90.6 (16.0) 89.7 (15.4) 81.9 (15.6) 94.0 (16.7) 85.8 (16.1)*** 
BMI (kg/m
2
) 32.7 (3.1) 29.9 (3.5) 31.2 (3.3) 28.5 (4.1) 31.8 (3.2) 29.1 (3.8)*** 
FM 40.9 (8.8) 33.9 (12.0) 35.8 (8.7) 29.7 (10.9) 38.1 (9.0) 31.6 (11.4)*** 
Body-fat % 41.4 (6.7)  37.2 (10.1) 40.2 (7.3) 36.2 (9.9) 40.7 (6.9) 36.6 (9.8)*** 
Insulin 13.0 (6.4) 10.4 (5.5) 14.6 (6.5) 10.4 (3.7) 13.9 (6.4) 10.4 (4.5)** 
Glucose 6.4 (0.8) 6.0 (0.7) 6.3 (0.5) 5.9 (0.4) 6.4 (0.6) 5.9 (0.5)** 
HOMA-IR 3.7 (1.9) 2.8 (1.8) 4.2 (2.1) 2.7 (1.1) 4.0 (2.0) 2.8 (1.4)* 
CPM 302.4 (116.1) 262.2 (97.4) 380.1 (109.3) 338.5 (116.8) 345.2 (116.3) 304.2 (112.6) 
TFEQ f1 7.7 (4.4) 13.6 (2.8) 8.9 (4.8) 13.1 (3.5) 8.3 (4.5) 13.3 (3.1)*** 
TFEQ f2 7.5 (3.3) 6.4 (2.3) 8.6 (3.7) 7.5 (4.0) 8.1 (3.5) 7.0 (3.4) 
TFEQ f3 5.7 (3.0) 4.1 (3.1) 5.9 (3.6) 5.0 (3.6) 5.8 (3.3) 4.6 (3.3)* 
Data are presented as mean ± standard deviation. Differences over time between MP and HP were 
assessed by means of factorial repeated-measures ANOVA; none were found. Changes over time 
within groups were determined using repeated-measures ANOVA, * p<0.05, ** p<0.01, *** p<0.001. 
Abbreviations: MP = moderate protein group; HP = high protein group; HOMA-IR= homeostatic 
model assessment for insulin resistance; CPM, counts per minute, TFEQ = Three factor eating 
questionnaire, f1=factor 1 (cognitive restraint), f2=factor 2 (disinhibiton and emotional eating), f3 = 
factor 3 (feelings of hunger) 
Whole brain analysis - relations between brain activation and BMI, body-fat percentage, HOMA-
IR, protein intake, activity or eating behavior  
For the whole group, brain activation for the contrast food versus non-food images or high-
calorie versus low-calorie images was not significantly different at 2 years compared to baseline, 
assessed with whole brain analyses. To determine whether changes in brain reactivity to food cues 
were associated with anthropometrics, insulin resistance, protein intake, activity or eating 
behavior whole brain analyses with changes in BMI, body-fat percentage, HOMA-IR, protein 
intake (g/kg), physical activity (CPM) or TFEQ scores added as covariates were performed for the 
whole group (TABLE 2) (SUPPLEMENTAL FIGURE 2-6).  
Food>non-Food brain response 
Changes in body-fat percentage were negatively associated with changes in food versus non-
food images activation in the gyrus rectus and positively associated with changes in food versus 
non-food images activation in the left thalamus and left middle frontal gyrus. There were no 
significant clusters for changes in food versus non-food images activation and changes in other 
variables. 
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TABLE 2. Summary of whole brain fMRI results 
Contrast Variable AAL k r r* p* x y z Cluster extent 
∆ F>nF ∆Body-fat% gyrus rectus L 540 -0.66 -0.54* 0.005* -1 55 -16 906 
 
 
thalamus L  0.64 0.62* 0.001* -20 -22 13 1010 
 
 
no label (white matter L)  -0.63 -0.72* <0.001* -20 -13 38 579 
 
 
middle frontal gyrus L  0.63 0.65* <0.001* -24 23 41 1314 
∆ H>L ∆BMI rolandic operculum R 621 0.66 - - 55 0 9 688  
 
 
inferior frontal gyrus R  0.63 - - 47 17 3 1807 
 
 
middle frontal gyrus L  0.66 - - -41 50 8 1610 
 
 
rolandic operculum L  0.65 - - -58 -2 8 796 
 
∆Body-fat % angular gyrus R 675 0.65 0.71* <0.001* 61 -51 34 2881 
 
 
middle temporal gyrus R  0.62 0.72* <0.001* 48 1 -25 893 
 
 
putamen R  0.65 0.68* <0.001* 31 6 -1 11852 
 
 
superior frontal gyrus L  0.65 0.65* <0.001* -15 59 16 8828 
 
 
superior occipital gyrus R  0.64 0.57* 0.003* 17 -86 21 1269 
 
 
insula L  0.65 0.71* <0.001* -40 14 2 8394 
 
WM protein 
intake (g/kg) 
no label (white matter R) 405 -0.63 -0.71* <0.001* 20 4 49 4040 
 
superior frontal gyrus L  -0.64 -0.67* <0.001* -16 9 59 2398 
 
 
inferior temporal gyrus L  -0.64 -0.72* <0.001* -65 -34 -18 1062 
 
∆TFEQ f1 superior temporal gyrus R 569 -0.65 -0.69 <0.001* 59 -44 15 1835 
  precentral gyrus R  -0.67 -0.72 <0.001* 51 6 38 1127 
  superior occipital gyrus R    -0.64 -0.64 0.001* 28 -79 23 601 
  superior occitipal gyrus L  -0.66 -0.80 <0.001* -21 -79 33 1014 
Notes: Cluster extent threshold was determined by Monte Carlo simulation with a voxel threshold of p<0.001 and cluster alpha <0.005. Centre-of-gravity 
coordinates of each cluster are given in MNI space and the automated anatomical labeling atlas was consulted to obtain corresponding anatomical labels. 
*corrected for ∆BMI Abbreviations: k, cluster threshold in mm
3
; AAL, automated anatomical labeling; F>nF food images versus non-food images; H>L high 
calorie images versus low calorie images; R, right hemisphere; L, left hemisphere; TFEQ, three factor eating questionnaire, f1 = factor 1 (cognitive restraint) 
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High-calorie>Low-calorie brain response 
Changes in BMI were positively related to changes in high-calorie versus low-calorie images brain 
activation in regions associated with reward and control (FIGURE 1) (rolandic operculum, inferior 
frontal gyrus, middle frontal gyrus). Changes in body-fat percentage were positively related to 
changes in H>L brain activation in regions associated with visual processing, memory, reward and 
memory (middle temporal gyrus, angular gyrus, putamen, superior frontal gyrus, superior 
occipital gyrus, insula). Daily protein intake (g/kg) during weight maintenance was negatively 
related to high-calorie versus low-calorie images brain activation in the superior frontal gyrus and 
left inferior temporal gyrus (FIGURE 2). For high-calorie versus low-calorie images activation, 
changes in TFEQ dietary restraint (factor 1) were negatively associated with activation in the right 
superior temporal gyrus, the right precentral gyrus and the left and right superior occipital gyrus. 
There were no significant clusters for changes in high-calorie versus low-calorie brain activation 
and changes in HOMA-IR, CPM, TFEQ disinhibition or TFEQ hunger.  
 
 
  
FIGURE 1. Whole brain contrast map of brain regions with significant associations between changes in 
high>low calorie images brain activation and changes in BMI. Positive associations are shown in 
orange (P<0.005, corrected for multiple comparisons). Scatter plots of changes in BMI and changes in 
extracted high>low calorie images BOLD response are shown below. 
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FIGURE 2. Whole brain contrast map of brain regions with significant inverse associations between 
changes in high>low calorie images brain activation and daily protein intake (g/kg) during weight 
maintenance. Inverse associations are shown in blue (P<0.005, corrected for multiple comparisons). 
Scatter plots of protein intake and changes in extracted high>low calorie images BOLD response are 
shown below. 
ROI analysis - relations between brain activation and BMI, fat mass, HOMA-IR, protein intake, 
activity or eating behavior 
To specifically investigate the association in the a priori defined ROIs, average brain activation was 
extracted and associated with changes in BMI, fat mass, HOMA-IR, protein intake (g/kg), physical 
activity (CPM) or TFEQ scores.  
 Food>non-food brain response 
Adjusted for changes in BMI, changes in HOMA-IR were positively related to changes in F>nF 
brain activation in the left nucleus accumbens (r=0.60; p=0.001). Changes in F>nF brain activation 
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in the ROIs were not associated with changes in BMI, body-fat percentage, CPM , eating behavior 
or protein intake during weight maintenance. 
 High calorie>Low-calorie brain response 
For the H>L contrast, there was a positive association between changes in BMI and brain 
activation in the right insula (r=0.62; p=0.001) and right anterior cingulate (r=0.58; p=0.002). 
Adjusted for changes in BMI, there were positive associations between changes in body-fat 
percentage and brain activation in the left insula (r=0.71; p<0.001), the right (r=0.54; p=0.005) 
and left nucleus accumbens (r=0.58; p=0.002). Changes in CPM, TFEQ scores and protein intake 
during weight maintenance were not associated with changes in H>L brain activation. 
DISCUSSION  
The aim of this study was to investigate the effects of weight loss and subsequent weight 
maintenance with relatively increased protein intake on brain reward activity in response to visual 
food in two groups of participants with overweight/obesity and IFG/IGT. There were no 
differences between the two protein groups in brain reactivity to food cues. However, we did not 
find differences in protein intake between the groups determined with urinary nitrogen excretion, 
implying the intervention was not successful in inducing the deliberate difference in protein 
intake between the groups.  
Therefore, we applied post-hoc analyses on the whole group of participants to assess effects of 
protein intake on brain reactivity to food cues. Protein intake during the weight maintenance 
period in the whole group was negatively related to changes in brain activation contrasting high-
calorie with low-calorie images in regions associated with frontal control (the superior frontal 
gyrus) and visual processing (the left inferior temporal gyrus). This is in line with evidence coming 
from short-term studies (18, 19). A high-protein breakfast was shown to further reduce 
hippocampal and parahippocampal reactivity to food cues compared to a normal-protein 
breakfast, measured in 20 overweight/obese girls in a randomized crossover study (18). Moreover, 
in 23 healthy women a 12-day low-protein diet compared to a high-protein diet led to an 
increased BOLD response in the orbitofrontal cortex and striatum in response to food cues (19). 
Based on our data, it is not possible to determine the causality of the relation between protein 
intake and brain reactivity to food cues, but multiple explanations have been postulated. Protein 
intake may influence brain signaling via changes in the neurotransmitter precursor availability. 
The amino acid tryptophan is the precursor for serotonin and tyrosine and phenylalanine are 
precursors for dopamine (25). Ingestion of protein increases the availability of these precursors, 
potentially resulting in higher neurotransmitter synthesis (26, 27). Furthermore, protein was shown 
to modulate food reward via activation of the vagus nerve, which projects to the nucleus tractus 
solitaries in the brain stem to relay satiety signals to the brain. Glutamate has shown to activate 
branches of the vagus nerve (28) and ingestion of glutamate led to activation of the amygdala, 
hippocampus and lateral hypothalamus in rats (29) while activation was fully suppressed after 
vagatomy. Indirectly, amino acids could also influence brain reward signaling through an 
increased release of anorectic hormones from the gut (15). It needs to be mentioned however, 
that in our particular study, the effects expected to be due to increased protein intake, could also 
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be related to decreased carbohydrate or fat intake during the intervention (30). Increased protein 
intake during the dietary intervention may be part of a general change of a healthier lifestyle and 
other factors advocated in the PREVIEW intervention guidelines aiming at a generally healthier 
lifestyle could contribute to the results.  
As expected, participants significantly reduced their body weight and fat mass during the 
intervention period. Changes in BMI were positively related to changes in brain reactivity to high-
calorie compared to low-calorie images in the rolandic operculum, inferior frontal gyrus and 
middle frontal gyrus. Especially the inferior frontal gyrus and middle frontal gyrus have been 
implicated in dietary self-control (31, 32). The association with reactivity to high-calorie images 
versus low-calorie images is in line with studies reporting that activation in these regions 
modulates value-encoding regions when participants choose healthy over unhealthy foods (33). A 
positive relationship between brain response to food versus non-food cues in the anterior 
cingulate and BMI was also found in a study by Martens et al. (4). Furthermore, weight loss using 
a 6-month lifestyle intervention in overweight/obese individuals has previously shown to reduce 
brain activation to high-calorie images and cause a shift in relative activation favoring low-calorie 
versus high-calorie food cues in the putamen (34). Weight loss after bariatric surgery was shown 
to support reduced neuronal responses to food cues in multiple food reward regions (14, 35). In 
our study, changes in body fat percentage were positively related to changes in brain activation 
contrasting high-calorie with low-calorie images in various gustatory and frontal control regions, 
including the putamen and insula. This may be interesting in terms of linking eating behavior and 
body-fat mass (36). Higher cue reactivity in the putamen and insula has been associated with food 
cravings and may be a mechanism to match higher energy needs with increased adiposity (10,37). 
Our findings are in line with a study that reported a positive association between brain activation 
to high-calorie food cues and abdominal fat in girls, independent of BMI (38). Suggested 
mechanisms through which fat mass may influence brain reward signaling are increased leptin 
concentrations or increased low-grade inflammation. Prior research reported a positive 
association between leptin concentrations and brain responses to high-calorie food versus non-
food cues in the putamen/caudate, insula and amygdala in lean and obese individuals (39, 40). 
Leptin injections were able to reduce weight loss-induced effects on neural activity to visual food 
cues in brain areas associated with regulatory, emotional and cognitive control of food intake 
(41). Adiposity-related inflammation has been suggested as another mechanism via which 
increased fat mass may moderate brain reward. Increased inflammation was shown to be related 
to reduced integrity and lower functional connectivity in food reward-related brain areas (42), but 
also to decreases in dopamine availability and release, leading to alterations in motivation and 
reward (43). Changes in body-fat percentage were positively associated with changes in reactivity 
to high-calorie images versus low calorie-images in the putamen and insula.  
Region-of-interest analysis revealed that in our participants, changes in peripheral insulin 
resistance were positively related to changes in food versus non-food brain activation in the left 
nucleus accumbens. These results follow up on findings of a previous study in which we reported 
brain activation to food cues to be positively related to HOMA-IR (11). This observation is 
corroborating other studies reporting positive relations between markers of insulin resistance and 
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brain reward signaling in different study populations (8-10). In the present study we used HOMA-
IR as a marker insulin resistance, but our results are also supported by studies investigating the 
effects of intranasal insulin administration on brain reward signaling (44). Intranasal insulin 
administration was shown to inhibit forward projections from the ventral tegmental area to the 
nucleus accumbens, and this was related to a reduction in food value, but these modulatory 
effects of insulin were not present in participants with increased insulin resistance (45). We found 
a significant relation between changes in insulin resistance and changes in brain reward signaling 
over a two year period, further illustrating the importance of reducing insulin resistance.  
With regard to eating behavior, we found that changes in high versus low-calorie images were 
negatively associated with changes in dietary restraint in gustatory and visual processing regions. 
Dietary restraint increased during the intervention, which converges with studies reporting 
increased dietary restraint after caloric restriction (46, 47). This relation between dietary restrained 
and brain response to food images could be a possible mechanism via which dietary restraint 
leads to more healthy food habits (48, 49).  
Our study is limited by the lack of difference in protein intake between the two intervention 
groups. Due to this, we cannot exclude that the lack of differences in changes in brain reactivity 
between the intervention groups may be due to type II errors. Therefore, post-hoc analyses were 
performed on the whole group to assess the relation between protein intake and brain reactivity 
to food cues. We acknowledge the need of replicating our results in long-term studies with 
provided dietary protein in order to achieve the goals of protein intake levels as indicated. 
In conclusion, we found an association between the relatively increased intake of protein and a 
reduction in brain response to high-calorie food images compared to low-calorie food images in 
brain reward related regions in the total group of participants. Changes of anthropometric 
parameters, including body weight and body fat percentage during the intervention period, were 
positively associated with changes in brain responses to high-calorie versus low-calorie images. 
The reduction in insulin resistance throughout the intervention period was associated with a 
general reduction in the food reward response, evidenced by the positive association of brain 
activation contrasting food versus non-food images. Changes in dietary restraint were inversely 
associated with changes in brain response to high-calorie food images compared to low-calorie 
food images in gustatory and visual processing regions.  
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SUPPLEMENTARY MATERIAL  
The following are available online at www.mdpi.com/2072-6643/10/11/1771/s1, Figure S1: 
Participant flowchart, Figure S2: A priori selected regions of interest, Figure S3: Whole brain 
contrast map of brain regions with significant associations between changes in food>non-food 
brain activation and changes in body-fat percentage, Figure S4: Whole brain contrast map of 
brain regions with significant inverse associations between changes in food>non-food brain 
activation and changes in body-fat percentage, Figure S5: Whole brain contrast map of brain 
regions with significant associations between changes in high>low calorie images brain activation 
and changes in body-fat percentage, Figure S6: Whole brain contrast map of brain region with 
significant inverse associations between changes in high>low calorie images brain activation and 
changes in TFEQ dietary restraint (factor 1)  
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SUPPLEMENTAL FIGURE 1. Participant flowchart  
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<8% weight loss (n=2) 
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1 Dropout: 
<8% weight loss (n=1) 
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   No valid fMRI data 
Start weight maintenance 
intervention (n=18) 
2 year fmri scan (n=15)  
 
2 year fmri scan (n=12) 
 
 8-week weight loss period 
Start weight maintenance 
intervention (n=16) 
Assessed for eligibility (n=106) 
Enrolled in study (n=40) 
HP group (n=20) 
+ baseline fmri scan 
 
MP group (n=20) 
+ baseline fmri scan 
Excluded  (n= 66) 
   Not meeting inclusion criteria (n=36) 
   Declined to participate (n=30) 
 
6 Dropouts: 
Lost to follow-up (n=6) 
1 Dropout: 
Lost to follow-up (n=1) 
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SUPPLEMENTAL FIGURE 2. A priori selected regions of interest 
Regions were selected from Drummen et al. (2018; AJCN) based on significant associations brain reactivity to food 
cues and insulin resistance. ROIs included the right and left insular cortex, the left and right nucleus accumbens 
and the right anterior cingulate.  
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SUPPLEMENTAL FIGURE 3. Whole brain contrast map of brain regions with significant associations between 
changes in food>non-food brain activation and changes in body-fat percentage. Positive associations are shown 
in orange (P<0.005, corrected for multiple comparisons). Scatter plots of changes in body-fat percentage and 
changes in extracted food>non-food BOLD response are shown below. 
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SUPPLEMENTAL FIGURE 4. Whole brain contrast map of brain regions with significant inverse associations 
between changes in food>non-food brain activation and changes in body-fat percentage. Inverse associations are 
shown in blue (P<0.005, corrected for multiple comparisons). Scatter plots of changes in body-fat percentage and 
changes in extracted food>non-food BOLD response are shown below. 
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SUPPLEMENTAL FIGURE 5. Whole brain contrast map of brain regions with significant associations between 
changes in high>low calorie images brain activation and changes in body-fat percentage. Positive associations are 
shown in orange (P<0.005, corrected for multiple comparisons). Scatter plots of changes in body-fat percentage 
and changes in extracted high>low calorie images BOLD response are shown below. 
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SUPPLEMENTAL FIGURE 6. Whole brain contrast map of brain region with significant inverse associations 
between changes in high>low calorie images brain activation and changes in TFEQ dietary restraint (factor 1). 
Inverse associations are shown in blue (P<0.005, corrected for multiple comparisons). Scatter plot of changes in 
TFEQ dietary restraint and changes in extracted high>low calorie images BOLD response are shown below. 
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The research presented in this thesis focused on the effects of a lifestyle intervention, with special 
attention for the effects of protein intake on intrahepatic lipid content and the brain reward 
system. In participants with pre-diabetes, the three-year weight loss and weight maintenance 
PREVIEW intervention with four intervention arms aimed to prevent the development of T2D. The 
intervention arms during the weight maintenance phase differed in dietary and physical activity 
programs. All participants started with a low energy diet period of eight weeks during which 
differences in weight loss between men and women were investigated. Dietary programs during 
the weight maintenance period after the weight loss period differed regarding protein intake and 
glycemic index/glycemic load (GI/GL). This provided the opportunity to determine effects of 
weight loss and relatively increased protein intake with lower GI/GL on intrahepatic lipid content, 
brain reward activity and brain structure. Physical activity programs during the weight 
maintenance period differed regarding physical activity intensity and duration.  
Characterizing pre-diabetes 
Pre-diabetes has been used as a concept to characterize individuals at risk for developing 
diabetes. We recruited a large cohort of 2326 individuals with pre-diabetes to further characterize 
the differences but also the commonalities in this population. Different criteria to define pre-
diabetes are currently in use (1, 2). In the PREVIEW-study, pre-diabetes was defined according to 
the ADA criteria of having: (i) impaired fasting glucose (IFG) with venous plasma glucose 
concentration of 5.6-6.9 mmol/l when fasted; and/or (ii) impaired glucose tolerance (IGT) with 
venous plasma glucose concentration of 7.8-11.0 mmol/l at 2 hours after a standard 75 gram oral 
glucose tolerance test (OGTT) and a fasting plasma glucose <7.0 mmol/l (3). From the 2326 
recruited participants, 1389 (62%) had IFG, 506 (23%) had IGT and 286 (13%) had both IFG and 
IGT (CHAPTER 2) (4). More recently, the ADA has recommended using HbA1c as an additional 
standard for the diagnosis of pre-diabetes, with levels of 5.7% - 6.4% defining a state of pre-
diabetes. In PREVIEW, participants started with an HbA1c concentration of 5.5%, suggesting that 
many of them did not meet this new pre-diabetes classification. This may pose a serious impact 
on the number of participants developing T2D during the PREVIEW intervention and therefore has 
to be taken into account when evaluating effects of the PREVIEW intervention groups on T2D 
incidence.  
From previous studies it was reported that the annual incidence rate of diabetes was 4-6% for 
isolated IGT, 6-9% for IFG and 15-19% for combined IFG and IGT (5). The progression from being 
healthy to T2D manifestation is suggested to be a continuous process that starts years before 
hyperglycemia is present (1, 6). Initially, an increase in insulin resistance or loss of β-cell mass is 
compensated for by increased insulin secretion and increased β-cell mass, maintaining 
normoglycemia (7). Over time however, compensation fails and insulin secretion decreases. The 
progression in β-cell failure and dedifferentiation leads to relatively rapid rises in glucose levels 
and eventually to the manifestation of T2D. Based on this process, insulin resistance can be 
detected before hyperglycemia is present. Therefore, the assessment of insulin resistance is 
important in IFG, IGT and T2D, but has also been implicated as an important link between pre-
diabetes and the development of dementia, renal failure and cancer (8-10). In the PREVIEW study, 
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insulin resistance was assessed using the HOMA-IR, which is calculated using fasting glucose and 
insulin concentrations. The average HOMA-IR was 3.75 with a range of 0.23 – 31.37. This indicates 
that insulin resistance was present in most individuals, but also emphasizes the heterogeneity of 
the population.  
Impaired fasting glucose versus impaired glucose tolerance 
Although IFG and IGT are both intermediates of the progression to T2D, the pathogenesis of the 
two is suggested to be different (11, 12). Epidemiological studies have demonstrated that 
individuals with IFG or IGT represent distinct populations and only partially overlap (13). This is 
further illustrated by the differences in blood glucose curves during an OGTT (12, 13). 
Furthermore, it is suggested that IFG and IGT differ in their site of insulin resistance; IFG is 
associated with hepatic insulin resistance while IGT is more strongly associated with muscle 
insulin resistance (11).   
Pre-diabetes and physical activity 
Multiple lifestyle and heritable factors have been associated with the etiology of IFG or IGT. IFG 
seems more strongly related to heritable factors and smoking, while IGT may be more related to 
lifestyle factors like physical inactivity (11). We measured physical activity (PA) and sedentary time 
(ST) at baseline in 2326 adults with pre-diabetes using seven-day accelerometry (CHAPTER 3) 
(14).The purpose of this study was to quantify the relationship between objectively measured PA 
and ST with cardiometabolic health and risk of diabetes. We found distinct associations between 
fasting glucose and 2-hour glucose after glucose ingestion with parameters of PA in a large 
population with pre-diabetes. MVPA and total physical activity were inversely related to 2-hour 
glucose concentrations after glucose ingestion. HOMA-IR was positively associated with ST, but 
inversely associated with MVPA and total physical activity. Given that ST and MVPA are 
interchangeable components of a day depending on arbitrary thresholds, it is difficult to attribute 
effects to an increase in one variable or a decrease in the other. Replacing ST with light activity 
was shown to be related to reductions in HOMA-IR (15). In another study, both, replacing sitting 
with light-intensity walking and simple resistance activities reduced incremental area under the 
curve for glucose, insulin and c-peptide concentrations equally during consumption of 
standardized meals (16). Thus, while it remains unclear if the specific intensity of physical activity 
has effects on glucose or insulin sensitivity, the exchange of ST with PA seems pivotal to changes 
in cardiometabolic health and insulin resistance in individuals with pre-diabetes.  
Pre-diabetes and diet 
An ‘unhealthy’ diet has also been associated with disturbed glucose homeostasis and insulin 
resistance (11). Bagheri et al. reported that a healthy dietary pattern (characterized by high intake 
of vegetables, fruits, legumes, chicken, nuts, fish, etc.) was inversely associated, while an unhealthy 
dietary pattern (characterized by high intake of high-fat products, solid fats, soft drinks, red and 
processed meats, etc.) was positively associated with pre-diabetes risk, including fasting blood 
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glucose and 2-hour glucose after glucose ingestion (17). These dietary patterns also 
corresponded with dietary patterns found to prevent T2D in meta-analyses (18, 19). Differences in 
macronutrient intake have also been related to changes in T2D risk, but all include some 
‘footnotes’. High-carbohydrate diets have been suggested to be detrimental for prevention and 
management of T2D (20), unless they are rich in fiber and with a low GI/GL (21, 22). Lowering 
GI/GL may reduce T2D risk via reductions in hyperglycemia, glucose concentration variability, 
hyperinsulinemia or free fatty acids (23, 24). However, it is not clear whether these effects persist 
after controlling for weight loss or dietary fiber intake (25-27).  Regarding dietary fat intake, many 
studies reported increased insulin resistance with higher levels of total dietary fat intake (28). 
However, replacing short-chain fatty acids and trans fatty acids with mono- and polyunsaturated 
fatty acids was suggested to be beneficial for insulin sensitivity (29-31). Whether protein intake is 
related to prevention or development of T2D beyond the benefits for a negative energy balance, 
weight loss, and subsequent weight maintenance is still unclear and may depend on the source of 
protein (CHAPTER 4) (32). Total protein and animal protein is most likely associated with 
increased relative risk for T2D and plant protein with a decreased risk (33). Furthermore, red and 
processed meats were also reported to be risk factors for T2D and soy and dairy products were 
reported to be protective. Based on all these conditional statements of macronutrient intake 
effects on T2D prevention, a dietary lifestyle combining these conditional effects should be 
pursued for optimal results. 
Effects of a lifestyle intervention - Weight loss 
The PREVIEW study was directed to prevent diabetes by combining a weight loss period with a 
long-term intervention period focused on diet and physical activity. During the 8-week weight 
loss period with a LED, participants lost an average of 11% body weight and the average BMI after 
weight loss was 31.4 kg/m
2 
(CHAPTER 6) (34). Therefore, most of the participants were still in the 
range of obesity which raises the question if the weight loss achieved was sufficient in terms of 
metabolic benefit. In previous studies, 5 to 10 percent weight loss was already sufficient for 
clinically relevant changes in health, suggesting the weight loss rate can be considered successful 
in our pre-diabetic population (35). Favorable changes were also evident in our participants 
including reductions in metabolic syndrome and 694 of the 2224 pre-diabetic participants 
reverting to normo-glycaemia based on fasting plasma glucose concentrations. Average HOMA-
IR decreased from 3.75 at baseline to 2.28 after weight loss. Based on an often used HOMA-IR 
threshold of <2.5, the body weight loss was enough to reduce insulin resistance to normal 
proportions (36-39).  
It has to be noted that 204 (9.2%) participants dropped-out during the weight loss period. 
Attrition is a common problem in weight loss studies and affects data collection quality, and 
inference. Moreover, the population of dropouts may represent an even more vulnerable 
population which is unable to respond to different treatment and prevention programs. On a 
positive note, the drop-out rate was lower compared to a similar weight loss period in the 
DioGenes study (40). This may be explained by the implementation of the PREMIT program, which 
was designed within the PREVIEW study to enhance behavioral change based on theory-driven 
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and evidence-based approaches (41). In particular, we have shown that experiencing less 
discouragement for healthy eating by a supportive environment and perceiving fewer 
disadvantages of a healthy diet were positively associated with weight loss (42).  
When comparing men and women during the weight loss period, we found greater weight loss 
and reductions in metabolic syndrome Z-scores in men compared to women, possibly indicating 
that men might have benefited more from an 8-week LED than women. This could have been 
explained by the fixed energy provided by the LED (3.4 MJ/d) for both, men and women. Based 
on the calculated baseline energy requirement using Westerterp et al. (43), the percentage energy 
intake of energy requirement during the LED was higher in men than in women, and therefore 
suggests women should have lost more weight.  
Based on the accelerometry data, there were no differences in physical activity between men and 
women at baseline (CHAPTER 3) (14) and all participants received instructions to maintain the 
same level of physical activity during the weight loss period. We did not measure physical activity 
during weight loss and therefore cannot exclude that physical activity changed differently 
between men and women. Another explanation may be that men preserved their FFM better. 
Based on the calculations of Westerterp et al. (43), after the weight loss period men would have a 
body-fat percentage of 33.6% and women a body-fat percentage of 44.0%. The actual body-fat 
percentages after the weight loss period were 31.7% and 42.9% in men and women respectively, 
indeed showing more preservation of FFM in men. A reason for this may be that the men had 
larger relative protein intake (CHAPTER 4) (32). During energy restriction it was shown that a daily 
protein intake of 0.8 g/kg body weight was sufficient for weight loss, but a daily protein intake of 
1.2 g/kg body weight resulted in the preservation of FFM (44). The findings are in line with a study 
by Westerterp-Plantenga et al, which reported that relatively high protein intake led to increased 
energy expenditure, fat oxidation and protein anabolism in men versus increased satiety in 
women (45). The relative preservation of FFM may also explain the larger reductions in metabolic 
syndrome Z-scores in men compared to women even after adjusting for changes in body weight, 
since higher muscle mass has been inversely related to insulin resistance and metabolic syndrome 
(46, 47). The preservation of FFM is also necessary for weight maintenance after body weight loss, 
because FFM is the main determinant of basal energy expenditure.   
Weight maintenance 
The second phase of the PREVIEW-intervention was aimed at maintaining the lost body weight 
and participants were randomized to four intervention groups with differences in dietary 
programs and physical activity programs. For the studies presented in this thesis, we were 
especially interested in the long-term effects of the PREVIEW-intervention with the high protein 
versus moderate protein group on intrahepatic lipid content and brain reward activation.  
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Intrahepatic lipid content 
Due to its crucial role in glucose homeostasis, the liver is a central player in the development of 
insulin resistance, IFG, IGT and T2D. The liver is our first line of defense against hyperglycemia , 
taking up postprandial glucose to store as glycogen (48). Excess liver fat has been related with 
hepatic and skeletal muscle insulin resistance (49). Furthermore, intrahepatic lipid (IHL) content is 
progressively increased in individuals with normal glucose tolerance, isolated IFG, isolated IGT, IFG 
+ IGT to T2D (50). When IHL exceeds 5% it is classified as non-alcoholic fatty liver disease, which 
has been shown to be an independent predictor for the development of T2D (51). We measured 
the amount of IHL in 25 individuals with pre-diabetes and found an average IHL content of 8.7% 
(CHAPTER 7) (52). Moreover, of these 25 individuals, 15 were classified as having NAFLD. The 
reduction in IHL was successfully established in the PREVIEW-intervention (CHAPTER 7). After 2 
years, IHL were reduced compared to baseline and the number of individuals with NAFLD 
decreased from 15 to 7. Even though we did not see different changes in IHL between the two 
protein groups, we found that there was an effect of protein intake assessed with urinary nitrogen 
on IHL in the whole group of participants. Using mixed modeling analysis we found that protein 
intake at 6 months was inversely associated with IHL and this was independent of BMI. Increasing 
protein intake may lead to downregulation of lipogenesis and upregulation of hepatic lipid 
oxidation, lowering hepatic lipid content (53, 54). The relation between protein intake and IHL was 
not significant after 2 years. Protein-specific effects on IHL may be clouded by other factors 
attributable to a fading compliance to the general guidelines over time. This also directs that 
there may be a need for continuous application of the intervention guidelines.  
Throughout the intervention IHL was positively associated with insulin resistance, independent of 
BMI. Furthermore, there were no relations between visceral adipose tissue (VAT) or subcutaneous 
adipose tissue (SAT) and insulin resistance. These findings are in line with Fabbrini et al. which 
reported that insulin sensitivity was lower in individuals with higher IHL matched on VAT, but was 
not different in individuals with higher VAT matched on IHL (55). We are not able to determine 
the causality between IHL and insulin resistance in our study. Causality between IHL and insulin 
resistance is often debated and there is evidence that both factors can be a consequence of the 
other. IHL may impair insulin signalling and affect glucose concentrations by reducing glycogen 
synthesis and increasing gluconeogenesis (56). On the other hand, insulin resistance in adipose 
tissue may lead to increased lipolysis and free fatty acids, resulting in increased lipid uptake in the 
liver (57). Importantly, the degree of insulin resistance is not necessarily similar in the three major 
insulin-sensitive tissues, liver, skeletal muscle and adipose tissue (58) and insulin resistance in 
these different tissues may have a different place and timing in the causal relation between insulin 
resistance and IHL accumulation. Based on our results, we postulate the hypothesis that 
increasing protein intake may indirectly increase insulin sensitivity via reductions in IHL. More 
research is needed to establish the exact mechanisms and causality of these relations. Moreover, 
in a previous study it was shown that IHL content was an independent predictor of non-response 
to a lifestyle intervention (59). Therefore, focusing on reducing IHL seems to be trivial within 
diabetes prevention interventions 
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Brain reward system 
Another relevant component for the success of lifestyle interventions is the brain reward system, 
which plays a role in regulating ingestive behavior. The regulation of food intake and eating 
behavior is often divided into homeostatic and non-homeostatic or hedonic regulation (60), but is 
currently progressively viewed as a complex and highly interactive system unifying homeostasis, 
reward, cognition and emotion (61). It is apparent that physiological factors are able to act on the 
brain and vice versa. We investigated which factors were related to food-reward related brain 
activation in 39 individuals with pre-diabetes (CHAPTER 5). We observed that food-reward 
related brain activation was positively related to insulin resistance and emotional 
eating/disinhibition and inversely related to habitual physical activity. The relation between insulin 
resistance and brain activation in reward areas was also reported in other studies (62-64). Insulin 
is suggested to play a role in dopamine homeostasis by regulating dopamine release and 
dopamine transporter density and function (65). Disruption of this pathway has been shown to 
lead to hyperphagia and weight gain (66). We found changes in brain reward activation to be 
positively related with changes in insulin resistance during the 2-year weight loss and weight 
maintenance intervention, independent of BMI (CHAPTER 8). We specifically found this relation in 
the nucleus accumbens, insular cortex and anterior cingulate, which are all brain regions rich in 
dopaminergic neurons (67), pointing at the role of insulin for dopamine signalling. Furthermore, 
these regions have also been suggested to play an key role in addiction and eating disorders (68-
71). Based on our results in brain reactivity, individuals with pre-diabetes may be ‘wired’ for 
unhealthy eating and hyperphagia, snowballing the risk to develop T2D. 
A main point of discussion remains whether central insulin resistance exists and subsequently if 
we can measure it. In favor of the existence of central insulin resistance are studies reporting that 
brain insulin levels are proportional to plasma insulin levels and that insulin is able to cross the 
blood-brain barrier (72-74). Furthermore, using intranasal insulin administration it was shown that 
a decrease in cerebral blood in response to insulin was only present in lean individuals, but not in 
overweight and obese individuals, and the decrease was related to insulin sensitivity (64). We also 
found food-reward related brain activation in the supramarginal gyrus to be positively related to 
emotional eating and disinhibition, measured by the three factor eating behavior questionnaire. 
The supramarginal gyrus has been implicated with reward, motivation and drug abuse. 
Disinhibition has previously been linked with obesity and high-energy intakes (75). It is not exactly 
clear how the relation between brain reward activity and emotion/disinhibition is established, but 
it further underlines the higher-order interplay of multiple brain pathways mentioned before (61). 
The inverse association between habitual physical activity and food-reward related brain 
activation is in line with previous work (76, 77) and since it is not possible to determine causality 
in our study, it has to be investigated whether increasing different types of physical activity and 
exercise are able to lead to long-term changes in brain activity and healthier eating habits. In that 
way, physical activity may be able to have secondary health benefits next to its primary effects on 
fitness and energy expenditure.  
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In 27 participants, measurements of food-reward related brain activation were repeated after 2 
years to assess effects of the intervention in the two protein groups (CHAPTER 8). We found no 
different changes in brain reactivity to food cues between the groups and no differences in brain 
reactivity to food cues comparing 2 years with baseline in the whole group of participants. 
However, in the whole group of participants we found an inverse association between protein 
intake assessed with urinary nitrogen during the weight maintenance period and changes in food 
reward-related brain activation, independent of BMI. Other studies have reported modulating 
effects of protein intake on brain activation to food cues (78, 79), but we found these effects after 
a 2 year period. This implies protein intake may have long-term benefits for eating behavior via 
changes in brain reward reactivity. Protein intake may influence brain activity via changes in 
neurotransmitter precursor availability or activation of the vagus nerve to relay satiety signals (80-
82). Effects of protein intake may also be caused by increased release of anorectic hormones (83). 
Changes in brain reactivity to high-calorie images versus low-calorie images were negatively 
related to changes in dietary restraint in multiple regions. This mechanism may be crucial for 
long-term body weight maintenance by enhancing compliance to dietary lifestyle. Diets high in 
protein intake may be difficult to maintain (CHAPTER 4) (84). Efforts to increase dietary restraint 
should be incorporated in lifestyle interventions to increase total efficacy. In the PREVIEW study, 
this issue was addressed by implementation of the PREMIT behavioral change toolbox. 
Grey matter volume and cortical thickness 
Next to brain activation, we also measured brain structure during the PREVIEW study to 
determine whether grey matter volume or cortical thickness would change during the 
intervention period along with changes in body weight or insulin resistance (CHAPTER 9). 
Previously reported associations between BMI or T2D and grey matter volume and cortical 
thickness included cross-sectional data only and it is unknown whether reversal of grey matter 
loss or cortical thinning is possible by reducing body weight or insulin resistance. We found that 
changes in body weight or insulin resistance were not mirrored by changes in grey matter volume 
or cortical thickness. It may be that the number of participants was too small to find small 
changes relative to the large inter individual variation. However, it may also be that the timing of 
these changes is very different and that changes in grey matter volume are gradual processes not 
responding to rapid changes in body weight or insulin resistance. Moreover, the relations 
between BMI/insulin resistance and grey matter volume/cortical thickness may have been 
induced via irreversible brain damage. In this light, Ronan et al. reported that obesity modulated 
age-related brain structural changes (85). More studies over a longer period and with larger 
number of participants are needed to shine light on these processes.  
Considerations 
It is necessary to consider that effects of protein intake may be indirectly caused by changes in 
carbohydrate or fat intake. Protein intake was assessed with urinary nitrogen, but biomarkers for 
carbohydrate or fat intake were not available. It was shown already that body-weight loss and 
weight-maintenance are associated with high-protein intake, independent of carbohydrate and 
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fat-content of the diet and effects of a low-carbohydrate diet are depending on high-protein 
intake (86). Effects of protein intake on IHL content have been shown in mice with both low 
carbohydrate and low fat conditions (54). In favor of protein-specific effects on food reward 
related brain activation are studies showing reductions in brain activation after the ingestion of 
solely protein (78). Furthermore, the dietary programs that participants received did not only 
contain instructions to achieve high and moderate protein intake, but also instructions to 
consume low and moderate GI foods respectively. Therefore, it is possible that effects of protein 
intake are caused by correlated changes in GI and GL. Since we only have a biomarker of protein 
intake, we are unable to exclude this issue. 
Another point of consideration is the lack of difference in protein intake between the two protein 
groups. While this may be a power issue of the subgroups that are reported in this thesis, it may 
also be a consequence of the study design. It seems that participants in the high protein group on 
average did not reach the amount of protein that was aimed for and participants in the moderate 
protein group ingested more than was aimed for. Reasons for this can be manifold, but it may be 
an effect of the PREMIT behavioral change toolbox and the general healthy guidelines of the 
PREVIEW study. Participants may have prioritized pursuing the guidelines for a general healthy 
lifestyle over the instructions aimed to yield group differences. This is underlined by the equal 
long-term beneficial changes of anthropometric and metabolic parameters in both intervention 
groups.  
We did not find differences between men and women regarding changes in IHL, brain reactivity 
or brain structure (CHAPTERS 7-9). This may be explained by the sample sizes in these sub-
studies, as is also discussed in the respective chapters. 
Conclusions 
The heterogeneous PREVIEW cohort consisting of participants with overweight/obesity and pre-
diabetes successfully achieved 8% body weight loss using the 8-week low energy diet and 
showed the relevance of the PREVIEW intervention especially for evaluating changes in insulin 
resistance and changes on organ level, like liver and brain.   
In the participants, insulin resistance was reduced after 2 years of diet and exercise intervention 
accompanied by reductions in IHL and by reduced food reward related brain activation. The 
changes in brain reactivity were linked to increased control of eating behavior, adjusted for 
changes in BMI. More specifically and on group level, protein intake was related to reductions in 
IHL and changes in brain reward reactivity, demonstrating that higher protein intake has 
beneficial effects that supersede effects on body weight loss or body weight management. 
Future perspectives 
From the results presented in this thesis it becomes clear that pre-diabetes is not a simple 
physiological state, but rather a tool to captivate a vulnerable population. Future efforts to map 
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differences and similarities within this heterogeneous population may help to elucidate 
underlying pathologies and find more effective treatment methods. For example, it will be 
relevant to investigate discrepancies between individuals with different markers of pre-diabetes 
such as isolated IFG or IGT. 
In terms of treatment methods, we have underlined the relevance of weight loss in a population 
with pre-diabetes and increased body weight. The 8-week LED of the PREVIEW study was shown 
to be an effective method for reducing body weight in almost all participants. The weight loss was 
accompanied by significant reductions in body-fat percentage and insulin resistance, despite the 
average BMI still being in the obesity range after weight loss. It remains unclear whether 
additional weight loss would lead to even greater effects or to a prolongation of effects. Using 
post-hoc analyses this can be partly investigated within the PREVIEW-study, but future studies 
with longer duration are needed to clarify this issue. 
The effects of the PREVIEW study on the incidence of T2D are not known yet, so this still needs to 
be analyzed and reported. We did find relevant changes in IHL considering the findings by other 
studies that IHL accumulation seems to be a pathological factor in many different conditions. 
Factors specifically reducing IHL should therefore be incorporated in lifestyle interventions. We 
reported the relevance of increased protein intake in this regard, but future studies should be 
aimed at finding other factors. Furthermore, there may be differential effects of protein from 
different sources or effects of specific amino acids. We also found protein intake during weight 
maintenance to be inversely associated with changes in brain reactivity to high calorie food cues. 
This may be part of the mechanism via which protein intake can help to lose weight or maintain 
weight loss, but may also be correlated to the adaptation to a healthier lifestyle in general. Future 
studies with intranasal administration of protein or specific amino acids may help to resolve 
whether protein or amino acids have direct affects on brain signalling. Furthermore, it will be 
necessary to assess whether the brain response to food cues is trainable, as has been shown in 
other study settings (87). This may be an additional tool to increase compliance to a healthy 
lifestyle. Similarly, future studies could be designed to disentangle effects of protein intake or 
effects of concomitant changes in other parameters like reductions in GI/GL. 
Next to brain and liver, paying particular attention to other organs may contribute to an in depth 
understanding of the progression to T2D. For instance, the accumulation of lipids in different 
sites, e.g. the pancreas, may play independent roles for the development or worsening of insulin 
resistance. Other organs of interest, especially when evaluating effects on protein intake for T2D 
prevention, are the intestines and kidneys. The intestines are important for digestion and 
absorption of protein but are also considered important for food intake regulation via the gut-
brain axis. Investigating the role of gut hormones secreted by the intestines (e.g. GLP-1, CCK) in 
response to protein and other foods may help unraveling the exact mechanisms of this 
regulation. Kidney disease is a common concomitant disease in T2D patients and there have been 
some concerns about whether high protein consumption leads to increased risk for kidney 
disease (88). In a sub-group of the PREVIEW study participants there were no indications of 
impaired kidney function after one year with higher protein intake (89). However, future studies 
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are needed to determine whether higher protein diets have detrimental renal effects in 
populations with kidney problems or whether these effects occur after a longer period. 
A central issue in large and lengthy lifestyle studies similar to the PREVIEW study is a reduction in 
compliance to the study guidelines. Based on the results presented in this thesis, protein intake or 
physical activity may hardly differ, or may differ in different directions between the intervention 
groups, suggesting participants followed a personal intervention instead of a group intervention. 
While this is closer to a real life situation than strictly controlled study designs, this also hampers 
the occurrence of group differences and inferences. Therefore, it will be crucial to include 
biomarkers of diet and physical activity in the final analyses next to group allocations. Future 
studies may also consider providing supplements like protein powder or guided physical activity 
sessions to increase differences between groups, especially when they are aimed at investigating 
physiological mechanisms. Another possible study design to investigate effects of a lifestyle 
intervention is to provide all participants with a range of dietary en physical activity instructions 
and retrospectively assign groups using biomarkers. This will permit the assessment of long-term 
responses to different instruction groups, but has the disadvantage that there is no randomization 
and is therefore prone to selection biases. Furthermore, intrinsic characteristics or physiological 
states may be responsible for the resulting groups, decreasing the generalizability.    
Another concern of large intervention studies is the rate of attrition. Participants that drop-out 
may represent a distinct population and it will be interesting to determine which factors lead to 
attrition. This may help designing tailored interventions and enhancing the success of lifestyle 
interventions aimed at increasing health or preventing diseases. To achieve this, future studies 
should enhance efforts to follow-up participants that drop-out.  
C
H
A
P
T
E
R
 1
0
 
 
 CHAPTER 10 
170 
REFERENCES 
1. Tabák AG. Prediabetes: A high-risk state for developing. 2012;379(9833):2279-2290. 
2. Buysschaert M, Bergman M. Definition of prediabetes. Med Clin North Am. 2011;95(2):289-297, vii. 
3. 2. Classification and Diagnosis of Diabetes: <em>Standards of Medical Care in Diabetes—2018</em>. 
Diabetes Care. 2018;41(Supplement 1):S13-S27. 
4. Fogelholm M, Larsen TM, Westerterp-Plantenga M, et al. PREVIEW: Prevention of Diabetes through 
Lifestyle Intervention and Population Studies in Europe and around the World. Design, Methods, and 
Baseline Participant Description of an Adult Cohort Enrolled into a Three-Year Randomised Clinical Trial. 
Nutrients. 2017;9(6). 
5. Gerstein HC, Santaguida P, Raina P, et al. Annual incidence and relative risk of diabetes in people with 
various categories of dysglycemia: a systematic overview and meta-analysis of prospective studies. 
Diabetes Res Clin Pract. 2007;78(3):305-312. 
6. Weir GC, Bonner-Weir S. Five stages of evolving beta-cell dysfunction during progression to diabetes. 
Diabetes. 2004;53 Suppl 3:S16-21. 
7. Chen C, Cohrs CM, Stertmann J, Bozsak R, Speier S. Human beta cell mass and function in diabetes: Recent 
advances in knowledge and technologies to understand disease pathogenesis. Mol Metab. 2017;6(9):943-
957. 
8. Nerpin E, Risérus U, Ingelsson E, et al. Insulin Sensitivity Measured With Euglycemic Clamp Is Independently 
Associated With Glomerular Filtration Rate in a Community-Based Cohort. Diabetes Care. 2008;31(8):1550-
1555. 
9. Baker LD, Cross DJ, Minoshima S, Belongia D, Watson GS, Craft S. Insulin resistance and Alzheimer-like 
reductions in regional cerebral glucose metabolism for cognitively normal adults with prediabetes or early 
type 2 diabetes. Arch Neurol. 2011;68(1):51-57. 
10. Huang Y, Cai X, Qiu M, et al. Prediabetes and the risk of cancer: a meta-analysis. Diabetologia. 
2014;57(11):2261-2269. 
11. Færch K, Borch-Johnsen K, Holst JJ, Vaag A. Pathophysiology and aetiology of impaired fasting glycaemia 
and impaired glucose tolerance: does it matter for prevention and treatment of type 2 diabetes? 
Diabetologia. 2009;52(9):1714-1723. 
12. Meyer C, Pimenta W, Woerle HJ, et al. Different mechanisms for impaired fasting glucose and impaired 
postprandial glucose tolerance in humans. Diabetes Care. 2006;29(8):1909-1914. 
13. Abdul-Ghani MA, Tripathy D, DeFronzo RA. Contributions of β-Cell Dysfunction and Insulin Resistance to 
the Pathogenesis of Impaired Glucose Tolerance and Impaired Fasting Glucose. Diabetes Care. 
2006;29(5):1130-1139. 
14. Swindell N, Mackintosh K, McNarry M, et al. Objectively Measured Physical Activity and Sedentary Time Are 
Associated With Cardiometabolic Risk Factors in Adults With Prediabetes: The PREVIEW Study. Diabetes 
Care. 2018;41(3):562-569. 
15. Duvivier B, Bolijn JE, Koster A, Schalkwijk CG, Savelberg H, Schaper NC. Reducing sitting time versus adding 
exercise: differential effects on biomarkers of endothelial dysfunction and metabolic risk. Sci Rep. 
2018;8(1):8657. 
16. Dempsey PC, Sacre JW, Larsen RN, et al. Interrupting prolonged sitting with brief bouts of light walking or 
simple resistance activities reduces resting blood pressure and plasma noradrenaline in type 2 diabetes. J 
Hypertens. 2016;34(12):2376-2382. 
17. Bagheri F, Siassi F, Koohdani F, et al. Healthy and unhealthy dietary patterns are related to pre-diabetes: a 
case-control study. Br J Nutr. 2016;116(5):874-881. 
18. Esposito K, Kastorini CM, Panagiotakos DB, Giugliano D. Prevention of type 2 diabetes by dietary patterns: 
a systematic review of prospective studies and meta-analysis. Metab Syndr Relat Disord. 2010;8(6):471-476. 
19. Jannasch F, Kroger J, Schulze MB. Dietary Patterns and Type 2 Diabetes: A Systematic Literature Review and 
Meta-Analysis of Prospective Studies. J Nutr. 2017;147(6):1174-1182. 
20. Huntriss R, Campbell M, Bedwell C. The interpretation and effect of a low-carbohydrate diet in the 
management of type 2 diabetes: a systematic review and meta-analysis of randomised controlled trials. Eur 
J Clin Nutr. 2018;72(3):311-325. 
21. Brand-Miller J, Hayne S, Petocz P, Colagiuri S. Low-glycemic index diets in the management of diabetes: a 
meta-analysis of randomized controlled trials. Diabetes Care. 2003;26(8):2261-2267. 
22. Greenwood DC, Threapleton DE, Evans CEL, et al. Glycemic Index, Glycemic Load, Carbohydrates, and Type 
2 Diabetes: Systematic review and dose–response meta-analysis of prospective studies. Diabetes Care. 
2013;36(12):4166-4171. 
 General Discussion 
171 
23. Aston LM. Glycaemic index and metabolic disease risk. Proc Nutr Soc. 2006;65(1):125-134. 
24. Gellar L, Nansel TR. High and Low Glycemic Index Mixed Meals and Blood Glucose in Youth with Type 2 
Diabetes or Impaired Glucose Tolerance. J Pediatr. 2009;154(3):455-458. 
25. Sacks FM, Carey VJ, Anderson CAM, et al. Effects of High vs Low Glycemic Index of Dietary Carbohydrate on 
Cardiovascular Disease Risk Factors and Insulin Sensitivity: The OmniCarb Randomized Clinical Trial. Jama. 
2014;312(23):2531-2541. 
26. Goff LM, Cowland DE, Hooper L, Frost GS. Low glycaemic index diets and blood lipids: a systematic review 
and meta-analysis of randomised controlled trials. Nutr Metab Cardiovasc Dis. 2013;23(1):1-10. 
27. Jebb SA, Lovegrove JA, Griffin BA, et al. Effect of changing the amount and type of fat and carbohydrate on 
insulin sensitivity and cardiovascular risk: the RISCK (Reading, Imperial, Surrey, Cambridge, and Kings) trial. 
Am J Clin Nutr. 2010;92(4):748-758. 
28. Mayer-Davis EJ, Monaco JH, Hoen HM, et al. Dietary fat and insulin sensitivity in a triethnic population: the 
role of obesity. The Insulin Resistance Atherosclerosis Study (IRAS). Am J Clin Nutr. 1997;65(1):79-87. 
29. Risérus U, Willett WC, Hu FB. Dietary fats and prevention of type 2 diabetes. Prog Lipid Res. 2009;48(1):44-
51. 
30. van Dam RM, Willett WC, Rimm EB, Stampfer MJ, Hu FB. Dietary fat and meat intake in relation to risk of 
type 2 diabetes in men. Diabetes Care. 2002;25(3):417-424. 
31. Harding AH, Sargeant LA, Welch A, et al. Fat consumption and HbA(1c) levels: the EPIC-Norfolk study. 
Diabetes Care. 2001;24(11):1911-1916. 
32. Drummen M, Tischmann L, Gatta-Cherifi B, Adam T, Westerterp-Plantenga M. Dietary Protein and Energy 
Balance in Relation to Obesity and Co-morbidities. Frontiers in Endocrinology. 2018;9:443. 
33. Tian S, Xu Q, Jiang R, Han T, Sun C, Na L. Dietary Protein Consumption and the Risk of Type 2 Diabetes: A 
Systematic Review and Meta-Analysis of Cohort Studies. Nutrients. 2017;9(9). 
34. Christensen P, Meinert Larsen T, Westerterp-Plantenga M, et al. Men and women respond differently to 
rapid weight loss: Metabolic outcomes of a multi-centre intervention study after a low-energy diet in 2500 
overweight, individuals with pre-diabetes (PREVIEW). Diabetes Obes Metab. 2018. 
35. Blackburn G. Effect of degree of weight loss on health benefits. Obes Res. 1995;3 Suppl 2:211s-216s. 
36. Salgado AL, Carvalho L, Oliveira AC, Santos VN, Vieira JG, Parise ER. Insulin resistance index (HOMA-IR) in 
the differentiation of patients with non-alcoholic fatty liver disease and healthy individuals. Arq 
Gastroenterol. 2010;47(2):165-169. 
37. Owei I, Umekwe N, Provo C, Wan J, Dagogo-Jack S. Insulin-sensitive and insulin-resistant obese and non-
obese phenotypes: role in prediction of incident pre-diabetes in a longitudinal biracial cohort. BMJ Open 
Diabetes Res Care. 2017;5(1):e000415. 
38. Calori G, Lattuada G, Piemonti L, et al. Prevalence, metabolic features, and prognosis of metabolically 
healthy obese Italian individuals: the Cremona Study. Diabetes Care. 2011;34(1):210-215. 
39. Kuk JL, Ardern CI. Are Metabolically Normal but Obese Individuals at Lower Risk for All-Cause Mortality? 
Diabetes Care. 2009;32(12):2297-2299. 
40. Papadaki A, Linardakis M, Plada M, et al. A multicentre weight loss study using a low-calorie diet over 8 
weeks: regional differences in efficacy across eight European cities. Swiss Med Wkly. 2013;143:w13721. 
41. Kahlert D, Unyi-Reicherz A, Stratton G, et al. PREVIEW Behavior Modification Intervention Toolbox 
(PREMIT): A Study Protocol for a Psychological Element of a Multicenter Project. Front Psychol. 2016;7:1136. 
42. Hansen S, Huttunen-Lenz M, Sluik D, et al. Demographic and Social-Cognitive Factors Associated with 
Weight Loss in Overweight, Pre-diabetic Participants of the PREVIEW Study. Int J Behav Med. 2018. 
43. Westerterp KR, Donkers JHHLM, Fredrix EWHM, oekhoudt P. Energy intake, physical activity and body 
weight: a simulation model. British Journal of Nutrition. 1995;73(3):337-347. 
44. Soenen S, Martens EA, Hochstenbach-Waelen A, Lemmens SG, Westerterp-Plantenga MS. Normal protein 
intake is required for body weight loss and weight maintenance, and elevated protein intake for additional 
preservation of resting energy expenditure and fat free mass. J Nutr. 2013;143(5):591-596. 
45. Westerterp-Plantenga MS, Lejeune MP, Smeets AJ, Luscombe-Marsh ND. Sex differences in energy 
homeostatis following a diet relatively high in protein exchanged with carbohydrate, assessed in a 
respiration chamber in humans. Physiol Behav. 2009;97(3-4):414-419. 
46. Srikanthan P, Karlamangla AS. Relative muscle mass is inversely associated with insulin resistance and 
prediabetes. Findings from the third National Health and Nutrition Examination Survey. J Clin Endocrinol 
Metab. 2011;96(9):2898-2903. 
47. Atlantis E, Martin SA, Haren MT, Taylor AW, Wittert GA. Inverse associations between muscle mass, 
strength, and the metabolic syndrome. Metabolism. 2009;58(7):1013-1022. 
C
H
A
P
T
E
R
 1
0
 
 
 CHAPTER 10 
172 
48. Moore MC, Coate KC, Winnick JJ, An Z, Cherrington AD. Regulation of Hepatic Glucose Uptake and Storage 
In Vivo. Adv Nutr. 2012;3(3):286-294. 
49. Deivanayagam S, Mohammed BS, Vitola BE, et al. Nonalcoholic fatty liver disease is associated with hepatic 
and skeletal muscle insulin resistance in overweight adolescents. Am J Clin Nutr. 2008;88(2):257-262. 
50. Borel AL, Nazare JA, Smith J, et al. Visceral, subcutaneous abdominal adiposity and liver fat content 
distribution in normal glucose tolerance, impaired fasting glucose and/or impaired glucose tolerance. Int J 
Obes (Lond). 2015;39(3):495-501. 
51. Zelber-Sagi S, Lotan R, Shibolet O, et al. Non-alcoholic fatty liver disease independently predicts 
prediabetes during a 7-year prospective follow-up. Liver International. 2013;33(9):1406-1412. 
52. Drummen M, Dorenbos E, Vreugdenhil AC, et al. Long-term effects of increased protein intake after weight 
loss on intrahepatic lipid content and implications for insulin sensitivity - a PREVIEW study. Am J Physiol 
Endocrinol Metab. 2018. 
53. Margolis LM, Rivas DA, Ezzyat Y, et al. Calorie Restricted High Protein Diets Downregulate Lipogenesis and 
Lower Intrahepatic Triglyceride Concentrations in Male Rats. Nutrients. 2016;8(9). 
54. Schwarz J, Tome D, Baars A, Hooiveld GJ, Muller M. Dietary protein affects gene expression and prevents 
lipid accumulation in the liver in mice. PLoS One. 2012;7(10):e47303. 
55. Fabbrini E, Magkos F, Mohammed BS, et al. Intrahepatic fat, not visceral fat, is linked with metabolic 
complications of obesity. Proc Natl Acad Sci U S A. 2009;106(36):15430-15435. 
56. Samuel VT, Shulman GI. The pathogenesis of insulin resistance: integrating signaling pathways and 
substrate flux. J Clin Invest. 2016;126(1):12-22. 
57. Delarue J, Magnan C. Free fatty acids and insulin resistance. Curr Opin Clin Nutr Metab Care. 
2007;10(2):142-148. 
58. Honka MJ, Latva-Rasku A, Bucci M, et al. Insulin-stimulated glucose uptake in skeletal muscle, adipose 
tissue and liver: a positron emission tomography study. Eur J Endocrinol. 2018;178(5):523-531. 
59. Schmid V, Wagner R, Sailer C, et al. Non-alcoholic fatty liver disease and impaired proinsulin conversion as 
newly identified predictors of the long-term non-response to a lifestyle intervention for diabetes 
prevention: results from the TULIP study. Diabetologia. 2017;60(12):2341-2351. 
60. Berthoud HR. Homeostatic and non-homeostatic pathways involved in the control of food intake and 
energy balance. Obesity (Silver Spring). 2006;14 Suppl 5:197s-200s. 
61. Berthoud HR, Münzberg H, Morrison CD. Blaming the brain for obesity: Integration of hedonic and 
homeostatic mechanisms. Gastroenterology. 2017;152(7):1728-1738. 
62. Adam TC, Tsao S, Page KA, Hu H, Hasson RE, Goran MI. Insulin sensitivity and brain reward activation in 
overweight Hispanic girls: a pilot study. Pediatr Obes. 2015;10(1):30-36. 
63. Jastreboff AM, Sinha R, Lacadie C, Small DM, Sherwin RS, Potenza MN. Neural correlates of stress- and 
food cue-induced food craving in obesity: association with insulin levels. Diabetes Care. 2013;36(2):394-
402. 
64. Kullmann S, Heni M, Veit R, et al. Selective insulin resistance in homeostatic and cognitive control brain 
areas in overweight and obese adults. Diabetes Care. 2015;38(6):1044-1050. 
65. Stouffer MA, Woods CA, Patel JC, et al. Insulin enhances striatal dopamine release by activating cholinergic 
interneurons and thereby signals reward. Nature Communications. 2015;6:8543. 
66. Bruning JC, Gautam D, Burks DJ, et al. Role of brain insulin receptor in control of body weight and 
reproduction. Science. 2000;289(5487):2122-2125. 
67. Figlewicz DP, Evans SB, Murphy J, Hoen M, Baskin DG. Expression of receptors for insulin and leptin in the 
ventral tegmental area/substantia nigra (VTA/SN) of the rat. Brain Res. 2003;964(1):107-115. 
68. Salgado S, Kaplitt MG. The Nucleus Accumbens: A Comprehensive Review. Stereotact Funct Neurosurg. 
2015;93(2):75-93. 
69. Droutman V, Read S, Bechara A. Revisiting the role of the insula in addiction. Vol 192015. 
70. Bär KJ, de la Cruz F, Berger S, Schultz CC, Wagner G. Structural and functional differences in the cingulate 
cortex relate to disease severity in anorexia nervosa. J Psychiatry Neurosci. 2015;40(4):269-279. 
71. Naqvi NH, Bechara A. The insula and drug addiction: an interoceptive view of pleasure, urges, and decision-
making. Brain Struct Funct. 2010;214(0):435-450. 
72. Strubbe JH, Porte D, Jr., Woods SC. Insulin responses and glucose levels in plasma and cerebrospinal fluid 
during fasting and refeeding in the rat. Physiol Behav. 1988;44(2):205-208. 
73. Banks WA, Kastin AJ. Differential permeability of the blood-brain barrier to two pancreatic peptides: insulin 
and amylin. Peptides. 1998;19(5):883-889. 
74. Banks WA. The source of cerebral insulin. Eur J Pharmacol. 2004;490(1-3):5-12. 
 General Discussion 
173 
75. Lindroos AK, Lissner L, Mathiassen ME, et al. Dietary intake in relation to restrained eating, disinhibition, 
and hunger in obese and nonobese Swedish women. Obes Res. 1997;5(3):175-182. 
76. Cornier MA, Melanson EL, Salzberg AK, Bechtell JL, Tregellas JR. The effects of exercise on the neuronal 
response to food cues. Physiol Behav. 2012;105(4):1028-1034. 
77. Killgore WD, Kipman M, Schwab ZJ, et al. Physical exercise and brain responses to images of high-calorie 
food. Neuroreport. 2013;24(17):962-967. 
78. Leidy HJ, Ortinau LC, Douglas SM, Hoertel HA. Beneficial effects of a higher-protein breakfast on the 
appetitive, hormonal, and neural signals controlling energy intake regulation in overweight/obese, 
"breakfast-skipping," late-adolescent girls. Am J Clin Nutr. 2013;97(4):677-688. 
79. Griffioen-Roose S, Smeets PA, van den Heuvel E, Boesveldt S, Finlayson G, de Graaf C. Human protein 
status modulates brain reward responses to food cues. Am J Clin Nutr. 2014;100(1):113-122. 
80. Choi S, Disilvio B, Fernstrom MH, Fernstrom JD. Meal ingestion, amino acids and brain neurotransmitters: 
effects of dietary protein source on serotonin and catecholamine synthesis rates. Physiol Behav. 2009;98(1-
2):156-162. 
81. Growdon JH, Cohen EL, Wurtman RJ. Effects of oral choline administration on serum and CSF choline levels 
in patients with Huntington's disease. J Neurochem. 1977;28(1):229-231. 
82. Kondoh T, Mallick HN, Torii K. Activation of the gut-brain axis by dietary glutamate and physiologic 
significance in energy homeostasis. Am J Clin Nutr. 2009;90(3):832s-837s. 
83. Journel M, Chaumontet C, Darcel N, Fromentin G, Tome D. Brain responses to high-protein diets. Adv Nutr. 
2012;3(3):322-329. 
84. Leidy HJ, Clifton PM, Astrup A, et al. The role of protein in weight loss and maintenance. The American 
Journal of Clinical Nutrition. 2015;101(6):1320S-1329S. 
85. Ronan L, Alexander-Bloch AF, Wagstyl K, et al. Obesity associated with increased brain age from midlife. 
Neurobiol Aging. 2016;47:63-70. 
86. Soenen S, Bonomi AG, Lemmens SG, et al. Relatively high-protein or 'low-carb' energy-restricted diets for 
body weight loss and body weight maintenance? Physiol Behav. 2012;107(3):374-380. 
87. Bryck RL, Fisher PA. Training the Brain: Practical Applications of Neural Plasticity From the Intersection of 
Cognitive Neuroscience, Developmental Psychology, and Prevention Science. Am Psychol. 2012;67(2):87-
100. 
88. Marckmann P, Osther P, Pedersen AN, Jespersen B. High-protein diets and renal health. J Ren Nutr. 
2015;25(1):1-5. 
89. Moller G, Rikardt Andersen J, Ritz C, et al. Higher Protein Intake Is Not Associated with Decreased Kidney 
Function in Pre-Diabetic Older Adults Following a One-Year Intervention-A Preview Sub-Study. Nutrients. 
2018;10(1). 
 
  
C
H
A
P
T
E
R
 1
0
 
 
  
 
  
  
 
SUMMARY
 
  
 Summary 
176 
The increasing prevalence in type-2 diabetes (T2D) has also increased the surge for finding 
optimal T2D prevention and treatment strategies. Many of these strategies have been directed at 
reducing the risk factors obesity and insulin resistance, a precursor in the pathogenesis of T2D. In 
this perspective, the PREVIEW-study (Prevention of Diabetes through lifestyle intervention and 
population studies in Europe and around the World) was initiated. The PREVIEW-study is a multi-
centre trial, in which the impact of a high-protein, low-glycaemic index (GI) vs. moderate protein, 
moderate-GI diet in combination with moderate or high-intensity physical activity on the 
incidence of T2D are investigated in individuals with pre-diabetes (CHAPTER 2).  
In total, 2326 participants who met the ADA pre-diabetes inclusion criteria were recruited. They 
presented with increased body weight and insulin resistance (CHAPTER 2). At baseline, we found 
multiple relationships that helped to characterize this population. Physical activity (PA) was 
positively associated and sedentary time (ST) was inversely associated with cardiometabolic 
health, including insulin resistance, within this population (CHAPTER 3). Therefore, replacing ST 
with PA may be a practical approach to improve cardiometabolic health. Furthermore, the 
participants were characterized by positive associations of insulin resistance with intrahepatic 
lipids (IHL) (CHAPTER 7) and with brain reactivity to food cues (CHAPTER 5). Moreover, reactivity 
to food cues was positively related to TFEQ disinhibition/emotional eating and inversely related to 
Baecke habitual physical activity during leisure time in multiple brain regions associated with the 
attention and reward network. 
Taken together, these findings at the start of the PREVIEW study underlined the relevance of an 
intervention to prevent T2D in these participants but also showed that longitudinal measurements 
of IHL and brain reward activity along with the assessment of changes in body weight, body 
composition or insulin resistance were relevant to gain more insights in the underlying pathology.  
The PREVIEW intervention started with an 8-week low energy diet (LED) to establish body weight 
loss. We showed that this was a suitable method to reach the contemplated 8% body weight loss, 
evidenced by an average weight loss of 11% (CHAPTER 6). The weight loss was higher in men 
than in women and this was accompanied by relatively larger reductions in metabolic syndrome 
scores. Still, more weight loss could have been achieved with full compliance to the LED based on 
a theoretically achievable weight loss of 14%. The second phase of the PREVIEW intervention 
consisted of a 34-month lifestyle intervention aimed to maintain the lost body weight in four 
intervention groups, differing in physical activity and dietary guidelines. Dietary guidelines of the 
PREVIEW intervention consisted of two groups differing in protein intake and GI/GL. Increasing 
protein intake has been recommended to achieve weight loss and a daily protein intake of at least 
0.8 g/kg body weight was sufficient for weight maintenance after weight loss (CHAPTER 4). 
However, the additional value of a relatively high protein diet for T2D, cardiovascular diseases, 
non-alcoholic fatty liver disease remains inconclusive.  
The lifestyle intervention led to long-term reductions in body weight and insulin resistance. 
Effects of the intervention on IHL were assessed in 25 participants using magnetic resonance 
spectroscopy (CHAPTER 7). Simultaneously, visceral adipose tissue (VAT) and subcutaneous 
adipose tissue (SAT) were determined using magnetic resonance imaging. IHL, VAT and SAT were 
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reduced at 6 months and 2 years compared to baseline. We did not find different changes in IHL, 
VAT or SAT between the two protein groups. We also did not find differences in protein intake 
assessed with urinary nitrogen excretion between the two groups. In the whole group of 
participants daily protein intake was inversely related to IHL at 6 months. Furthermore, IHL was 
positively related to insulin resistance throughout the intervention, independent of BMI. These 
findings suggest that protein intake may indirectly increase insulin sensitivity via reductions in IHL 
and focusing on reducing IHL may be crucial within diabetes prevention interventions. 
We also determined brain reward activation in response to visual stimuli using functional 
magnetic resonance imaging in a sub-group of the PREVIEW participants and assessed possible 
relations with anthropometric, metabolic or behavioral parameters (CHAPTER 8). As mentioned 
before, at baseline, food-reward related brain activation was positively associated with HOMA-IR, 
TFEQ disinhibition/emotional eating and inversely associated with Baecke habitual physical 
activity during leisure time. The relationship between food-reward related brain activation and 
insulin resistance was further evidenced by the positive association between changes in food 
reward-related brain activation and changes in insulin resistance from baseline to 2 years. 
Furthermore, changes in food reward-related brain activation were positively associated with 
changes in BMI and body-fat percentage and inversely associated with changes in TFEQ dietary 
restraint scores and with protein intake during the weight maintenance period. These findings 
indicate that people with pre-diabetes and overweight/obesity may have increased risk for 
hyperphagia and ‘unhealthy’ eating behaviors due to altered food reward processing in the brain, 
while behavioral factors like physical activity, protein consumption, weight loss and cognitive 
restraint may counteract these alterations. Next to brain activation, we also measured brain 
structure to determine if grey matter volume or cortical thickness would change during the 
PREVIEW intervention along with changes in body weight or insulin resistance (CHAPTER 9). We 
found an inverse association between grey matter volume and insulin resistance at baseline, but 
the intervention did not lead to changes in global grey matter volume. Furthermore we did not 
find changes in cortical thickness along with weight loss and long-term weight maintenance.  
In conclusion, the heterogeneous PREVIEW cohort successfully achieved 8% body weight loss 
using the 8-week low energy diet and showed the relevance of the PREVIEW intervention 
especially for evaluating changes in insulin sensitivity and its implications on organ level, like liver 
and brain.  In the participants, insulin resistance was reduced after 2 years of diet and exercise 
intervention accompanied by reductions in IHL and by reduced food reward related brain 
activation. The changes in brain reactivity were linked to increased control of eating behavior, 
adjusted for changes in BMI. More specifically and on group level, protein intake was related to 
reductions in IHL and changes in brain reward activity, demonstrating beneficial effects that 
supersede effects on body weight loss or body weight management. 
With these findings, we distinguished important aspects of a diabetes prevention program and 
future programs should incorporate efforts to reduce IHL and normalize brain signalling. 
Furthermore, mapping differences and similarities within the pre-diabetes population may 
contribute to better understanding of underlying pathologies and therefore may help to design 
tailored T2D prevention and treatment methods.   
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De huidige toename van type 2 diabetes (T2D) vergt meer onderzoek naar mogelijke preventie of 
behandeling. Dergelijk onderzoek is vooral gericht op reductie van het lichaamsgewicht, en 
daarmee reductie van insulineresistentie. Deze twee factoren vormen de grootste risico’s voor de 
ontwikkeling van T2D. In dit kader startte in 2013 het onderzoek naar “PREVentie van diabetes 
door leefstijlinterventie en populatie studies in Europa en in de Wereld”, afgekort PREVIEW. Dit 
PREVIEW onderzoek bestaat uit een zogeheten multi-center studie waarin de effecten van twee 
verschillende eiwit-diëten in combinatie met lichamelijke activiteit op twee verschillende 
intensiteitsniveaus werden vergeleken. De diëten verschilden in relatief hoog of medium eiwit-
niveau, gecombineerd met producten van respectievelijk lage of medium glycaemische index (GI); 
de intensiteitsniveaus van lichamelijke activiteit waren zeer intensief of medium intensief. De 
belangrijkste vraagstelling van het onderzoek was welke leefstijl combinatie (Hoog-eiwit, laag GI, 
zeer intensieve activiteit; hoog-eiwit, laag GI, medium intensieve activiteit; medium-eiwit, medium 
GI, zeer intensieve activiteit; medium-eiwit, medium GI, medium intensieve activiteit) het sterkst 
de ontwikkeling van T2D binnen 3 jaar zou voorkomen.  
De deelnemers werden zodanig geselecteerd dat zij aan de criteria voor ‘prediabetes’ voldeden; 
2326 deelnemers werden aldus in 8 verschillende centra over de gehele wereld geselecteerd, 
waaronder de Universiteit Maastricht. Allen hadden overgewicht en een verhoogde 
insulineresistentie (HOOFDSTUK 2). Voor de start van de interventie werden enige mogelijke 
assocciaties onderzocht. Lichamelijke activiteit bleek positief, en sedentair gedrag negatief 
geassocieerd te zijn met een gezond metabolisme van hart en bloedvaten. Vervanging van 
sedentair door actief gedrag zou wellicht een gezond metabolisme kunnen bevorderen 
(HOOFDSTUK 3). Tevens werd een positief verband gevonden tussen insulineresistentie en 
vetstapeling in de lever (HOOFDSTUK 7). Ten slotte werd een negatief verband aangetoond 
tussen de reactie in beloningsgebieden van de hersenen bij het zien van voedselplaatjes en 
lichamelijke activiteit, hetgeen inhoudt dat bij meer lichamelijke activiteit de reactie in de 
desbetreffende hersengebieden minder sterk is, en daarmee de beheersing van de voedsel 
inname sterker is (HOOFDSTUK 5). Deze bevindingen voor de start van de interventie bevestigen 
ten aanzien van lichamelijke activiteit de relevantie van de interventie op zich, maar geven ook de 
noodzaak aan om specifieke effecten ten aanzien van voedselinname beheersing (in de hersenen) 
en levervetstapeling te onderzoeken.  
Het eerste deel van de PREVIEW interventie bestond uit een 8 weken durend afvaldieet. Om 
daarna door te kunnen gaan dienden de deelnemers ten minste 8% van hun lichaamsgewicht te 
verliezen. Het gemiddelde gewichtsverlies van hen die dat bereikten, bleek 11% te zijn. 
Desondanks zou het gewichtsverlies zelfs 14% geweest kunnen zijn wanneer de deelnemers zich 
strikt aan het afvaldieet gehouden hadden. Mannen hadden een groter gewichtsverlies dan 
vrouwen, en daarmee een sterkere vermindering van hun zogeheten metabool syndroom 
(HOOFDSTUK 6). Hierna startte de 34 maanden durende leefstijlinterventie, met het doel het 
verkregen lichaamsgewicht te stabiliseren, en behouden. De eerder genoemde vier types 
leefstijlinterventie werden toegepast, en begeleid via specifieke groepsinstructies. De eiwit-diëten 
met een dagelijkse eiwit-inname van ten minste 0,8 g/kg lichaamsgewicht zijn op basis van 
eerdere studies succesvol gebleken. Echter, of een hoog-eiwit dieet naast het effect van 
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gewichtsbeheersing toegevoegde effecten heeft op T2D, cardiovasculaire ziektes of niet-
alcoholische leververvetting was tot nu toe niet bekend (HOOFDSTUK 4). 
Na 6 maanden, en na 2 jaar, zijn de metingen van de leververvetting bij de desbetreffende 
deelnemers herhaald. Het lichaamsgewicht en de insulineresistentie van de deelnemers waren 
sterk afgenomen. Tevens bleek de leververvetting sterk te zijn afgenomen, alsook het buikvet en 
onderhuids vet. Tussen de twee eiwit-dieet groepen waren geen verschillen hierin ontstaan, maar 
deze dieet groepen bleken in de praktijk ook niet in eiwit-inname te verschillen. Wel was er na 6 
maanden een negatieve associatie tussen eiwit-inname en vetstapeling in de lever, hetgeen 
impliceert dat degenen met een hogere eiwit-inname een geringere vetstapeling in de lever lieten 
zien. De reeds aanwezige positieve associatie tussen insulineresistentie en leververvetting bleef 
aanwezig, onafhankelijk van het lichaamsgewicht. De combinatie van deze waarnemingen 
suggereert dat de eiwit-inname een indirect effect op de insulineresistentie heeft, via verandering 
in leververvetting. Voorts duiden deze resultaten op het belang van vermindering van 
leververvetting, voor preventie van T2D (HOOFDSTUK 7).  
De veranderingen in hersenactiviteit in de voedsel gerelateerde beloningsgebieden zijn 
beschreven in hoofdstuk 8. Na twee jaar bleken deze veranderingen in hersenactiviteit positief 
geassocieerd te zijn met veranderingen in insulineresistentie, hetgeen impliceert dat degenen met 
een sterkere reductie in insulineresistentie verminderde voedsel gerelateerde hersenactiviteit 
vertoonden, ofwel, een sterkere beheersing van hun voedselinname. Bovendien waren de 
veranderingen in hersenreactiviteit positief gerelateerd aan veranderingen in lichaamsgewicht en 
lichaamsvetpercentage en negatief gerelateerd aan de veranderingen in geremd eetgedrag en 
eiwit inname gedurende de gewichtsbehoudfase. Gewichtsvermindering, geremd eetgedrag, en 
een hogere eiwit-inname gaan dus samen met sterkere beheersing van de voedselinname 
(HOOFDSTUK 8). Naast hersenreactiviteit zijn de effecten van de PREVIEW interventie op het 
volume van de grijze hersenstof en de dikte van de hersenschors bepaald. Voor de interventie 
was er een negatieve relatie tussen het volume van de grijze hersenstof en insulineresistentie, 
maar tijdens de interventie traden geen veranderingen hierin op. Ook de dikte van de 
hersenschors veranderde niet (HOOFDSTUK 9). 
De conclusie van dit proefschrift is dat de PREVIEW deelnemers met succes het afval-dieet 
gevolgd hebben, met meer dan 8% gewichtsverlies in de eerste 8 weken. Vervolgens leidde de 
PREVIEW interventie tot een significante vermindering in insulineresistentie na 2 jaar, tot verlaging 
van de mate van leververvetting, en tot sterkere beheersing van de voedselinname. Deze 
veranderingen in leververvetting en beheersing van de voedsel-inname hielden verband met de 
eiwit-inname na twee jaar, met de veranderingen in insulineresistentie, lichaamsgewicht en 
lichaamsvet, en verandering in geremd eetgedrag. De bevindingen wijzen op additionele effecten 
van eiwitinname, naast effecten op gewichtsverlies of gewichtsbehoud. 
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SOCIETAL RELEVANCE 
Diabetes is one of the fastest growing chronic diseases worldwide and already 422 million people 
have diabetes according to the WHO. Every year, 1.6 million deaths are directly attributable to 
diabetes. Around 90% of all diabetes cases are made up by type-2 diabetes (T2D), which usually 
develops later in life. The development T2D has been associated with lifestyle and environmental 
factors and therefore the key for successful prevention of T2D may lie in changing these factors.  
The PREVIEW study was initiated in 2013 with the aim to find the most effective lifestyle-
components (diet and physical activity) in the prevention of T2D. Furthermore, the study was set 
out to increase our knowledge on the relationship between lifestyle factors, health and well-
being. The PREVIEW intervention was shown to be highly successful for long-term body weight 
loss and reductions in insulin resistance. The large number of participants benefitted directly from 
the intervention and our findings are especially relevant for the increasing number of people 
classified as having pre-diabetes. However, since we found beneficial effects on a variety of 
anthropometric, metabolic and behavioral parameters, it really indicates the importance of 
lifestyle intervention for improving health in a population with pre-diabetes. 
In the first 8-weeks of the PREVIEW intervention participants started with a low-energy diet (LED) 
to achieve at least 8% weight loss. During this period, participants consumed a range of formula 
products of the Cambridge Weight Plan (Northants, UK). The average weight loss of the 
participants was 11%, showing the success of the LED. Our results contribute to the evidence that 
a LED is a safe and suitable method to achieve weight loss and by presenting our findings at 
national and international meetings we hoped to stimulate the usage of LEDs in clinical settings.  
It is evident that a better understanding of processes in specific organs and their role in diabetes 
development and prevention will help to develop new therapeutic or preventive methods for T2D. 
We were able to show effects of the intervention on intrahepatic lipids and brain reward reactivity 
using non-invasive imaging techniques.  
Moreover, the close association of intrahepatic lipid accumulation and insulin resistance that we 
found throughout the intervention underlined the importance to address intrahepatic lipids in the 
prevention of T2D. Furthermore, with the increasing number of people presenting with liver 
diseases including non-alcoholic fatty liver disease, better strategies to reduce intrahepatic lipids 
are needed. We showed that sufficiently high protein intake after weight loss was associated with 
reduced intrahepatic lipids. This finding may contribute to developing optimal diet strategies to 
reduce intrahepatic lipids or prevent intrahepatic lipid accumulation. 
We also found multiple factors interacting with brain reward reactivity. Increased body weight, 
body-fat percentage and insulin resistance was related to increased brain reactivity to food 
images, while increased protein intake during weight maintenance and dietary restraint was 
related to reduced brain reactivity to food images. These findings may suggest that people with 
increased body weight or insulin resistance are more sensitive for food cues in terms of 
anticipated reward and therefore overeat and have less control over their food intake. This is an 
important issue to address especially for long-term weight loss and interventions. Since we also 
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found inverse relations between protein intake during the weight maintenance phase and 
changes in cognitive restraint and brain reactivity to food cues, these factors may be exploited to 
reduce the increased sensitivity to food cues and therefore increase compliance to a diet or 
intervention.  
ECONOMIC RELEVANCE 
According to the WHO, 2.5% to 15% of annual national health care budgets are direct healthcare 
costs of diabetes. Therefore, the prevention of T2D is also relevant from an economical aspect. 
PREVIEW will assess the costs, effectiveness and benefits of providing extended support, 
reinforcement and motivation to make lifestyle changes and maintain these in the longer term. 
This information will be relevant for future prevention programs and assigning clinical value to 
such designs. The research was funded by the 7
th
 Framework Programme of the European 
Commission, which also indicates the interest for the whole society.  
The findings will also help in the debate of the validity and consequences of the ‘pre-diabetes’ 
classification. Especially since the pre-diabetes cut points were lowered by the American Diabetes 
Association, people have argued that the resulting rise in people with pre-diabetes exceed the 
capacity of health care systems. Moreover, the ranges in parameters like insulin resistance, body 
weight, age etc. of the population with pre-diabetes increased, leading to difficulties in the 
interpretation of interventions and outcomes.  
ACTIVITIES AND PRODUCTS 
Obviously, research alone will not lead to a reduction in the risk of diabetes. Therefore, an 
important part of the PREVIEW study was to facilitate the new knowledge from the project to all 
relevant stakeholders. This has been achieved in different ways and forms.  
First of all we used the PREVIEW website (www.previewstudy.com), via which everyone had and 
still has easy access to the study information, newsletters and results/publications. Moreover, the 
website includes an e-learning module which has been specifically designed using the knowledge 
of the PREVIEW study and PREVIEW partners to educate the general public. The e-learning 
module contains study material to learn about diabetes, diet, physical activity and behavior 
change using an interactive format. 
Furthermore, we developed and published the PREMIT toolbox, which is a theory-driven, 
evidence-based program to change physical activity and dietary behaviors people with pre-
diabetes. This toolbox was designed for the PREVIEW study, but by publishing it we shared this 
knowledge for future interventions and treatment programs.  
Other features of the project that by themselves or in combinations may lead to future practical 
applications include the cook books with recipes designed by Meyers Madhus to reach or limit a 
glycaemic index level and eating plans based on food unit systems. Moreover, information on 
glycaemic index values have been made available to national food databases so it can be reached 
by the general public.  
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TRANSLATION INTO PRACTICE 
A major strength of the PREVIEW study is the feasibility to translate the study and especially the 
intervention into practice. Results and conclusions can therefore be readily transferred to clinical 
interventions and treatment methods. The intervention was applied in free living conditions and 
dietary and physical activity guidelines were designed to be feasible for everyone without 
additional resources or personal counseling. Guidance was provided via group counseling 
sessions, which is a practical and economical way to reach a larger audience. Next to these 
practical issues, this type of research is pivotal to translate findings from animal work or smaller 
and controlled studies to daily life settings.  
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